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“Science is not the straight and narrow path to truth, but rather, 
a trail fraught with many nooks, crannies and traverses. 
After all, what is the purpose of science but to learn from 
the universe the principles of love and meekness? 
Could there be no higher purpose of scientists?”
(High Eagle)
“No is a word on your path to Yes. Don’t give up too soon. 
Not even if well-meaning parents, relatives, friends, and 
colleagues tell you to get a real job. 
Your dreams are your real job.” 
(Joyce Spizer)
“A successful career will no longer be about promotion. 
It will be about mastery.”
(Michael Hammer)

Abstract
Background
It has been suggested that the intake of fish and marine n-3 polyunsaturated fatty 
acids could protect against age-related cognitive decline and impaired mental 
well-being. However, results from observational studies are inconclusive and 
data from randomized controlled trials in older people without clinical dementia 
or depression are scarce. The objective of this thesis was to investigate the effect 
of daily supplementation with eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) on cognitive performance and mental well-being in an older non-
clinical population. We also examined the effect of fish oil on gene expression 
profiles in white blood cells to identify early changes in pathways possibly 
related to mental health. Furthermore, we assessed the association of fish and 
EPA+DHA intake with mental health in different aging populations.
Methods
The effect of low and high doses of EPA+DHA (400 and 1,800 mg per day, 
respectively) on cognitive performance, several measures of mental well-being, 
and gene expression was examined in a 26-week randomized, double-blind, 
placebo-controlled trial. This study was conducted in 302 individuals aged 65 years 
or older with no clinical diagnosis of dementia or depression. Furthermore, the 
cross-sectional association between fatty fish and EPA+DHA intake with cognitive 
performance and the association with cognitive change during 6 years of follow-
up was assessed in 1,025 aging US men who participated in the Veterans Affairs 
Normative Aging Study (NAS). In addition, the associations of EPA+DHA and fish 
intake with depressive symptoms and dispositional optimism were assessed in 
644 free-living Dutch subjects with a history of myocardial infarction.
Results
Daily intake of low or high doses of EPA+DHA did not affect cognitive 
performance, mental well-being, anxiety, or quality of life, after 13 or 26 weeks 
of intervention. However, treatment with EPA+DHA for 26 weeks altered gene 
expression in white blood cells to a more anti-inflammatory and more anti-
atherogenic profile. In elderly US men we found no association of fatty fish or 
EPA+DHA intake with cognitive performance or 6-year cognitive change. Intake 
of EPA+DHA was positively associated with dispositional optimism in subjects 
with a history of myocardial infarction. There was also a tendency for less 
depressive symptoms with a higher EPA+DHA or fish intake, but this association 
was no longer statistically significant after controlling for confounders.
Conclusion
Supplemental intake of EPA+DHA is unlikely to have a short-term impact on 
cognitive performance or mental well-being of older people without a clinical 
diagnosis of dementia or depression. Whether long-term intake of EPA+DHA 
and fish could be beneficial to the maintenance of cognitive performance or 
mental well-being of older people in Western populations still needs to be 
established. 
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The importance of good nutrition for the maintenance of health has long been 
advocated. Decades ago specific attention was drawn to dietary influences of 
fish consumption on health by observation of benefits of fish oil on the risk 
for cardiovascular disease in the Japanese1,2 and in the Inuit of Greenland3,4, 
populations with a high consumption of fish. Fish oil has also been inversely 
associated with atopic eczema5, hypercholesterolemia6, and arthritis7. Moreover, 
a low risk of Alzheimer’s disease has been reported in the Cree in northeastern 
Canada, another population with high fish intake8. These observations led to an 
increase in research on the beneficial effects of n-3 polyunsaturated fatty acids 
(n-3 PUFA) from fish on various health conditions. Beneficial effects include anti-
atherogenic, anti-arrhythmic, anti-thrombotic and anti-inflammatory actions9. 
Also, evidence is accumulating for a potential benefit of n-3 PUFA on mental 
health in older individuals; they may slow down cognitive decline, delay the 
onset of dementia and improve mental well-being. In this thesis we have further 
examined the intake of fish and the n-3 PUFA eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) in relation to cognitive decline and mental well-
being of older people by means of observational and intervention studies.
About n-3 PUFA
About 90% of fats in our diet come in the form of triglycerides, which 
consist of fatty acids and glycerol. N-3 PUFA (also called omega-3 PUFA) are 
polyunsaturated fatty acids where the first double bond is located at the third 
carbon atom, counting from the methyl end (Figure 1.1).
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Figure 1.1  Structure of the n-3 PUFA alpha-linolenic acid (ALA), eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA).
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N-3 PUFA are present in the diet as alpha-linolenic acid (ALA; C18:3n-3) 
of which vegetable oils and nuts are main sources and as very long-chain 
polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA; C20:5n-3) 
and docosahexaenoic acid (DHA; C22:6n-3), which are mainly supplied by 
(fatty) fish. ALA is an essential fatty acid, which can be converted into EPA and 
DHA by a series of desaturations and elongations. However, in humans the 
conversion of ALA to EPA and DHA is very limited; only 5 to 10% of ALA is 
converted into EPA, and 1 to 5% of ALA or EPA is converted into DHA10-14. This 
conversion may also be influenced by the amount of ALA and linoleic acid in 
the diet15,16. Because EPA and DHA are not efficiently synthesized in humans 
it is more effective when they are obtained directly from the diet or otherwise 
e.g. from fish oil capsules. 
The Netherlands Health Council recommends an intake of at least 450 mg 
EPA+DHA from fish per day, which is roughly equivalent to eating two portions 
of fish per week, one of which is oily fish17. The recommended EPA+DHA 
values that have been proposed by different organizations are globally in 
the range of 200 to 600 mg/d18. There is a large variation in intake across 
studies and countries, but in most western populations intakes are far below 
recommendations. In the US and Europe, the mean intake of EPA+DHA varies 
between 100 and 500 mg per day19-22 while in Japan intakes are around 1 g 
per day22. Average fish intake of the general Dutch population as estimated in 
1998 was 10 g per day23. In a population of Dutch older men, assessed in 2000, 
28% did not consume fish at all and 41% consumed >20 g per day, only 11% 
of which comprised fatty fish24.
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Dementia, cognitive decline and depression
Dementia and cognitive decline
Because of the aging population there is an increase in age-related diseases, 
of which dementia is one of the most common. Dementia is a progressive 
neurodegenerative disease characterized by loss of function and death of nerve 
cells in several areas of the brain, complicated by inflammatory reactions25. 
This results in a loss of mental functions such as memory and learning, which 
together with a decline in activities of daily living and behavioral changes impair 
every day functioning. Different types of dementia exist, including Alzheimer’s 
disease (AD), vascular dementia, dementia with Lewy bodies, and frontotemporal 
dementia26. 
At present, AD accounts for 70% of prevalent dementias. In 2006 the estimated 
number of Alzheimer’s disease patients worldwide was nearly 27 million. The 
EPA and DHA need to be obtained from the diet. There is a large variation 
in intakes between countries. Average intake in the Netherlands and other 
western countries is far below the recommendation of 450 mg per day.
14
incidence is increasing markedly due to aging populations, and the forecast for 
the future is that the numbers might have increased fourfold by 2050 to 106.8 
million, thus affecting 1 in every 85 older persons27. AD is characterized by the 
presence of neurofibrillary tangles and amyloid plaques that are clearly visible 
by microscopy in brains of those afflicted with AD. Neurofibrillary tangles are 
aggregates of the protein tau which has become hyperphosphorylated and 
accumulates inside the cells. Plaques are dense, mostly insoluble deposits of 
the protein amyloid-beta and cellular material outside and around neurons. 
AD is distinguished from vascular dementia, the second most common form 
of dementia, which is characterized by cerebrovascular lesions secondary to 
vascular disease. However, this distinction is not complete since associations 
between vascular risk factors and Alzheimer’s disease have been demonstrated 
and therefore pathologies may overlap28. 
Dementia is preceded by impaired cognitive functioning: the process of receiving, 
processing, storing and using information. Main cognitive functions are memory 
and learning, attention and concentration, thinking, language, and visual and 
spatial skills. There are different cognitive stages ranging from normal cognitive 
functioning to cognitive impairment and dementia or AD (Figure 1.2). These 
stages are often age-related, but the level of cognitive functioning, the onset 
of cognitive decline and the rate of cognitive decline differ between persons 
of the same age, which indicates that also other factors are of influence. The 
pathogenesis of neurological damage and relevance to cognitive impairment is 
still uncertain. A better understanding of the risk factors is needed to maintain 
good cognitive performance as long as possible. The social, medical, and 
IntroductionChapter 1
Figure 1.2  Differences in cognitive functioning over time between persons. A = difference 
in level of cognitive functioning; B = difference in onset of cognitive decline; C = difference 
in rate of cognitive decline.
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economical impact of dementia and cognitive impairment is huge29. Since no 
effective treatment for dementia is available there is an urgent need to develop 
strategies to prevent or postpone the onset of cognitive decline. A delay in onset 
by 1 year would reduce the prevalence of dementia by 25%, and a 5-year delay 
would decrease the prevalence by 50%30.
Depression
The WHO estimates that 121 million people worldwide are affected by 
depressive disorders31, which was the fourth leading contributor to the global 
burden of disease in high-income countries in 200032. The main symptoms of 
depression are depressed mood, loss of interest or pleasure, feelings of guilt 
or low self-worth, disturbed sleep or appetite, fatigue or low energy, and poor 
concentration31. 
There are different forms of depression, which mainly differ in severity and 
duration of symptoms. Bipolar disease is characterized by alternating periods 
of depression and mania (feeling of extreme elation and euphoria) and unipolar 
depression, also called major depressive disorder, occurs without periods of 
mania. Major depressive disorder is defined by having one core symptom 
(depressed mood or loss of interest or pleasure) and at least four other symptoms 
for at least two weeks according to the criteria of the 4th edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV)33. This distinguishes major 
depression from the somewhat less severe type, the so-called minor depressive 
disorder, which is defined by having at least one core symptom, but only one 
to three other symptoms for two weeks or longer. When the symptoms of minor 
depression last 2 years or longer it is called dysthymia.
The prevalence of clinical depression ranges from 1-15% in the general elderly 
population34,35 and because of the aging population this prevalence is likely 
to increase. In the Netherlands the number of depressed people amounted to 
856,000 in 2003 which is 6.3% of the inhabitants aged 13 years or older. It is 
expected that the incidence of depressive disorders will increase by 4% between 
2005 and 202536. Despite the high prevalence the majority of depressed older 
patients remains undetected and does not receive treatment37. Comorbidity 
with physical illness and cognitive impairment are often mentioned as factors 
hindering the detection of depressive symptoms37,38. 
It appears that anti-depressant therapy is not always effective; it is estimated that 
20-30% of those with major depressive disorders treated with antidepressant 
medication continue to experience depressive symptoms. In addition, persons 
with a history of depression have a more than threefold higher risk of recurrence39. 
Furthermore, long term use of antidepressant medication gives rise to a number 
of common and unpleasant side effects, such as weight gain, gastrointestinal 
disturbances, blurred vision, drowsiness and dizziness40. Also, depression has 
a major influence on a person’s quality of life, their relatives, and society. This 
calls for effective preventive measures.
Chapter 1Introduction
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Other measures of mental well-being
Anxiety
Anxiety is a psychological and physiological state characterized by cognitive, 
somatic, emotional, and behavioral components41. These components together 
create an unpleasant feeling that is typically associated with uneasiness, fear, 
or worry. Anxiety occurs without an identifiable triggering stimulus, which 
distinguishes it from fear, which occurs in the presence of an observed threat. 
Furthermore, it is distinct from depression, because depression is dominated by 
the emotion of sadness and is associated with feelings of sorrow, hopelessness, 
and gloom. However, separating these two states strictly on clinical grounds is not 
always straightforward, because anxiety is also a common symptom of depressive 
illness, and depression is a common complication in anxiety states.
Dispositional optimism
Dispositional optimism is defined in terms of generalized positive expectancies 
for one’s future42 and has been associated with healthy lifestyle and dietary 
habits43,44. It is not simply the reverse of depression, but both affect mental 
well-being. Optimism has been shown to protect against the development 
of depressive symptoms45. Because a low intake of fish or n-3 PUFA may be 
beneficial to depression, it may also be related to a lack of optimism.
Quality of life
Depression and dementia often coincide and it is difficult to disentangle which 
disease came first46,47. The impact of both diseases on quality of life (QOL) is 
large and comparable to other serious diseases. QOL is a broader concept than 
mental well-being; it encompasses physical health, psychological state, level of 
independence, social relationships, and relationship to salient features of the 
environment48. It assesses the individual’s perceptions in the context of their 
culture and value systems, and their personal goals, standards and concerns. 
Effective interventions that would prevent cognitive impairment and depression, 
consequently improving QOL, are needed.
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The worldwide prevalence of dementia and depression is high and 
increasing rapidly due to the aging population. Both diseases affect quality 
of life. This calls for effective preventive measures.
Risk factors for cognitive decline, dementia and depression
Epidemiological studies could make a valuable contribution to understanding 
the etiology and pathogenesis of dementia and depression and the identification 
of risk factors. During the past decades several risk factors for these diseases 
have been identified, which are summarized below. 
Non-modifiable risk factors. Major risk factors for dementia and depression are 
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increasing age49,50 and female gender50,51. Another major risk factor for dementia 
is the apolipoprotein E-ε4 (APOE4)52-54. APOE is a plasma protein involved in the 
metabolism of cholesterol and triglycerides, which exists in three allelic forms 
(ε2, ε3, and ε4). Individuals with two copies of the APOE-ε4 allele (2% of the 
total population) have a 50% to 90% chance of developing AD by the age of 
85, and those with one copy of APOE-ε4 (15% of the total population) have 
45% chance of developing the disease52, compared with 20% in the general 
population55.
Sociodemographic and lifestyle factors. There is convincing observational 
evidence for a relation between low educational level and dementia50,51,56. 
Furthermore, marital status57,58, living situation57-59, smoking60,61, high alcohol 
consumption62,63, low physical activity level64,65, frailty66, low walking speed67,68, 
underweight or weight loss69-72, having few social relationships or social 
activities73,74 or the absence of intellectual or other activities75-77 have all been 
suggested as risk factors, also for the occurrence of depression78. For depression 
additional risk factors are specific personality traits and stressful life events79.
Nutritional factors. Current epidemiological data are in favor of a protective 
role of certain micronutrients, such as B-vitamins (related to the homocysteine 
metabolism), the antioxidant vitamins C and E and flavonoids80. Cochrane reviews 
that have evaluated the trial evidence available for these micronutrients do not 
support these associations, but they are also based on a very limited amount 
of RCTs. Furthermore, coffee consumption81,82 and more recently vitamin D83,84 
have been inversely associated with cognitive decline. Fish and n-3 PUFA from 
fish (EPA+DHA) have also been identified as potentially important candidate 
nutrients for the prevention of cognitive decline80, dementia85 and mood 
disorders86. However, also here evidence has mainly come from observational 
studies and data from randomized controlled trials (RCTs) in healthy adults are 
limited87 and inconsistent88.
Underlying mechanisms
The nervous system has the highest lipid content of all organs in the human 
body. Approximately 50 to 60% of the dry weight of the brain consists of lipids 
and PUFA constitute approximately 35% of that lipid content. DHA is the 
major constituent as an important building block of neuronal membranes89. 
N-3 PUFA are very important for brain development during both the foetal and 
postnatal period90,91. With aging and late onset AD, DHA levels in the brain 
tend to decrease90,92-94, suggesting that a drop in DHA levels may contribute to 
a deterioration in memory and other cognitive functions.
Several biological mechanisms for the possible association between fish or n-3 
PUFA and mental health have been proposed. Most likely a combination of 
various mechanisms could play a role in mental health. It is at present unknown 
to what extent these different mechanisms are shared by mental processes like 
cognitive decline, specific domains of cognitive functioning, and depression. 
Therefore, a number of the proposed mechanisms are described below, but 
Chapter 1Introduction
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current knowledge is too limited to separate these for the specific impact on 
cognition, separate cognitive domains or depression. Proposed mechanisms are 
roughly classified as short-term (i.e. weeks to months) or long-term (months to 
years). Acute mechanisms influencing cognitive functioning or mood are beyond 
the scope of this thesis. It should be noted that fish is also rich in other nutrients 
than n-3 PUFA that could be beneficial to health, such as proteins, selenium 
and vitamin D, but we will only discuss the mechanisms of n-3 PUFA, which 
are the main focus of this thesis.
‘Short-term’ mechanisms
Membrane fluidity. The high concentration of DHA in membrane phospholipids 
has a role in maintaining membrane integrity and fluidity. EPA and DHA are 
already incorporated in the phospholipid fraction of cell membranes within 2-4 
weeks, thereby influencing physical properties and fluidity of the cells. As such 
they could affect the structure and functioning of proteins embedded in the 
membrane, including enzymes, receptors, and ion channels, thereby influencing 
cellular signaling and neurotransmission of for example serotonin, dopamine, 
and acetylcholine95,96. 
Cerebral blood flow. Neuroimaging studies have shown that impaired cerebral 
perfusion is related to worse cognitive functioning. N-3 PUFA have been shown 
to improve cerebral blood flow in animals within several weeks97,98 or months99 
and it has been hypothesized that mental health benefits of n-3 PUFA may be 
mediated by improvements in cerebral vascular function100. 
Gene regulation. N-3 PUFA regulate the expression of genes and the binding 
of fatty acids to specific nuclear receptors in various tissues, including the liver, 
heart, adipose tissue, and brain. Modulation of gene transcription by EPA and/
or DHA may eventually reduce the risk of various chronic diseases, such as AD, 
cardiac disease, and depression101. PUFA exert their effects on gene expression 
rapidly; in animals fed with diets rich in PUFA changes in expression of lipogenic 
genes have been observed within hours102,103.
‘Long-term’ mechanisms
Vascular factors. Vascular disease appears to be closely related to the 
development of cognitive impairment and dementia104. The beneficial effects 
of n-3 PUFA in reducing vascular risk include anti-arrhythmic, anti-thrombotic, 
anti-inflammatory, and anti-atherogenic effects105 resulting in a reduction of 
atherosclerosis106 and risk of stroke107. N-3 PUFA can be incorporated into 
atherosclerotic plaques, enhancing their stability, which may reduce the risk of 
brain infarction108. Consumption of n-3 PUFA may also lower serum cholesterol 
and triglycerides levels and improve endothelial function by enhanced nitric 
oxide production. It has been shown that all these vascular risk factors also have 
measurable beneficial effects on the brain and are associated with cognitive 
functioning109. 
Inflammation. Inflammation plays a major role in the pathophysiology of 
IntroductionChapter 1
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dementia110 and n-3 PUFA may be protective through their anti-inflammatory 
properties. During aging, the increase of peripheral cytokines leads to an increase 
of brain cytokines that could be responsible for the development of cognitive 
disorders. EPA and DHA decrease the synthesis of inflammatory eicosanoids from 
arachidonic acid111 and inhibit the release of pro-inflammatory cytokines112. 
Oxidative stress. Oxidative stress is a condition of increased free radicals 
production and/or decrease of availability of antioxidants. Oxidative stress is 
a key mechanism underlying the aging process and the aging brain is more 
vulnerable to oxidative stress. N-3 PUFA can protect against the damaging effects 
of oxidative stress by reducing lipid peroxidation113. However, in high doses n-3 
PUFA can deplete antioxidant levels because they are easily oxidized. 
Plaques and tangles. The protein beta-amyloid is toxic to nerve cells and when 
levels become excessive, large areas of brain cells are destroyed, resulting in 
amyloid plaques. N-3 PUFA may directly limit AD pathology by reducing the 
production of β-amyloid, minimizing its aggregation into plaques, and increasing 
its clearance. N-3 PUFA may also reduce the accumulation of the protein tau, 
thereby inhibiting the formation of neurofibrillary tangles114. 
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There are several plausible mechanisms that support a role for EPA and/or 
DHA in cognitive performance and mental well-being. Some mechanisms 
may exert an effect in weeks or months, whereas other processes take 
years.
Scientific evidence
Numerous studies have addressed the potential benefits of n-3 PUFA in relation 
to cognitive impairment, dementia and depression. We will give an overview 
of observational and intervention studies (RCTs) that have been performed 
with dementia, cognitive decline or depression as outcome measures. Both 
kind of studies are complementary, not only because epidemiological studies 
cannot prove causation, while RCTs studies can, but also because longitudinal 
observational studies could provide insight into long-term underlying 
mechanisms, while the time window of RCTs matches more with short-term 
mechanisms.
Dementia and cognitive decline: observational evidence
Most of the evidence originates from a number of different epidemiological 
investigations (Table 1.1). The association of fish and EPA+DHA with cognitive 
decline and dementia has been examined in different populations, both cross-
sectionally93,94,115-120 and prospectively116-119,121-129. 
In five out of eight cross-sectional studies of cognitive performance or dementia 
in relation to intake of fish, dietary n-3 PUFA, or blood n-3 PUFA concentrations 
an inverse association was observed93,94,115,116. The other three studies showed no 
association117-119. In 12 out of 16 longitudinal population-based studies with 4 to 
20
IntroductionChapter 1
Ta
bl
e 
1.
1 
 O
bs
er
va
tio
na
l s
tu
di
es
 o
n 
th
e 
as
so
ci
at
io
n 
of
 fi
sh
 a
nd
 n
-3
 P
U
FA
 w
ith
 c
og
ni
tiv
e 
pe
rf
or
m
an
ce
 in
 o
ld
er
 a
du
lts
Au
th
or
, y
ea
r (
st
ud
y)
St
ud
y 
po
pu
la
tio
n 
(n
)
n-
3 
PU
FA
 a
ss
es
sm
en
t
Fi
nd
in
gs
*
Cr
os
s-
se
ct
io
na
l s
tu
di
es
D
ul
le
m
ei
je
r, 
20
07
 (F
AC
IT
)11
9
H
ea
lth
y 
el
de
rly
, 5
0-
70
y 
(n
=8
07
)
Pl
as
m
a 
n-
3 
PU
FA
 
pr
op
or
tio
ns
N
o 
as
so
ci
at
io
n 
be
tw
ee
n 
pl
as
m
a 
n-
3 
PU
FA
 p
ro
po
rt
io
ns
 a
nd
 
co
gn
iti
ve
 p
er
fo
rm
an
ce
va
n 
G
el
de
r, 
20
07
 (Z
ut
ph
en
 
st
ud
y)
11
7
El
de
rly
 m
en
, 7
0-
89
y 
(n
=2
10
)
Fi
sh
 a
nd
 E
PA
+D
H
A
 
in
ta
ke
, d
ie
ta
ry
 h
is
to
ry
 
m
et
ho
d
N
o 
di
ffe
re
nc
e 
in
 M
M
SE
 s
co
re
s 
be
tw
ee
n 
ca
te
go
rie
s 
of
 fi
sh
 
(>
20
g/
d:
 2
6.
5 
vs
 0
 g
/d
: 2
6.
4,
 P
=0
.8
1)
 o
r E
PA
+D
H
A
 in
ta
ke
 (Q
1:
 
26
.3
 v
s 
Q
3:
 2
6.
6,
 P
=0
.3
6)
N
ur
k,
 2
00
7 
(H
U
SK
 s
tu
dy
)12
0
G
en
er
al
 p
op
ul
at
io
n,
 7
0-
74
y 
(n
=2
,0
31
)
Fi
sh
 in
ta
ke
, F
FQ
D
ie
t h
ig
h 
in
 fi
sh
 a
nd
 fi
sh
 p
ro
du
ct
s 
as
so
ci
at
ed
 w
ith
 b
et
te
r 
co
gn
iti
ve
 p
er
fo
rm
an
ce
 o
n 
se
ve
ra
l c
og
ni
tiv
e 
te
st
s, 
as
so
ci
at
io
n 
do
se
-d
ep
en
de
nt
Ka
lm
ijn
, 2
00
4 
(D
oe
tin
ch
em
 
st
ud
y)
11
5
Co
gn
iti
ve
 im
pa
irm
en
t (
n=
16
3)
, n
o 
co
gn
iti
ve
 im
pa
irm
en
t (
n=
1,
45
0)
, 
45
-7
0y
Fi
sh
 a
nd
 n
-3
 P
U
FA
 in
ta
ke
, 
FF
Q
H
ig
he
r f
is
h 
an
d 
n-
3 
PU
FA
 in
ta
ke
s 
as
so
ci
at
ed
 w
ith
 lo
w
er
 ri
sk
 o
f 
ov
er
al
l c
og
ni
tiv
e 
im
pa
irm
en
t (
O
R=
0.
77
; 0
.6
0-
0.
97
) a
nd
 0
.8
1;
 
0.
66
-1
.0
0 
re
sp
ec
tiv
el
y)
 a
nd
 s
pe
ed
 (O
R=
0.
71
; 0
.5
5-
0.
92
 a
nd
 
0.
72
; 0
.5
7-
0.
90
 re
sp
ec
tiv
el
y)
La
ur
in
, 2
00
3 
(C
SH
A
)11
8
Se
le
ct
io
n 
of
 s
ub
je
ct
s 
w
ith
 c
lin
ic
al
 
ev
al
ua
tio
n,
 ≥
65
y;
 fo
llo
w
-u
p 
≅ 
5y
 
(n
=1
74
): 
co
gn
iti
ve
 im
pa
irm
en
t (
n=
43
), 
no
 c
og
ni
tiv
e 
im
pa
irm
en
t (
n=
79
), 
de
m
en
tia
 (n
=5
2)
Pl
as
m
a 
ph
os
ph
ol
ip
id
s
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 n
-3
 P
U
FA
 c
on
ce
nt
ra
tio
ns
Tu
lly
, 2
00
39
4
Iri
sh
 A
D
 p
at
ie
nt
s, 
co
m
m
un
ity
-b
as
ed
 
(n
=1
48
)
Se
ru
m
 c
ho
le
st
er
yl
 
EP
A
+D
H
A
A
D
 p
at
ie
nt
s 
ha
ve
 lo
w
er
 E
PA
 (P
<0
.0
5)
 a
nd
 D
H
A
 (P
<0
.0
01
) 
st
at
us
Co
nq
ue
r, 
20
00
93
77
-8
3y
, c
og
ni
tiv
e 
im
pa
irm
en
t (
n=
36
), 
no
 c
og
ni
tiv
e 
im
pa
irm
en
t (
n=
19
)
Pl
as
m
a 
n-
3 
PU
FA
 
ph
os
ph
ol
ip
id
s
Lo
w
er
 n
-3
 P
U
FA
 c
on
ce
nt
ra
tio
ns
 (P
<0
.0
5)
 in
 c
og
ni
tiv
el
y 
im
pa
ire
d 
gr
ou
ps
Ka
lm
ijn
, 1
99
7 
(Z
ut
ph
en
 
st
ud
y)
12
9
D
ut
ch
 p
op
ul
at
io
n,
 6
4-
89
y,
 c
og
ni
tiv
e 
im
pa
irm
en
t (
n=
15
3)
, n
o 
co
gn
iti
ve
 
im
pa
irm
en
t (
n=
32
3)
Fi
sh
 in
ta
ke
, d
ie
ta
ry
 
hi
st
or
y 
m
et
ho
d
H
ig
h 
fis
h 
co
ns
um
pt
io
n,
 in
ve
rs
el
y 
co
rr
el
at
ed
 w
ith
 p
re
va
le
nt
 
co
gn
iti
ve
 im
pa
irm
en
t (
O
R=
0.
63
; 0
.3
3-
1.
21
), 
n-
3 
PU
FA
 in
ta
ke
 
no
t
21
Chapter 1Introduction
Lo
ng
itu
di
na
l s
tu
di
es
D
ev
or
e,
 2
00
9 
(R
ot
te
rd
am
 
St
ud
y)
13
2
D
ut
ch
 p
op
ul
at
io
n,
 ≥
55
y,
 fo
llo
w
-u
p 
≈9
.6
y 
(n
=5
,3
95
)
Fi
sh
 a
nd
 n
-3
 P
U
FA
 in
ta
ke
, 
FF
Q
N
o 
as
so
ci
at
io
n 
be
tw
ee
n 
fis
h 
or
 n
-3
 P
U
FA
 in
ta
ke
 a
nd
 lo
ng
-
te
rm
 d
em
en
tia
 ri
sk
Kr
ög
er
, 2
00
9 
(C
SH
A
)13
1
G
en
er
al
 p
op
ul
at
io
n,
 ≥
65
y,
 fo
llo
w
-u
p 
≈4
.9
y 
(n
=6
63
)
Er
yt
hr
oc
yt
e 
m
em
br
an
e 
n-
3 
PU
FA
N
o 
as
so
ci
at
io
ns
 b
et
w
ee
n 
n-
3 
PU
FA
 a
nd
 d
em
en
tia
 o
r A
D
Be
yd
ou
n,
 2
00
7 
(A
RI
C)
12
7
Ad
ul
ts
 a
ge
d 
50
-6
5y
, f
ol
lo
w
-u
p 
6y
; c
og
ni
tiv
e 
de
cl
in
e 
(n
=1
40
), 
no
 
co
gn
iti
ve
 d
ec
lin
e 
(n
=2
,1
11
)
Pl
as
m
a 
n-
3 
PU
FA
 
ph
os
ph
ol
ip
id
s 
an
d 
ch
ol
es
te
ry
l e
st
er
s
H
ig
he
r n
-3
 P
U
FA
 p
la
sm
a 
ch
ol
es
te
ry
l e
st
er
 (O
R=
0.
74
; 0
.5
7-
0.
97
) 
an
d 
pl
as
m
a 
ph
os
ph
ol
ip
id
 c
on
ce
nt
ra
tio
ns
 (O
R=
0.
73
; 0
.5
8-
0.
93
) 
as
so
ci
at
ed
 w
ith
 lo
w
er
 ri
sk
 o
f d
ec
lin
e 
in
 v
er
ba
l f
lu
en
cy
D
ul
le
m
ei
je
r, 
20
07
 (F
AC
IT
)11
9
H
ea
lth
y 
el
de
rly
, 5
0-
70
y,
 fo
llo
w
-u
p 
3y
 
(n
=4
04
)
Pl
as
m
a 
n-
3 
PU
FA
 
pr
op
or
tio
ns
H
ig
he
r p
la
sm
a 
n-
3 
PU
FA
 p
ro
po
rt
io
ns
 a
ss
oc
ia
te
d 
w
ith
 le
ss
 
co
gn
iti
ve
 d
ec
lin
e 
in
 s
pe
ed
 re
la
te
d 
co
gn
iti
ve
 d
om
ai
ns
 (P
= 
0.
02
 
fo
r s
en
so
rim
ot
or
 s
pe
ed
 a
nd
 P
<0
.0
1 
fo
r c
om
pl
ex
 s
pe
ed
)
Va
n 
G
el
de
r, 
20
07
 (Z
ut
ph
en
 
st
ud
y)
11
7
El
de
rly
 m
en
, 7
0-
89
y,
 fo
llo
w
-u
p 
5y
 
(n
=2
10
)
Fi
sh
 a
nd
 E
PA
+D
H
A
 
in
ta
ke
, d
ie
ta
ry
 h
is
to
ry
 
m
et
ho
d
H
ig
he
r f
is
h 
in
ta
ke
 (>
20
g/
d:
 -0
.3
 v
s 
0 
g/
d:
 -1
.2
, P
=0
.0
1)
 a
nd
 n
-3
 
PU
FA
 in
ta
ke
 (Q
1:
 -0
.9
 v
s 
Q
3:
 0
.2
, P
-t
re
nd
=0
.0
1)
 a
ss
oc
ia
te
d 
w
ith
 
lo
w
er
 M
M
SE
 s
co
re
s 
Sc
ha
ef
er
, 2
00
6 
(F
ra
m
in
gh
am
 
H
ea
rt
 S
tu
dy
)12
6
U
S 
po
pu
la
tio
n,
 fo
llo
w
-u
p 
9.
1y
 
(n
=8
99
), 
99
 c
as
es
 o
f d
em
en
tia
Pl
as
m
a 
ph
op
ha
tid
yl
ch
ol
in
e 
(P
C)
Th
e 
to
p 
qu
ar
til
e 
of
 p
la
sm
a 
PC
 D
H
A
 w
as
 a
ss
oc
ia
te
d 
w
ith
 a
 
si
gn
ifi
ca
nt
 ri
sk
 re
du
ct
io
n 
of
 a
ll-
ca
us
e 
de
m
en
tia
 (R
R=
0.
53
; 
0.
29
-0
.9
7,
 P
=0
.0
4)
 a
nd
 A
D
 (R
R=
0.
61
; 0
.3
1-
1.
18
)
H
ua
ng
, 2
00
5 
(C
H
CS
)12
3
U
S 
po
pu
la
tio
n,
 ≥
65
y,
 fo
llo
w
-u
p 
5.
4y
 
(n
=2
,2
33
)
Fi
sh
 in
ta
ke
, F
FQ
Co
ns
um
pt
io
n 
of
 fa
tt
y 
fis
h 
w
as
 a
ss
oc
ia
te
d 
w
ith
 a
 re
du
ce
d 
ris
k 
of
 d
em
en
tia
 (H
R=
0.
72
; 0
.5
1-
1.
02
) a
nd
 A
D
 (H
R=
0.
59
; 0
.3
6-
0.
95
), 
bu
t o
nl
y 
in
 th
os
e 
w
ith
ou
t t
he
 A
PO
E-
ε4
 a
lle
le
 
M
or
ris
, 2
00
5 
(C
H
A
P)
13
0
U
S 
po
pu
la
tio
n,
 ≥
65
y,
 fo
llo
w
-u
p 
6y
 
(n
=3
,7
18
)
Fi
sh
 a
nd
 n
-3
 P
U
FA
 in
ta
ke
, 
FF
Q
Fi
sh
 in
ta
ke
 (1
 fi
sh
 m
ea
l/w
ee
k 
10
%
, P
=0
.0
3 
an
d 
13
%
, P
=0
.0
42
 
or
 m
or
e 
fis
h 
m
ea
ls
/w
ee
k)
, b
ut
 n
ot
 n
-3
 P
U
FA
 in
ta
ke
, w
as
 
as
so
ci
at
ed
 w
ith
 a
 s
lo
w
er
 ra
te
 o
f c
og
ni
tiv
e 
de
cl
in
e
La
ur
in
, 2
00
3 
(C
SH
A
)11
8
Se
le
ct
io
n 
of
 s
ub
je
ct
s 
w
ith
 c
lin
ic
al
 
ev
al
ua
tio
n,
 ≥
65
y;
 fo
llo
w
-u
p 
≅ 
5y
 
(n
=1
74
): 
co
gn
iti
ve
 im
pa
irm
en
t (
n=
43
), 
no
 c
og
ni
tiv
e 
im
pa
irm
en
t (
n=
79
), 
de
m
en
tia
 (n
=5
2)
Pl
as
m
a 
EP
A
+D
H
A
 
ph
os
ph
ol
ip
id
s
U
ne
xp
ec
te
dl
y,
 h
ig
he
r E
PA
 c
on
ce
nt
ra
tio
ns
 (3
1%
, P
<0
.0
1)
 in
 
co
gn
iti
ve
ly
 im
pa
ire
d 
gr
ou
p 
an
d 
hi
gh
er
 D
H
A
 c
on
ce
nt
ra
tio
ns
 
(3
0%
, P
=0
.0
7)
 in
 d
em
en
tia
 c
as
es
.
22
IntroductionChapter 1
Ab
br
ev
ia
tio
ns
: A
D
: A
lz
he
im
er
’s 
di
se
as
e;
 E
PA
: e
ic
os
ap
en
ta
en
oi
c 
ac
id
; D
H
A
: d
oc
os
ah
ex
ae
no
ic
 a
ci
d;
 M
M
SE
: M
in
i-M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n;
 Q
: q
ua
rt
ile
; F
FQ
: f
oo
d 
fr
eq
ue
nc
y 
qu
es
tio
nn
ai
re
St
ud
y 
ac
ro
ny
m
s: 
FA
CI
T:
 F
ol
ic
 A
ci
d 
an
d 
Ca
ro
tid
 In
tim
a-
m
ed
ia
 T
hi
ck
ne
ss
; H
U
SK
: H
or
da
la
nd
 H
ea
lth
 S
tu
dy
; C
SH
A
: C
an
ad
ia
n 
St
ud
y 
of
 H
ea
lth
 a
nd
 A
gi
ng
; A
RI
C:
 
A
th
er
os
cl
er
os
is
 R
is
k 
in
 C
om
m
un
iti
es
 S
tu
dy
; C
H
CS
: C
ar
di
ov
as
cu
la
r H
ea
lth
 C
og
ni
tio
n 
St
ud
y;
 C
H
A
P:
 C
hi
ca
go
 H
ea
lth
 a
nd
 A
gi
ng
 P
ro
je
ct
; E
VA
: E
tu
de
 d
u 
Vi
ei
lli
ss
em
en
t 
A
rt
er
ie
l; 
PA
Q
U
ID
: P
er
so
nn
es
 A
gé
es
 Q
U
ID
. 
* 
Sh
ow
n 
ar
e 
re
la
tiv
e 
ris
ks
 (R
R)
, h
az
ar
d 
ra
tio
s 
(H
R)
, o
dd
s 
ra
tio
s 
(O
R)
 o
r m
ea
n 
va
lu
es
 b
as
ed
 o
n 
th
e 
m
ul
tiv
ar
ia
te
 a
dj
us
te
d 
m
od
el
 (w
he
n 
ad
ju
st
ed
), 
al
on
g 
w
ith
 9
5%
 
co
nfi
de
nc
e 
in
te
rv
al
s 
or
 s
ta
nd
ar
d 
de
vi
at
io
ns
 b
et
w
ee
n 
pa
re
nt
he
se
s.
Au
th
or
, y
ea
r (
st
ud
y)
St
ud
y 
po
pu
la
tio
n 
(n
)
n-
3 
PU
FA
 a
ss
es
sm
en
t
Fi
nd
in
gs
*
H
eu
de
, 2
00
3 
(E
VA
 s
tu
dy
)12
5
Co
gn
iti
ve
 d
ec
lin
e 
(n
=2
7)
, n
o 
co
gn
iti
ve
 
de
cl
in
e 
(n
=2
19
), 
63
-7
4y
, f
ol
lo
w
-u
p 
4y
N
-3
 P
U
FA
 in
 e
ry
th
ro
cy
te
 
m
em
br
an
es
H
ig
he
r n
-3
 P
U
FA
 c
on
ce
nt
ra
tio
ns
 a
ss
oc
ia
te
d 
w
ith
 lo
w
er
 ri
sk
 o
f 
co
gn
iti
ve
 d
ec
lin
e 
(O
R=
0.
59
; 0
.3
8-
0.
93
)
M
or
ris
, 2
00
3 
(C
H
A
P)
12
2
El
de
rly
, ≥
65
y 
(n
=3
,7
18
), 
fo
llo
w
-u
p 
3.
9y
Fi
sh
 a
nd
 E
PA
+D
H
A
 
in
ta
ke
, F
FQ
Fi
sh
 in
ta
ke
 ≥
1/
w
ee
k 
(R
R=
0.
4;
 0
.2
-0
.9
, P
-t
re
nd
=0
.0
7)
, a
nd
 n
-3
 
PU
FA
 in
ta
ke
 (R
R 
Q
5=
0.
4;
 0
.1
-0
.9
, P
-t
re
nd
=0
.0
1)
 a
ss
oc
ia
te
d 
w
ith
 s
lo
w
er
 c
og
ni
tiv
e 
de
cl
in
e
Ba
rb
er
ge
r-
G
at
ea
u,
 2
00
2 
(P
AQ
U
ID
)12
1
Fr
en
ch
, c
om
m
un
ity
 d
w
el
lin
g 
po
pu
la
tio
n,
 ≥
68
y,
 fo
llo
w
-u
p 
7y
 
(n
=1
,4
16
)
Fi
sh
 in
ta
ke
, F
FQ
Fi
sh
 c
on
su
m
pt
io
n 
≥1
/w
ee
k 
ha
d 
a 
bo
rd
er
lin
e 
si
gn
ifi
ca
nt
 e
ffe
ct
 
on
 ri
sk
 o
f d
ev
el
op
in
g 
de
m
en
tia
 (H
R=
0.
73
; 0
.5
2-
1.
03
) o
r A
D
 
(H
R=
0.
69
; 0
.4
7-
1.
01
)
En
ge
lh
ar
t, 
20
02
 (R
ot
te
rd
am
 
st
ud
y)
12
8
D
ut
ch
 p
op
ul
at
io
n,
 fo
llo
w
-u
p 
6y
 
(n
=5
,3
95
)
N
-3
 P
U
FA
 in
ta
ke
, F
FQ
N
o 
as
so
ci
at
io
n 
(R
R=
1.
07
; 0
.9
4-
1.
22
) b
et
w
ee
n 
n-
3 
PU
FA
 in
ta
ke
 
an
d 
ris
k 
of
 d
em
en
tia
Ky
le
, 1
99
91
24
U
S 
po
pu
la
tio
n,
 m
ea
n 
ag
e 
75
y,
 fo
llo
w
-
up
 1
0y
 (n
=1
,1
88
)
Se
ru
m
 
ph
op
ha
tid
yl
ch
ol
in
e 
(P
C)
Lo
w
 le
ve
ls
 o
f P
C-
D
H
A
 a
ss
oc
ia
te
d 
w
ith
 h
ig
he
r r
is
k 
of
 A
D
 (6
7%
, 
P<
0.
05
)
Ka
lm
ijn
, 1
99
7 
(Z
ut
ph
en
 
st
ud
y)
12
9
Co
gn
iti
ve
 d
ec
lin
e 
(n
=5
1)
, n
o 
co
gn
iti
ve
 
de
cl
in
e 
(n
=2
91
), 
64
-8
9y
, f
ol
lo
w
-u
p 
3y
Fi
sh
 a
nd
 n
-3
 P
U
FA
 in
ta
ke
, 
di
et
ar
y 
hi
st
or
y 
m
et
ho
d
In
ta
ke
 o
f n
-3
 P
U
FA
 n
ot
 a
ss
oc
ia
te
d,
 b
ut
 h
ig
h 
fis
h 
in
ta
ke
 
as
so
ci
at
ed
 w
ith
 c
og
ni
tiv
e 
de
cl
in
e 
(O
R=
0.
45
; 0
.1
7-
1.
16
)
Ka
lm
ijn
, 1
99
7 
(R
ot
te
rd
am
 
st
ud
y)
11
6
N
on
-d
em
en
te
d 
pa
rt
ic
ip
an
ts
, ≥
55
y,
 
fo
llo
w
-u
p 
2.
1y
 (n
=5
,3
86
)
Fi
sh
 in
ta
ke
, F
FQ
Fi
sh
 in
ta
ke
 w
as
 in
ve
rs
el
y 
re
la
te
d 
to
 in
ci
de
nt
 d
em
en
tia
 
(R
R=
0.
4;
 0
.2
-0
.9
) a
nd
 A
D
 (R
R=
0.
3;
 0
.1
-0
.9
)
Ta
bl
e 
1.
1 
 C
on
tin
ue
d
23
10 years of follow-up, a higher fish or n-3 PUFA intake or status was associated 
with less cognitive decline or a lower risk of dementia116,117,119,121-127,129,130. One 
study in 174 subjects could not demonstrate a relation between baseline plasma 
n-3 PUFA and cognitive impairment or dementia after ≈5 years of follow-up118. 
A second analysis in a larger sample (n=663) of the same study population also 
showed no association131. Another study that was considerably larger (n=5,395), 
did show an association of fish intake with incident dementia116, but the relation 
was no longer present after 6 and ≈10 years of follow-up128,132. The authors 
ascribed this discrepancy to the small number of incident dementia cases in the 
first phase, making it more prone to bias.
All together, the results of cross-sectional studies lack consistency while longitudinal 
studies mostly show an inverse association. More longitudinal studies focusing on 
specific cognitive domains such as memory, speed, and attention, are needed.
Dementia and cognitive decline: trial evidence
RCTs of fish or EPA+DHA and cognition are limited (Table 1.2). Two trials were 
performed in elderly patients with dementia133,134. Though both trials observed 
a beneficial effect of n-3 PUFA supplementation on general cognitive outcomes 
they add little weight to the evidence, because the first trial was small in sample 
size (n=20) and the second trial was of short duration (4 weeks). In a 6-month 
trial in 174 subjects with mild to moderate AD no overall effect of n-3 PUFA 
on global cognitive performance was found, except in a small subgroup (n=32) 
of patients with only mild cognitive impairment135. Trials in subjects without 
cognitive impairment are lacking. 
Depression: observational evidence
We identified 22 observational studies in non-clinical adult populations on 
the association between fish or EPA+DHA and depression, of which only one 
had a prospective design (Table 1.3). Most studies (n=17) showed an inverse 
association of fish or n-3 PUFA intake136-152 with depression, whereas four 
studies did not show an association153-156. In some studies associations were 
only observed in women138,139,141. Gender differences have been attributed to 
the fact that the endogenous n-3 fatty acid status is higher in women141 and the 
uptake of DHA is enhanced due to estrogens157. However, sex-specific findings 
are not completely consistent and do not fully explain a lack of associations in 
(predominantly) male populations. In 11 studies the intake of fish fatty acids 
was assessed by food frequency questionnaire or other dietary methods, in 
nine studies blood n-3 PUFA concentrations were measured and in two studies 
n-3 PUFA were assessed in adipose tissue. Fish intake was inversely related to 
depression in six studies136-139,143,147. Of five other studies focusing on n-3 PUFA 
intake140,141,153-155, two studies did not find an association153,154. All studies using 
n-3 PUFA concentrations in the blood145,148-151 or in adipose tissue142,146 found 
higher concentrations to be associated with less depression, except one156. It 
should be noted, however, that most studies that used biomarkers were small 
(n=20 to n=192), except the study by Tiemeier et al. (n=3,884)145. 
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Chapter 1Introduction
To the best of our knowledge, there is only one prospective study of fish and 
n-3 PUFA intake and incident depression. This study in a population of 7,903 
university graduates with a mean age 41 years suggested a potential benefit of 
moderate n-3 PUFA intake after 2 years of follow-up158. A major limitation in 
this study was that data on depression were obtained by self-report.
Five studies of n-3 PUFA concentrations and depression have been performed 
in coronary heart disease patients and all found depression to be related to 
lower plasma or erythrocyte n-3 PUFA levels, in particular DHA159-163 (studies 
not included in Table 1.3). Depressed subjects had 13 to 25% lower DHA 
levels and 12 to 20% lower total n-3 PUFA levels compared with non-depressed 
subjects. 
Depression: trial evidence
An overview of trials (n=12) in healthy adults and adults with depressive disorders 
is shown in Table 1.4. Trials in patients with other diseases than depression 
and in children or postpartum mothers were beyond the scope of our research 
and therefore not included. We identified one randomized trial on n-3 PUFA 
and depressed mood in a non-depressed population. Thirty-three subjects with 
a mean age of 33 years experienced an improvement in mood during daily 
supplementation with 1.6 g EPA and 0.8 g DHA for 35 days164. Recently, Rogers 
et al. performed a trial in a general population with mild to moderate depression 
and did not observe an effect after three months of daily supplementation with 
1.5 g EPA+DHA165.
Of 10 studies in clinical populations, five found a beneficial effect166-170, and 
five did not find an effect of EPA+DHA supplementation171-175. Most participants 
had a diagnosis of unipolar or major depression. Trials were heterogeneous with 
respect to sample size (n=20 to 280) and duration (28 to 120 days) and EPA+DHA 
treatment was often provided as an adjunctive therapy to pharmacological 
treatment. The daily dose of supplementation ranged from 1.0 to 9.6 g n-3 PUFA 
and comprised EPA only, DHA only or the combination. 
In 2006 Appleton et al. performed a meta-analysis of 12 studies, some of which 
were not included in our overview because of different inclusion criteria. They 
concluded that the available evidence provided little support for the use of n-3 
PUFA to improve depressed mood, although the interpretation was hampered by 
the large heterogeneity of trials176. Effects were mainly observed in populations 
with depressive disorders, but it should be noted that there were only two trials 
in non-depressed populations of older people. 
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Rationale and outline of this thesis
This thesis addresses two primary research questions: 
1) Is there a role for fish or EPA+DHA intake in the prevention of cognitive 
decline?
2) Is there a role for fish or EPA+DHA intake in the maintenance of mental 
well-being?
To answer these research questions we performed several studies, which are 
briefly described below.
Evidence from trials focusing on cognitive performance is limited and intervention 
studies on the effect of EPA+DHA on cognitive performance in non-demented 
older people are lacking. Trials with sufficient power are needed to ascertain 
whether treatment with EPA+DHA offers significant benefits to cognitive 
performance and mental well-being in older individuals. We performed a 
double-blind, placebo-controlled trial in 302 independently living individuals 
aged 65 years or older to study the effects on cognitive performance of a low 
daily dose of EPA+DHA (400 mg) or a high daily dose of EPA+DHA (1,800 
mg) for 26 weeks (chapter 2). The high ‘pharmacological’ dose was chosen to 
maximize contrast between the groups and the low dose to comply with the 
recommended daily intake in the Netherlands of 450 mg EPA+DHA. With a 
study duration of 26 weeks we were only able to examine relatively short-term 
effects of EPA+DHA on cognitive performance. 
Evidence from cross-sectional and prospective studies suggests that an increased 
intake of fish and n-3 PUFA could protect against age-related cognitive 
decline and dementia. However, the results are inconsistent and studies that 
address changes in specific cognitive domains are limited. We investigated 
the association of fish and n-3 PUFA intake with cognitive performance and 
cognitive decline by a prospective epidemiological study in 1,025 older US 
men. We were able to assess cognitive decline during 6 years of follow-up, 
thereby focusing on relatively long-term effects of fish and n-3 PUFA intake on 
cognitive performance. Also, we related fish consumption to different domains 
of cognitive functioning, to examine differential effects of n-3 PUFA or other 
components in fish in specific parts of the brain (chapter 3).
Trials of EPA+DHA supplementation and depression have mainly been performed 
in populations of depressed patients and results are ambiguous. There is an 
obvious need for trials in non-depressed older populations. In a double-blind, 
placebo-controlled trial we examined the effect of supplementation with 400 
mg or 1,800 mg of EPA+DHA per day for 26 weeks on mental well-being in 
older individuals. In chapter 4 we describe the effect of EPA+DHA on mental 
well-being, as assessed by several depression rating scales and in chapter 5 we 
evaluate the reliability of the depression rating scales that we used, with a focus 
on the utility of these questionnaires in the general population.
Observational studies on fish and n-3 PUFA intake and mental well-being have 
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mainly been performed in the general population with a relatively low prevalence 
of mental disturbances. We performed a cross-sectional analysis of fish and 
EPA+DHA intake and mental well-being in a population of older subjects with 
a history of myocardial infarction that had a higher prevalence of depressive 
symptoms than the general population (chapter 6).
In chapter 7 we report the effect of daily supplementation with 400 mg or 
1,800 mg of EPA+DHA for 26 weeks on QOL. Improving QOL is becoming 
an increasingly important outcome in elderly research. For studies in health 
promotion, such generic outcomes may be considered more relevant than 
disorder-specific outcomes.
Furthermore, we investigated early process markers of mental deterioration by 
examining the effect of low- and high-dose supplementation with EPA+DHA on 
gene expression profiles in human blood mononuclear cells (chapter 8).
In the general discussion (chapter 9) the main findings of our studies are 
summarized, and a reflection on methodological issues is given. Also, directions 
for future research and implications for public health are addressed.
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Abstract
Background High intake of n-3 polyunsaturated fatty acids may protect against 
age-related cognitive decline. However, results from epidemiological studies 
are inconclusive and results from randomized trials in non-demented elderly 
are lacking.
Objective To investigate the effect of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) supplementation on cognitive performance.
Methods Double-blind, placebo-controlled trial involving 302 cognitively 
healthy (Mini-Mental State Examination score >21) individuals aged 65 years 
or older. Participants were randomly assigned to 1,800 mg/d EPA+DHA, 400 
mg/d EPA+DHA, or placebo capsules for 26 weeks. Cognitive performance was 
assessed using an extensive neuropsychological test battery that included the 
cognitive domains of attention, sensorimotor speed, memory, and executive 
function.
Results The mean age of the participants was 70 years, and 55% were male. 
Plasma concentrations of EPA+DHA increased by 238% in the high-dose and 
51% in the low-dose fish oil group compared with placebo, reflecting excellent 
compliance. Baseline scores on the cognitive tests were comparable in the 
three groups. Overall, there were no significant differential changes in any of 
the cognitive domains for either low-dose or high-dose fish oil supplementation 
compared with placebo.
Conclusions In this randomized, double-blind, placebo-controlled trial, 
we observed no overall effect of 26 weeks of eicosapentaenoic acid and 
docosaheaenoic acid supplementation on cognitive performance.
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Introduction
Age-related cognitive impairment is considered a strong risk factor for the 
development of dementia1. It is estimated that 24 million people worldwide 
have dementia, and as the population of elderly people is growing rapidly, this 
number is expected to double every 20 years2. Because no effective curative 
approaches are available yet, it is of major importance to develop and study 
preventive measures.
Increased intake of fish and n-3 polyunsaturated fatty acids (PUFAs), particularly 
eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, 
C22:6n-3), might play a protective role against age-related cognitive decline. 
DHA is the predominant n-3 fatty acid in the brain and is an integral component 
of neural membrane phospholipids3. Both DHA and EPA may reduce oxidative 
stress, have an anti-inflammatory action and have been linked with aspects of 
neuron function, including neurotransmission, membrane fluidity, ion channel 
and enzyme regulation, and gene expression4.
In a number of cross-sectional studies, cognitive performance was examined in 
relation to dietary intake data of n-3 PUFAs and fish5-7 or n-3 PUFA concentrations 
in the blood8,9. Results from these studies were inconsistent, showing either 
that a high intake of n-3 PUFAs was associated with less cognitive decline6,8 
or no associations5,7,9. Longitudinal studies of fish or n-3 PUFA intake and 
cognitive performance also yielded contradictory results. In some studies high 
fish or n-3 PUFAs consumption was protective against cognitive decline7,10-13, 
whereas no association was found in other studies6,14. Most studies of n-3 PUFA 
concentrations in the blood showed high concentrations to be associated with 
a lower risk of cognitive decline15-17.
A very small number of randomized trials with cognitive endpoints have been 
performed in elderly patients with established dementia18,19. These studies were 
limited because they were small in sample size (n=20 and n=100 respectively), 
were of short duration (1 year and 4 weeks respectively), or assessed cognitive 
performance using generalized tests. A trial conducted in subjects with mild 
to moderate Alzheimer’s Disease (AD) included more subjects (n=174) and 
the duration was 6 months. In this trial, no effect of n-3 PUFAs on cognitive 
performance was found. However, a reduction in cognitive decline rate was 
observed in a small subgroup of dementia patients with the mildest cognitive 
impairment20. Therefore, n-3 PUFAs might be beneficial in primary prevention 
of cognitive decline. We conducted a double-blind, randomized, placebo-
controlled trial to investigate the effect of daily supplementation with high 
or low doses of EPA+DHA for 26 weeks on cognitive performance in older 
individuals.
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Methods
Participants
Subjects aged >65 years were mainly recruited through an existing database of 
volunteers with interest in participating in studies at Wageningen University. Main 
exclusion criteria were: [1] a score of >16 on the Centre for Epidemiologic Studies 
Depression Scale (CES-D )21; [2] score of <21 on Mini-Mental State Examination 
(MMSE)22; [3] current or recent (<4 weeks) use of fish oil supplements; [4] intake 
of more than 800 mg of EPA+DHA from fish per day, as estimated from a fish 
consumption questionnaire; [5] current use of pharmacologic antidepressants 
or medication for dementia; or [6] use of more than four glasses of alcohol per 
day. Additionally, self-reported compliance during the 2-week placebo run-in 
period had to be >80%. The Wageningen University Medical Ethical Committee 
approved the study, and subjects gave written informed consent.
Study design
An independent person randomized subjects by means of computer-generated 
random numbers in stratified permuted blocks of six. Stratification factors 
included age (< and ≥69 years), gender, MMSE score (< and ≥28) and CES-D 
screening test score (< and ≥5). Individuals were randomly allocated to receive 
a daily dose of fish oil containing either approximately 400 mg or approximately 
1,800 mg EPA+DHA, or a placebo oil (high oleic sunflower oil) for 26 weeks 
(Lipid Nutrition, Wormerveer, the Netherlands). The high daily dose of fish oil 
provided 1,093 ± 17 mg EPA and 847 ± 23 mg DHA, and the low daily dose 
provided 226 ± 3 mg EPA and 176 ± 4 mg DHA: the mean EPA+DHA ± SD 
determined of 20 samples taken at regular times during the study. The placebo 
capsules contained mainly oleic acid (C18:1n-9). The oils were administered 
in soft gelatin capsules each containing 900 mg oil and 2.7 mg tocopherol as 
antioxidant (Banner Pharmacaps, Tilburg, the Netherlands). Capsules were 
packaged in foil strips containing the daily dose of six capsules per strip to 
facilitate compliance and recording of capsule use (Medipack, Gorredijk, the 
Netherlands). Capsules with fish oil or placebo oil were indistinguishable in 
appearance. Staff members and participants were blinded toward treatment 
allocation until completion of blind data analysis. At baseline and at 13 weeks, 
participants received a 14-week supply of capsules (1 week extra as reserve). 
Compliance was judged by capsule-return counts and a diary in which 
participants registered missed capsules.
Sample size calculation was based on the Word Learning Test, where a difference 
of four points was considered clinically relevant. With a mean ± SD of 45 ± 823, 
a minimum sample size of 63 subjects per group would be required to detect 
a difference (power 80%, two-sided α=0.05). We were able to include 100 
subjects per treatment group which allowed subgroup analysis and anticipated 
drop-out.
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Cognitive performance
Cognitive testing was performed at baseline and after 13 and 26 weeks 
of intervention by well-trained research assistants, under supervision of a 
neuropsychologist. An extensive cognitive test battery was used consisting of 
five tests that have no ceiling effects and are reported to be sensitive and robust 
in detecting small cognitive differences24. The Word Learning test measures the 
storage and retrieval of newly acquired verbal material25. The forward test of the 
Wechsler Digit Span task measures attention and the backward test measures 
working memory26. The Trail Making test version A measures sensomotoric speed 
and version B measures concept shifting interference (executive function)27. 
The Stroop Color-Word test measures selective attention and susceptibility to 
behavioral interference28. The Verbal Fluency test measures the ability to draw 
on one’s encyclopedic memory in a strategy-based manner (executive, verbal 
reasoning)29. Participants were tested by the same research assistant in 69% 
of the cases at 13 weeks and 56% of the cases at 26 weeks and underwent 
measurements on the same day of the week and at the same time the morning, 
after a standardized small snack at the research centre. Coffee and tea were not 
allowed before and during testing. A standard protocol was used, and all tests 
were performed in the same quiet room, without any obvious distracters.
Blood
Fasting venous blood samples were collected at baseline and after 13 and 26 
weeks of intervention. A blood sample for determination of n-3 PUFAs was 
collected into 10-ml ethylenediaminetetraacetic acid (EDTA) Vacutainers, 
immediately placed in ice water, centrifuged at 2,000 g at a temperature of 4°C, 
and stored at –80°C until laboratory analyses. n-3 PUFAs in plasma cholesteryl 
esters were determined as described previously30. A second blood sample was 
collected into a 4.5-ml EDTA Vacutainer and stored at –80°C for APOE genotype 
determination by the PCR-based restriction fragment length polymorphism 
method and restriction enzyme digestion with HhaI31.
Other measurements
Information on medical history, drug use, alcohol consumption, smoking habits, 
educational level and marital status was obtained by questionnaire. Education 
was categorized according to Statistics Netherlands (CBS). Physical activity level 
was estimated by means of a previously described questionnaire32.
Fish intake in the previous 3 months was estimated with a food frequency 
questionnaire. Participants had to indicate on a 60-item list which kinds of fish 
they had consumed and how often. These 60 items were categorized into three 
groups based on the amount of fat in the different types of fish, i.e. lean, medium-
fat, and fatty fish. Furthermore, information was obtained on how the fish was 
consumed: as main meal component during dinner, as a snack, or on toast or with 
a bread meal. EPA+DHA intake was calculated by multiplying the frequencies of 
portions of fish per month per group by an EPA+DHA conversion factor33. 
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Body height was measured at baseline with a wall-mounted stadiometer to the 
nearest 0.1 cm. Body weight and waist circumference were measured at each 
center visit in a standing position, with participants dressed in light clothing 
and without shoes. Body weight was measured to the nearest 0.1 kg with a 
calibrated digital scale. Waist circumference was measured in duplicate to the 
nearest 0.1 cm at the midpoint between the lowest rib and the top of the iliac 
crest with a nonelastic tape.
Statistical analysis
Data analysis was performed by intention to treat and according to a predefined 
data analysis plan using SPSS 12.0.1. A two-sided P-value <0.05 was considered 
significant. Baseline characteristics of treatment groups were compared by 
analysis of variance (ANOVA) or Kruskal-Wallis for continuous variables and 
chi-square for categorical variables. 
Crude cognitive test scores at baseline and after 26 weeks (or 13 weeks) were 
pooled to calculate the grand mean and SD per test. To compare the results of 
the individual cognitive tests and to limit the number of dependent variables, 
individual neuropsychological tests were clustered into compound Z scores for 
four primary composite endpoints on neuropsychological domains: 
Sensorimotor speed =
Memory = 
Executive function =
Attention = 
 
To test differential changes among the three intervention groups after 13 and 
after 26 weeks, ANOVA was used with the treatment group as factor and scores 
on the different cognitive domains as dependent variables. A Dunnett post hoc 
test was conducted to compare mean changes in the two treatment groups with 
changes in the control group. 
After performing the primary analysis, an additional per-protocol analysis was 
performed, as were preplanned subgroup analyses for gender and for (non)
carriers of the APOE-ε4 allele.
Effect of fish oil on cognitive performanceChapter 2
 
 
   
           
part B - part A part 1  part 2 WordFluency-animals WordFluency-letter
Trail Making Stroop-part 3 - 
part A 2
Z Z Z Z
4
          Trail Making-part A Stroop-part 1 Stroop-part 2Z Z Z
3
   15WordLearning-immediate 15WordLearning-delayed 15WordLearning-recognition DigitSpan-backwardZ Z Z Z
4
 DigitSpan-forwardZ
49
Chapter 2Effect of fish oil on cognitive performance
Figure 2.1  Flow of participants through study
 528 invited 
377 assessed for eligibility 
351 screened 
325 run-in period 
E x c lu d e d  (n =2 6 ) 
• Planning difficulties (n =2) 
• Use of n-3 capsules (n =1) 
• Disease (n =6) 
• Disease of spouse (n =1) 
• Second thoughts (n =16) 
E x c lu d e d  (n =2 6 ) 
• MMSE score <21 (n =1) 
• CES-D score >16 (n =13) 
• Habitual EPA+DHA intake >800 
mg/day (n =12) 
W it h d re w  (n =2 3 ) 
• Side effects capsules (n =2) 
• Difficulties with swallowing 
capsules (n =5) 
• Life threatening disease (n =1) 
• Surgery (n =2) 
• Personal problems (n =3) 
• Second thoughts (n =10) 
100 assigned  
EPA+DHA 400 mg 
96 assigned  
EPA+DHA 1,800 mg 
106 assigned placebo 
W e e k  1 3 : 
Analyzed: n =105 
Excluded: n =1  
(discontinued 
intervention) 
W e e k  2 6 : 
Analyzed: n =103 
Excluded: n =3  
(2 deceased, 1 
discontinued 
intervention) 
W e e k  1 3 : 
Analyzed: n =100 
Excluded: none 
W e e k  2 6 :  
Analyzed: n =100 
Excluded: none 
W e e k  1 3 : 
Analyzed: n =95 
Excluded: n =1 
(discontinued 
intervention)  
W e e k  2 6 : 
Analyzed: n =96 
Excluded: none 
302 randomized 
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Results
Subjects were screened between November 2005 and February 2006, and 
intervention took place between February and November 2006. Figure 2.1 
shows the participant flow through the study. Nine subjects discontinued the 
use of capsules: five discontinued use because of gastrointestinal complaints, 
two discontinued use because participation became too burdensome, and two 
died before the end of the intervention. 
Apart from the individuals who stopped treatment prematurely, the average 
adherence to treatments based on counts of returned capsules was high (99%, 
with only three subjects <80%) and did not differ among the treatment groups. 
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Table 2.1  Characteristics of 302 subjects participating in a randomized, placebo-controlled 
trial, by treatment group
a Mean ± SD (all such values)
b Mean consumption in consumers only
c Median (Q1-Q3) (all such values)
d Significant difference among the three treatment groups (one-way ANOVA/ Kruskal Wallis for continuous 
variables and chi-square analysis for categorical variables)
e Missing value for one participant
1,800 mg EPA+DHA
(n=96)
400 mg EPA+DHA
(n=100)
Placebo
(n=106)
Age (years) 69.9 ± 3.4a 69.5 ± 3.2 70.1 ± 3.7
Sex, Male (%) 55 55 56
Married/ living together (%) 80 81 77
Education Low/ Middle/ High (%) 10/ 54/ 35 11/ 49/ 40 5/ 59/ 37
BMI (kg/m2) 26.1 ± 3.0 26.2 ± 3.4 26.5 ± 3.9
Waist circumference (cm) 94.5 ± 11.4 94.2 ± 10.6 95.9 ± 12.1
Physical activity score 11.5 ± 6.4 11.1 ± 6.2 11.4 ± 6.2
Smoking behavior (%)
Smoker 8 8 10
Ex-smoker 64 54 56
Never smokers 28 38 34
Alcohol consumers (%) 80 87 88
Median alcohol consumption (glasses/ 
week)b
10 (6-14)c 8 (4-14) 8 (4-14)
Coffee consumers (%) 96 96 97
Median coffee consumption (cups/day)b,d 4 (3-5) 3 (3-4) 4 (3-4)
Fish consumption (times/ month) 7 (4-9) 5 (3-9) 6 (4-8)
EPA+DHA intake (mg/day) 306 (131-592) 278 (103-487) 316 (166-584)
Plasma EPA+DHA (mass%) 1.9 ± 0.9 1.9 ± 1.1 1.9 ± 1.1
APOE-ε4 allele 0/ 1/ 2 (%) 68/ 29/ 3 69/ 30/ 1 71/ 26/ 2e
MMSE (Mini-Mental State Examination) score 28 (27-29) 28 (27-29) 28 (27-29)
Range 23-30 24-30 23-30
Self-perceived memory impairment (%)d 53 50 68
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Compliance was confirmed by a change in the proportion of EPA+DHA in plasma 
cholesteryl esters of +51% in the low-dose fish oil group (from 1.88 ± 1.12 to 2.83 
± 1.03 g/100g fatty acids), +236% in the high-dose fish oil group (from 1.90 ± 
0.86 to 6.40 ± 1.53 g/100g fatty acids) and -2% in the placebo group (from 1.91 
± 1.15 to 1.87 ± 1.11 g/100g fatty acids). The supplements were well tolerated; 
main complaints concerned mild gastrointestinal discomfort. Adverse events were 
reported by 14% of the subjects in the high-dose fish oil group (gastrointestinal 
problems [n=10], poly-urination, restless and weight gain); 13% of the subjects in 
the low-dose fish oil group (gastrointestinal problems [n=9], feeling lifeless, blurred 
vision, sore throat and muscle pain) and 15% of the subjects in the placebo group 
(gastrointestinal problems [n=12], skin irritations, blurred vision, TIA and muscle 
pain). At the end of the study, blinding of subjects toward treatment allocation 
(fish oil, placebo or no idea) was evaluated. The proportion of participants who 
thought they had received fish oil or placebo did not differ among the groups. 
At baseline, treatment groups were equally distributed with regard to demographic, 
anthropometric and lifestyle factors (Table 2.1). Baseline scores on the cognitive 
tests were comparable among the three groups. In general, cognitive test scores 
in all three groups improved, but changes were not significantly different among 
the groups and were probably mostly due to learning effects because scores in 
the placebo group increased to the same extent (Table 2.2).
Mean baseline scores of all cognitive domains did not differ among the treatment 
groups. After 13 weeks, there was a decline in the domain of memory in the 
group supplemented with 400 mg EPA+DHA compared with the placebo group 
(P=0.03; difference in Z scores –0.18 [95% CI –0.34 to 0.01]). However, after 
26 weeks, this difference was no longer observed. After 13 and 26 weeks of 
supplementation, there were no significant differential changes for fish oil vs 
placebo in any of the other cognitive function domains (Table 2.3).
However, an interaction effect between treatment and APOE genotype on the 
cognitive domain of attention was observed, i.e., APOE-ε4 carriers in the low-
dose fish oil group (n=31; P=0.03; 0.47 [95%CI 0.03-0.91]) and in the high-dose 
fish oil group (n=31; P=0.04; 0.49 [0.01-0.96]) showed an improvement after 
26 weeks of intervention compared with placebo. An interaction effect was also 
demonstrated between treatment and sex on the cognitive domain of attention; 
i.e., an improvement in men (n=167; P=0.05; 0.36 [0.01-0.72]) after 26 weeks 
of intervention for the low-dose fish oil group compared with placebo.
Discussion
In this randomized, controlled trial in elderly people, daily supplementation with 
EPA+DHA had no overall effect on any of the domains of cognitive function. 
However, we cannot exclude the possibility of a favorable effect of EPA+DHA 
on the cognitive domain of attention in subjects carrying the APOE-ε4 allele 
and in male subjects.
We examined cognitive performance in the present study by means of sensitive 
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Table 2.2  Crude scores from neuropsychological tests of cognitive function in older Dutch 
adults at baseline and after 13 and 26 weeks of EPA+DHA supplementation, by treatment 
groupa
a Values are mean ± SD. No significant differences among the three treatment groups were observed for any of 
the neuropsychological tests (ANOVA)
b For treatment group 1; n=96 at baseline (n=94 for TMT part B and TMT interference), n=95 after 13 weeks and 
n=96 after 26 weeks.
c For treatment group 2; n=100 at baseline, after 13 and after 26 weeks.
d For treatment group 3; n=106 at baseline (n=105 for 15 WLT-Recognition and Stroop part 1 and n=104 for 
Stroop part 2, Stroop part 3 and Stroop interference), n=105 after 13 weeks and n=103 after 26 weeks.
e Higher scores indicate more time needed to complete a task, i.e. poorer performance.
f Higher scores indicate poorer interference abilities.
Test, maximum score 1,800 mg 
EPA+DHAb
400 mg 
EPA+DHAc
Placebod
Sensorimotor Speede
Trail Making, part A, seconds to complete the task Baseline 47.4 ± 16.3 48.3 ± 14.1 46.9 ± 16.8
13 weeks 44.9 ± 16.0 44.7 ± 14.2 43.2 ± 14.2
26 weeks 43.4 ± 15.1 42.3 ± 14.0 40.9 ± 16.2
Stroop part 1, seconds to complete the task Baseline 51.5 ± 9.2 50.0 ± 7.7 50.9 ± 8.0
13 weeks 50.8 ± 8.3 49.9 ± 7.7 49.5 ± 7.6
26 weeks 50.3 ± 8.5 49.6 ± 7.3 49.7 ± 7.9
Stroop part 2, seconds to complete the task Baseline 66.0 ± 12.0 63.6 ± 9.6 64.5 ± 11.5
13 weeks 64.0 ± 11.0 62.7 ± 9.5 62.8 ± 11.2
26 weeks 63.7 ± 10.9 61.6 ± 9.5 62.4 ± 10.8
Executive Function
Trail Making Test (Part B-Part A/Part A)f Baseline 0.73 ± 0.62 0.60 ± 0.53 0.65 ± 0.56
13 weeks 0.76 ± 0.60 0.58 ± 0.48 0.59 ± 0.64
26 weeks 0.73 ± 0.62 0.62 ± 0.46 0.66 ± 0.51
Stroop (Part 3 – [Part 1 + Part 2/2])f Baseline 50.8 ± 21.1 53.9 ± 24.4 51.9 ± 21.9
13 weeks 48.0 ± 19.8 47.4 ± 16.9 49.8 ± 21.4
26 weeks 47.1 ± 25.0 45.8 ± 15.7 45.8 ± 17.7
Word Fluency – Animals, number of words Baseline 23.9 ± 6.0 23.3 ± 6.0 23.2 ± 6.0
26 weeks 24.2 ± 5.7 23.6 ± 5.8 24.0 ± 5.8
Word Fluency – Letter P, number of words Baseline 15.7 ± 5.6 16.5 ± 5.4 16.0 ± 5.5
26 weeks 16.4 ± 5.8 15.9 ± 4.7 16.4 ± 5.5
Memory
15 Word Learning – Immediate recall, 75 words Baseline 39.3 ± 8.8 40.8 ± 8.6 39.6 ± 9.7
13 weeks 43.2 ± 8.8 43.2 ± 9.3 43.7 ± 9.4
26 weeks 44.9 ± 9.9 46.1 ± 10.1 44.8 ± 9.4
15 Word Learning – Delayed Recall, 15 words Baseline 7.6 ± 3.1 8.1 ± 2.9 7.9 ± 3.1
13 weeks 8.4 ± 3.0 8.5 ± 2.8 8.9 ± 3.1
26 weeks 9.1 ± 3.2 9.2 ± 3.0 9.0 ± 3.2
15 Word Learning – Recognition, 30 words Baseline 28.3 ± 2.4 28.7 ± 1.4 28.7 ± 1.8
13 weeks 28.4 ± 1.8 28.6 ± 1.4 28.8 ± 1.6
26 weeks 28.4 ± 2.1 28.7 ± 1.5 28.6 ± 1.7
Digit Span Backward, 14 points Baseline 5.6 ± 1.8 5.9 ± 2.0 5.9 ± 1.8
13 weeks 6.0 ± 2.0 6.0 ± 1.8 6.3 ± 2.1
26 weeks 5.8 ± 1.8 6.2 ± 1.9 6.4 ± 1.9
Attention
Digit Span Forward, 16 points Baseline 8.2 ± 2.0 8.4 ± 1.9 8.5 ± 1.9
13 weeks 8.4 ± 2.1 8.4 ± 1.8 8.5 ± 2.0
26 weeks 8.6 ± 2.0 8.6 ± 1.8 8.5 ± 2.0
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tests that were reported to decline with age24. Parallel versions of these tests were 
used to minimize learning effects. Despite these parallel versions, improvements 
in test scores were seen in all treatment groups, indicating that learning effects 
did occur. This emphasizes the necessity of the placebo group with which to 
compare all measurements with during intervention.
We improved the robustness of the underlying cognitive constructs by clustering 
crude test scores for several tests in compound performance measures, namely 
cognitive domains that are sensitive to aging24. This procedure decreased 
variation associated with the individual tests and aggregated our cognitive 
performance measures to four a priori defined outcomes. Furthermore, cognitive 
function tests were performed under standardized conditions that reduced 
variation due to factors such as caffeine, various types of breakfasts34, and the 
influence of the research assistant and test room.
Because fish intake seems to be low in Dutch elderly35, it was likely that many 
of our subjects had a suboptimal EPA+DHA status, which was also reflected in 
low plasma levels of EPA+DHA that were comparable to other general elderly 
populations17,36. Plasma cholesteryl esters are generally considered to adequately 
reflect intake of dietary fatty acids during the prior weeks37. The Spearman 
correlation between baseline EPA+DHA intake from the FFQ and baseline 
EPA+DHA plasma concentrations was 0.57 (P<0.01), which is adequate. 
We selected subjects who were cognitively still intact, as indicated by MMSE 
scores above 23. It is suggested that in subjects who already have cognitive 
impairment or dementia it might be too late for dietary supplementation to 
counteract the process of cognitive decline. Conversely, cognitive functioning 
of our population may have been too good for nutrient supplementation to 
be effective. However, in a study of n-3 PUFAs among patients with mild to 
Table 2.3  Changes in Z scores of cognitive performance domains in older Dutch adults 
after 13 and 26 weeks of EPA+DHA supplementation by treatment groupa
a Values are mean ± SD
b For treatment group 1; n=96 at baseline, n=95 after 13 weeks and n=96 after 26 weeks.
c For treatment group 2; n=100 at baseline, after 13 and after 26 weeks.
d For treatment group 3; n=106 participants at baseline (n=105 for Sensorimotor speed), n=105 after 13 weeks 
and n=103 after 26 weeks.
e Significant difference among the three treatment groups were observed (ANOVA with Dunnett’s post hoc 
test)
Cognitive domain 1,800 mg EPA+DHAb 400 mg EPA+DHAc Placebod
Memory 13 weeks - baseline 0.25 ± 0.52 0.10 ± 0.44e 0.27 ± 0.52
26 weeks - baseline 0.31 ± 0.48 0.26 ± 0.49 0.28 ± 0.51
Executive function 13 weeks - baseline 0.05 ± 0.52 0.16 ± 0.65 0.09 ± 0.63
26 weeks - baseline 0.09 ± 0.39 0.07 ± 0.46 0.13 ± 0.39
Attention 13 weeks - baseline 0.08 ± 0.85 0.01 ± 0.75 –0.03 ± 0.66
26 weeks - baseline 0.16 ± 0.83 0.06 ± 0.71 –0.07 ± 0.83
Sensorimotor speed 13 weeks - baseline 0.15 ± 0.45 0.11 ± 0.40 0.23 ± 0.41
26 weeks - baseline 0.21 ± 0.47 0.21 ± 0.34 0.28 ± 0.40
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moderate AD, cognitive decline was only reduced in subgroup (n=32) with the 
best-preserved cognitive function (MMSE score >27)20. Our study population was 
comparable with these subjects because 87% had a MMSE score of 27 or higher. 
However, the subjects in their study had mild to moderate dementia, and 72% 
were APOE-ε4 carriers. We also found an effect of EPA+DHA supplementation 
in subjects who carried the APOE-ε4 allele, but only on the cognitive domain 
of attention. Fish oil may be beneficial in these subjects who are most sensitive 
to developing dementia. Conversely, in an epidemiologic study, it was observed 
that consumption of fish was associated with a reduced risk of AD only in subjects 
without the APOE-ε4 allele13. Furthermore, because multiple comparisons were 
made in our study, it should be noted that our finding could also be a chance 
finding.
Compliance in our study was high. The dropout rate in this study was only 3%, 
and seven of the nine subjects who discontinued capsule use returned for their 
follow-up measurements. Therefore, bias that could result from withdrawal of 
participants with poor cognitive function38 is likely to be negligible. Per-protocol 
analysis excluding the dropouts and noncompliant subjects did not change the 
results.
We examined the effect of both a high (1,800 mg) and a low dose (400 mg) of 
EPA+DHA on cognitive functioning. The high “pharmacologic” dose was chosen 
to ensure maximal contrast between the groups to pick up an effect, if present. 
The low dose corresponds to the recommended intake in the Netherlands of 
450 mg/d EPA+DHA39. Such a dose is roughly equivalent to eating two portions 
of fish per week (one of which is oily fish) and can be more easily translated 
into dietary advice. Yet it is not yet clear which dose would be sufficiently high 
and most effective to influence cognitive performance. Moreover, because 
the causal mechanisms are not yet elucidated, it is not even clear whether an 
effect of n-3 PUFAs on the brain would be caused by either EPA or DHA or the 
combination of the two.
A limitation of this study is that the duration of intervention may have been too 
short. Mechanisms on how EPA+DHA might influence cognitive performance 
are not completely understood, and both short-term as well as long-term 
mechanisms have been proposed that could explain such an association4. With 
the present study duration of 26 weeks, it would only be possible to detect short-
term effects. We compared our study with other randomized trials of EPA+DHA 
supplementation in elderly patients. Two studies, performed in patients with 
established dementia, found a beneficial effect. One study on several cognitive 
outcomes after using an n-3/n-6 fatty acids compound for 4 weeks19 and another 
study observed that 0.72 g DHA per day during 6 months significantly improved 
scores of the MMSE and Hasegawa Dementia rating scale18. A more recent and 
larger study found no effect of daily supplementation of 1.7 g DHA and 0.6 g 
EPA after 6 months, except in a subgroup of 32 subjects with very mild cognitive 
dysfunction (MMSE score >27)20. 
In this randomized, controlled trial, we observed no effect of EPA+DHA 
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supplementation for 26 weeks on cognitive performance in healthy older 
individuals. However, our data suggested that in subjects carrying the APOE-ε4 
allele and in male subjects, EPA+DHA may improve attention. Based on these 
findings, longer-term EPA+DHA supplementation studies to investigate effects 
on cognitive performance are warranted, especially in groups at higher risk for 
cognitive decline.
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Abstract
High intake of fish and n-3 polyunsaturated fatty acids (PUFAs) may protect 
against age-related cognitive decline. However, results are inconsistent and 
limited data exist regarding changes in multiple cognitive functions over a 
longer period of time. In this study, we assessed the association between fatty 
fish intake as well as n-3 PUFA intake with cognitive performance and cognitive 
change over 6 years in 1,025 elderly men. Participants were from the Veterans 
Affairs Normative Aging Study (NAS). Cognitive function was assessed with a 
battery of cognitive tests focusing on factors representing memory/language, 
speed and visuospatial/attention. Dietary intakes were assessed with a validated 
food frequency questionnaire. General linear models were used to assess cross-
sectional associations and mixed models were used to assess the associations 
over time. Models were adjusted for age, education, BMI, smoking, diabetes, 
and intake of alcohol, saturated fat, vitamin C and vitamin E. The mean age of 
participating men was 68 years at baseline. Median fish consumption ranged 
from 0.2 to 4.2 servings per week across quartiles. Cross-sectional analyses 
showed no association between fatty fish or n-3 PUFA intake and cognitive 
performance. Longitudinal analyses, over 6 years of follow-up, also did not 
show any significant associations between fatty fish or n-3 PUFA intake and 
cognitive change. In this population of elderly men, intake of neither fatty fish 
nor n-3 PUFAs was associated with cognitive performance.
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Introduction
Age-related cognitive impairment is considered to be a strong risk factor for the 
development of dementia1. There has been increasing scientific interest in the 
hypothesis that fish consumption, particularly fatty fish, and the intake of the 
marine n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA, 
C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3) might play a protective 
role against age-related cognitive decline and dementia. Cognitive performance 
has been examined in relation to dietary intake of n-3 PUFAs and fish2-5 or n-3 
PUFA concentrations in the blood in several cross-sectional studies6,7. Results 
have been inconsistent, showing either that high intake or high concentrations of 
n-3 PUFAs in the blood were associated with better cognitive performance2,3,5,6 
or no association4,7. 
Longitudinal studies examining the association between fish or n-3 PUFA 
intake and cognitive performance have also yielded contradictory results. In 
some studies, high fish and/or n-3 PUFA intake was protective against 5 or 
6-y cognitive decline4,8, whereas no association was found in 3-y cognitive 
decline in the Zutphen Elderly Study3. Studies using n-3 PUFA concentrations 
in the blood have generally shown higher concentrations are associated with 
lower risk of cognitive decline9,10. Cognitive function in older adults declines 
differentially in specific cognitive domains11. If n-3 PUFAs are associated with 
cognitive functioning, they may affect specific cognitive domains differently, 
as different mechanisms could underlie each domain. However, data on these 
effects are limited because most studies have used only a global measure of 
cognitive performance. We know of only three studies that have addressed the 
association between n-3 PUFAs and cognitive performance in different domains. 
Two showed a reduced risk of impaired speed with higher intake of fatty fish 
or n-3 PUFAs2, or with higher plasma n-3 PUFA proportions over 3 years12 and 
one showed that higher proportions of n-3 PUFAs reduced the risk of decline 
in verbal fluency10. This prospective cohort study of elderly men was based on 
longitudinal data with three measurements over a 6-year follow-up period. We 
examined the association between fatty fish intake as well as n-3 PUFA intake 
with changes in multiple factors of cognitive functioning.
Subjects and methods
Subjects
The Normative Aging Study (NAS), a longitudinal study of aging established 
by the Veterans Administration (now Department of Veterans Affairs), started 
in 1963 by recruiting men in the Boston area who were originally free of heart 
disease or other major health problems. The study cohort initially consisted of 
2,280 community-dwelling men who were between 21 and 81 years of age 
(mean 42 y) on entry during 1963-1970. Participating men return every 3-5 years 
for a health examination, at which time they complete several questionnaires. 
Dietary intake data have been collected since 1987. Since 1993, a battery 
of cognitive tests was added to these visits and cognitive performance was 
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assessed in three cycles, approximately 3 years apart. Relations of B vitamin 
and homocysteine concentrations with cognitive performance13 and cognitive 
decline14 in a subgroup of this NAS population have been previously reported. 
The Institutional Review Boards of both the Boston Veterans Affairs Medical 
Center and Tufts New England Medical Center approved the study and all 
subjects gave written informed consent.
Cognitive measures
The battery of cognitive tests was designed to be appropriate for an aging 
population, including tests specifically chosen to assess cognitive status and 
changes in adults with various pathologic conditions such as Alzheimer’s 
Disease [Consortium to Establish a Registry for Alzheimer’s Disease [CERAD15]. 
Some tests from the Neurobehavioral Evaluation System were also included 
[NES216] Selected tests focus on language, speed, attention, memory, and 
spatial copying. The Vocabulary, Boston Naming, Continuous Performance and 
Pattern Memory tests were administered only once, the others tests repeatedly. 
The Mini-Mental State Examination (MMSE) was used as a global measure of 
cognitive function17.
Memory tests
Word List Memory Test (adapted from CERAD): Ten words are presented on a computer 
screen consecutively, for 2 s each, and participants are then asked to recall these 
words. Three consecutive trials are administered, and the score is the sum of 
words remembered (maximum score 30). After an intervening spatial copying 
task, subjects are asked again to recall the memorized words (delayed recall, 
maximum score 10). 
Backward Digit Span test (WAIS-R): Participants are read a list of digits and asked to 
recall these in backward sequence. The score is the total span of digits recalled 
correctly in backward order, with a maximum of eight. 
Pattern Memory (NES2): One pattern is presented on the computer screen, which 
is followed after a brief interval by three similar patterns, from which subjects 
are asked to identify the original pattern. The scores are the number of correct 
responses (maximum 25) and mean response latency for correct decisions.
Language tests
Verbal fluency (CERAD): Subjects are asked to name as many animals as possible 
within 1 min.
Boston Naming Test-short form (CERAD): Subjects are asked to identify 15 line-drawn 
objects by name (maximum score 15).
Vocabulary [Wechsler Adult Intelligence Scale-Revised (WAIS-R18)]: Subjects are asked 
to define words of increasing difficulty, which are scored according to quality 
of definition (maximum score 70).
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Tests of perceptual speed and attention
Pattern Comparison (NES2): Subjects are asked to choose the odd pattern from three 
similar patterns displayed on a computer monitor. The scores are the number 
of correct responses (maximum 25) and the mean response latency for correct 
decisions.
Continuous Performance Test (NES2): Subjects are asked to press a button when they 
see a large letter “S”, but no other letter, on a computer monitor. The score is 
the mean response latency for items in the best two of six trials (10 target items 
in each trial). Best trials are defined as trials on which no or minimal errors are 
made and for which the mean response latencies are the fastest19.
Spatial copying task-Constructional Praxis (CERAD)
Subjects are asked to copy a circle, crossed rectangles, a vertical diamond, 
and a cube. These figures are augmented by the tilted triangles, 8-dot circle, 
horizontal diamond, and tapered box (from the Developmental Test of Visual-
Motor Integration; VMI20) and the overlapping pentagons from the MMSE17. 
The accuracy of the copied figures is scored by trained staff using criteria from 
the CERAD and VMI. The resulting score is the total number of figures drawn 
correctly (maximum score 9). A second score is weighted by the degree of 
difficulty of the figure, resulting in a maximum score of 26.
Dietary assessment
The subject’s average frequency of consumption during the previous year 
is estimated with the 126-item semi-quantitative Willett food-frequency 
questionnaire (FFQ)21,22. This questionnaire requests participants to record the 
number of times they consume each of the food items using seven response 
categories ranging from rarely/never to 2 or more per day. The form was mailed 
to the participants before their examination visit and checked for completeness 
at the examination. Forms were processed through a nutrient database at the 
Channing Laboratory at Harvard University to obtain estimates of usual daily 
nutrient intake. Four fish items were included: dark-meat fish (e.g., bluefish, 
mackerel, salmon, sardines, or swordfish; 1.37 g of n-3 fatty acids per portion); 
canned tuna (0.69 g); other fish (0.17 g); and shrimp, lobster, or scallops (0.46 
g). We calculated average daily fish intake by summing these four fish items 
and we calculated fatty fish intake by summing the frequencies of tuna and 
dark-meat fish.
Other measurements
Information on education level, smoking history and medical history was 
obtained by questionnaire. Height and weight were measured to calculate 
body mass index (BMI, kg/m2). Fasting plasma samples were drawn at the VA 
field site and stored at –80°C. These samples were then taken to the Nutrition 
Evaluation Laboratory at Tufts University Human Nutrition Research Center on 
Aging for analysis. Total homocysteine (Hcy) in plasma was measured using an 
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adaptation of a previously described method23. Plasma folate and vitamin B12 
concentrations were measured by radio assay with the use of a commercially 
available kit from Bio-Rad (Hercules, CA).
Statistical analysis
Differences in baseline characteristics among different categories of fatty 
fish consumers and n-3 PUFA intake were compared by analysis of variance 
(ANOVA) or Kruskal-Wallis for continuous variables and chi-square for 
categorical variables. For the cognitive measures Tukey’s post hoc test was 
used to examine differences between quartiles. For privacy reasons, subjects 
aged >89 years (n=1 for cross-sectional analysis and n=4 for the longitudinal 
analysis) were recoded to 89 years. For the cross-sectional analysis, principal 
components analysis (SAS PROC FACTOR procedure) with varimax rotation was 
used to create composite scores for separate dimensions of cognitive function 
while retaining as much of the individual test’s variance as possible. This analysis 
included 451 men in total (who had baseline scores on all included tests) and 
resulted in three factors: 1) a memory/ language factor; 2) a visuospatial/attention 
factor; and 3) a speed factor.
We used general linear models (GLM) to investigate the association between fatty 
fish or n-3 PUFA intake (independent) and cognitive performance (dependent) 
at baseline. To test for linear trend, the quartile median value for dietary n-3 
PUFA or fatty fish was assigned to each subject in that quartile. To investigate 
the association of fatty fish and n-3 PUFA intake on 6-year cognitive change, 
a repeated mixed coefficients model (SAS PROC MIXED procedure) was used. 
This procedure takes into account the intra-individual correlation of repeated 
measurements and does not exclude subjects with incomplete data at follow-up. 
Logarithmic transformation was applied to all dietary measures before including 
them in the regression models to improve linearity. We calculated energy 
adjusted intake for all dietary measures with the residual method24 and created 
quartiles for fatty fish intake as well as n-3 PUFA intake. Fatty fish consumption 
and intake of n-3 PUFA were entered as class variables into the model, and the 
outcome variables, i.e. baseline cognitive functioning and 6-y cognitive change, 
were treated as continuous variables. Users of cod liver oil (n=29) and fish oil 
capsules (n=11) were excluded from the analysis.
Models were adjusted for age, educational level (<12, 12, 13-15, ≥16 y), BMI 
(kg/m2), smoking (current, past, or never), diabetes (yes/no), alcohol intake (g/d), 
saturated fat intake (g/d), vitamin C intake (mg/d) and vitamin E intake (mg/d). 
These confounders were included based on previously published associations, as 
well as associations with the exposure and outcome (change in the β coefficient 
≥10%) in the current data set. We checked for interaction between fish intake, as 
well as n-3 PUFA intake, with age, education, BMI and diabetes as categorical 
variables and no significant interactions were observed (P>0.05).
We also analyzed models additionally adjusted for physical activity, plasma 
folate, Hcy and vitamin B12. However, because including these variables did 
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not affect results they were removed from the final models. All statistical analyses 
were carried out using SAS (version 9.1; SAS Institute Inc, Cary, NC). Two-sided 
P-values ≤0.05 were considered statistically significant.
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Figure 3.1  Participant flow in the study from initiation to cognitive measures.
 Until 1970: 2,280 enrolled 
1993: 1,216 eligible in  
CHAMP study 
Not eligible: n=1,064 
• Survey only (n=401) 
• Died (n=448) 
• Lost to follow-up or drop-out (n=215) 
 
Cognitive testing: n=1,063 No cognitive testing: n=153 
• Survey only (n=38) 
• Died (n=92) 
• Drop-out (n=17) 
• Too ill (n=1) 
• Other reasons (n=5) 
Baseline analyses cognitive 
testing: n=1,025 
Excluded: n=38 
• Cod liver users (n=27) 
• Fish oil users (n=9) 
• Using both (n=2) 
Cognitive testing after  
≅ 3 years: n=671 
Cognitive testing after  
≅ 6 years: n=313 
No cognitive testing: n=354 
• Survey only (n=88) 
• Only lab and survey (n=54) 
• Drop-out (n=12) 
• Died (n=193) 
• Too ill (n=7) 
No cognitive testing: n=358 
• Survey only (n=62) 
• Lab only (n=3) 
• Only lab and survey (n=178) 
• Drop-out (n=5) 
• Lost (n=1) 
• Died (n=94) 
• Too ill (n=15) 
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Results
Baseline characteristics
Of the 2,280 men originally enrolled, 1,216 were still participating in the on-
site examination portion of the study in 1993 when the cognitive measures 
were initiated. Of these, 87% (1,063) completed baseline cognitive testing. 
After exclusion of fish and cod liver oil users 1,025 remained for our baseline 
analyses. See Figure 3.1 for the flow of participants. Of these, 671 completed a 
second battery at 3 years and 313 at 6 years. Reasons for loss to follow-up were 
mainly due to death or movement from the area. Men who moved continued 
participation by mail survey, but did not continue the in-person exam. Due to 
the high participant burden, not all men completed all tests. A shorter battery 
was offered to those refusing the full battery. Individual test completion ranged 
from 487 to 982 and when combined to create factors, this resulted in a sample 
size of 451 with complete measures for all included tests.
The mean age of completing participants at baseline cognitive measurement 
was 68 y. Total mean fish consumption was 2.4 servings/week of total fish and 
1.3 servings/week of fatty fish. Mean total n-3 PUFA intake was 0.28 g/day. 
Median fatty fish consumption ranged from 0.2 to 2.8 portions/week across 
quartiles. Men in the higher quartiles of n-3 PUFA consumption had more years 
of education and were less likely to be smokers than those in the lower quartiles. 
Men with low n-3 PUFA intake had higher intakes of total energy and saturated 
fat, and lower intakes of alcohol, and vitamins C and E (Table 3.1). Unadjusted 
baseline cognitive scores for Word List Memory tests (P=0.01 and 0.03), the 
Boston Naming Test (P=0.01) and Continuous Performance Test differed (P=0.01) 
among quartiles of fatty fish consumers (Table 3.2). Unadjusted baseline scores 
across the quartiles of n-3 PUFA intake did not differ significantly for any of the 
cognitive tests (data not shown).
Cognitive performance (cross-sectional analysis) 
After adjusting for age and education, as well as other potential confounding 
variables, there were no significant protective associations between quartiles 
of fatty fish or n-3 PUFA intake and cognitive dimensions, as measured by the 
factor scores. Rather, and in contrast to our hypothesis, performance tended to 
be impaired on the cognitive factor memory/language with greater intake of 
fatty fish (P=0.09) or n-3 PUFAs (P=0.17) (Table 3.3). However, examination 
of the main contributing cognitive test for each of the cognitive factors as the 
dependent variable did not show this (Table 3.4).
Change in cognitive performance over 6 y (prospective analysis) 
Of the 1,025 men included in the cross-sectional analysis, 671 returned for 
follow-up measurements after 3 years and 313 returned after 6 years. The 313 
men with complete follow-up were, on average, 2 years younger than those who 
did not return for the follow-up measurements, but did not differ significantly on 
any other variable examined here. Cognitive tests did not differ across quartiles 
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of fish intake or n-3 PUFA intake (Table 3.5). As in the cross-sectional analysis, 
performance on the cognitive factor memory/language tended to be impaired 
with greater intake of fatty fish (P=0.09) or n-3 PUFAs (P=0.17). Repeating these 
analyses with only the subjects who had complete follow-up over the 6 years 
did not show different results.
Discussion
The present study is one of the few prospective cohort studies to examine 
prospective associations between fish and n-3 PUFA intake with cognitive change 
in multiple cognitive factors. Our findings in this sample of aging men do not 
support the hypothesis that higher fish/ n-3 PUFA intake is associated with better 
cognitive function or with less cognitive decline on any of the cognitive tests. 
Strengths of the current study include the ability to assess cognitive performance 
not only cross-sectionally, but also prospectively with multiple repeated 
measurements. Furthermore, we used an extensive battery of cognitive tests, 
appropriate for an aging population. This is an important advantage over the 
use of only general cognitive tests such as the MMSE, which was originally 
designed as a screening tool and not as a measure of change17. To limit the 
number of outcome variables, we defined three cognitive factors which account 
for most of the variance observed. However, because not all cognitive tests were 
performed in all subjects, this also decreased the number of subjects for each 
cognitive factor, compared with the number of subjects that performed some 
of the individual cognitive tests. Therefore, we repeated our analyses with the 
cognitive test that contributed most to each cognitive factor. However, despite 
the fact that this increased the number of subjects, these analyses did not show 
different results. 
The Willett FFQ includes questions on different fish items and has been validated 
in several studies21,25,26. In a validation study with a random sample of 127 
men aged 45 to 70 years living in the Boston area, these four items on seafood 
intake were shown to be reproducible and useful measures of seafood intake. 
Correlations between two administrations of the questionnaire 1 year apart 
ranged from 0.48 (fish) to 0.67 (shellfish)26. The correlation between fish intake as 
reported on the questionnaire with fish intake assessed with two 1-week dietary 
records was 0.6125. Although plasma, erythrocyte or phospholipid proportions of 
n-3 PUFAs are often considered more objective measures of n-3 PUFA intake27, 
these values were not available in the present study. However, it has been shown 
that these biochemical measures may provide only limited information about 
absolute values of n-3 PUFA intake, because they may vary for participants 
with similar dietary intake due to other participant characteristics28. Welch et 
al. found that only ≈25% of the variation in plasma n-3 PUFA was explained by 
fish and fish-oil consumption29. Furthermore, because they only reflect intake 
over the past week or two, they may be less indicative of long term exposure 
than responses to a food frequency questionnaire for the past year27.
Because the number of subjects participating in the consecutive cognitive test 
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series of our study decreased substantially (from 1,025 to 671 after 3 years to 
313 after 6 years of follow-up) bias due to incomplete follow-up may have 
influenced our results. However, except for the fact that subjects with complete 
follow-up were on average 2 years younger, they were not different from the 
subjects with incomplete follow-up. An under- or overestimation of the effect 
is unlikely, because fish intake and cognitive scores were also comparable 
between completers and non-completers.
The trend for the impaired, though not significantly, memory/ language factor 
with greater fish or n-3 PUFA intake was unexpected and has, to our knowledge, 
not been shown before. We have no clear explanation for this result. Also, when 
we performed the same analysis with only the cognitive test that contributed 
most to each factor, we did not observe this trend, despite larger sample size. 
Because we made multiple comparisons it may also have been a chance finding. 
Our cross-sectional results are in agreement with those of two other studies, 
which also observed no significant associations3,4. They are also in agreement 
with two studies that evaluated n-3 concentrations in the blood and saw no 
association with cognitive function7,12. However, other studies have found 
positive associations with n-3 PUFA concentrations and cognitive function6 and 
with fish or n-3 PUFA intake and global cognitive function and speed2.
The null results of our longitudinal analyses are in line with the first publication 
from the Zutphen study data, which also showed no clear association between 
fish consumption and 3-y cognitive decline3. However, 5-y cognitive decline 
was later inversely associated with EPA+DHA intake in that study population4. 
The Chicago Health and Aging Project showed that fish consumption, but not 
intake of n-3 PUFAs, was associated with less cognitive decline8. A few studies 
have shown higher n-3 PUFA9 or EPA concentrations in blood7 to be associated 
with less cognitive decline. Dullemeijer et al. observed an association between 
n-3 PUFA plasma concentrations and sensorimotor and complex speed, but 
did not observe associations for memory, information-processing speed, or 
verbal fluency12. Beydoun et al. observed that lower concentrations of plasma 
n-3 fatty acids were associated with greater decline in verbal fluency, but not 
in memory or psychomotor speed10. The findings of these few studies assessing 
different cognitive domains are not consistent. More prospective studies, as 
well as intervention studies investigating the association between n-3 PUFAs 
and domain-specific measures are needed. 
Our study population consumed an average of 2.4 servings of total fish per 
week, which is relatively high compared to other study populations in the 
Netherlands and the United States, where average fish intake was once per 
week or less3,8,30, but lower than in a Norwegian population, where intake was 
on average 5 servings/week5. Our study population consisted of men only. The 
Zutphen study also included only men, but they observed a protective effect 
of a higher fish and n-3 PUFA intake on 5-y cognitive decline4. Relative to that 
study, the mean age of our men was 7 years younger, 68 compared to 75 years, 
and the mean MMSE was 1.3 points higher. The subjects of the Chicago Health 
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and Aging project, where fish consumption was also associated with slower 
cognitive decline, had a mean age of 74 years, also several years older than in 
our study8. It is, therefore, possible that a protective effect of fish intake may be 
more apparent with advancing age and cognitive decline. On the other hand, 
there is increasing concern with contaminants, such as mercury and dioxins 
in certain types of fish, although a review performed in 2006 showed that the 
benefits of moderate (1-2 servings/week) fish consumption exceed the potential 
risks, at least for cardiovascular and neurological outcomes31. Although we 
cannot assess this exposure directly, it remains possible that the benefits of the 
n-3 PUFA intake among the relatively high fish consumers in this study may 
have been attenuated by negative effects of contaminants. Further investigation 
in this area is needed.
In conclusion, higher intake of fish or n-3 PUFAs was not associated with better 
cognitive performance at baseline or with lower 6-year cognitive decline in 
any of the cognitive tests in this population of aging men. Studies with longer 
observation of changes in specific cognitive domains are needed to clarify the 
current conflicting results observed in the literature.
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Abstract
Background It is suggested that a low intake of fish and/or n-3 PUFA is associ-
ated with depressed mood. However, results from epidemiologic studies are 
mixed, and randomized trials have mainly been performed in depressed patients, 
yielding conflicting results.
Objective We investigated the effect of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) on mental well-being in a double-blind, placebo-
controlled trial.
Design Independently living individuals (n=302) aged ≥65 y were randomly 
assigned to consume 1,800 mg/d EPA+DHA, 400 mg/d EPA+DHA, or placebo 
capsules for 26 weeks. Changes in mental well-being were assessed as the 
primary outcome with the Center for Epidemiologic Studies Depression Scale 
(CES-D), Montgomery-Åsberg Rating Scale (MADRS), Geriatric Depression Scale 
(GDS-15), and Hospital Anxiety and Depression Scale (HADS-A).
Results Plasma concentrations of EPA+DHA increased by 238% in the high-
dose and 51% in the low-dose fish oil group compared to placebo, reflecting 
excellent compliance. Baseline CES-D scores ranged from 5.9 to 6.8 in the three 
groups and were not significantly different between groups. Mean changes in 
CES-D scores after 26 weeks were –0.2, 0.2 and –0.4 (P=0.87) in the high-dose 
fish oil, low-dose fish oil, and placebo groups, respectively. Treatment with 
neither 1,800 mg nor with 400 mg EPA+DHA differentially affected any of the 
measures of mental well-being after 13 or 26 weeks of intervention compared 
to placebo.
Conclusions In this randomized, double-blind, placebo-controlled trial we 
observed no effect of EPA+DHA supplementation for 26 weeks on mental well-
being in the general older population studied.
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Introduction
Depression is a common mental disorder with a complex etiology. Depressive 
disorders affect 121 million people worldwide1 and are the third leading cause 
of burden of disease in high-income countries2. Depression can be diagnosed 
reliably in primary care, but not all treatments are effective. According to a 
WHO report, 36-50% of serious cases in developed countries and 76-85% of 
serious cases in less-developed countries do not receive treatment3. Therefore, 
it is important to focus on factors that may help to prevent the development of 
depressive disorders.
Several studies showed depletions in n-3 polyunsaturated fatty acids (PUFAs) 
in blood or adipose tissue to be associated with depression4-10. PUFA are very-
long-chain fatty acids found in plants and marine sources. The marine-based 
n-3 PUFAs primarily consist of eicosapentaenoic acid (EPA, C20:5n-3) and 
docosahexaenoic acid (DHA, C22:6n-3). Because n-3 PUFAs are a major 
component of neural membranes and act as precursors of compounds involved 
in immune and inflammatory responses, it is biologically plausible that they 
could play a role in mood and behavioral disorders11.
Most observational studies showed an inverse association of fish intake with 
prevalence of depression12-15. Three epidemiologic studies with 3,204, 5,689, 
and 29,133 subjects, respectively, have been performed in the general Finnish 
population12,13,16, and one has been performed in 332 Dutch elderly men15. 
Tanskanen et al. and Timonen et al. found effects only in women12,13, which could 
explain why Hakkarainen et al.16, who studied a male population, did not find 
an association. However, this is contradictory to the findings of Kamphuis et al. 
who found an association in a male population. The age of this population (70-79 
y) could explain the difference in results found. Hibbeln made a cross-national 
comparison of 13 countries including 35,000 subjects and showed a negative 
association between fish intake and prevalence of major depression14. Studies 
using n-3 PUFA concentrations in the blood also found higher concentrations to 
be associated with less depression4-8, as was the case for n-3 PUFAs in adipose 
tissue9,10. 
Until now, 19 randomized trials investigating the effects of n-3 PUFAs on depressed 
mood have been performed. Twelve studies, most of them performed in depressed 
patients, were included in a recent meta-analysis by Appleton et al. who stated 
that the evidence available provided little support17. Fontani et al. performed the 
only trial in healthy subjects (n=33) with a mean age of 33 y, who experienced 
an improvement in mood during daily supplementation of 1.6 g EPA and 0.8 g 
DHA for 35 days18. Recently, Rogers et al. performed a trial in mild to moderately 
depressed individuals from the general population and did not observe an effect 
after 3 months of supplementation with 1.5 g EPA+DHA/d19.
The aim of the present study was to investigate whether supplementation 
of n-3 PUFAs would be beneficial in improving the mental well-being of 
nondepressed, older individuals. We conducted a double-blind, randomized, 
placebo-controlled trial in 302 Dutch individuals who were administered a high 
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dose (1,800 mg/d) or a low dose (400 mg/d) of EPA+DHA or placebo capsules 
for 26 weeks.
Subjects and methods
Subjects
The subjects were screened between November 2005 and February 2006, 
and the intervention took place between February 2006 and November 2006. 
The subjects were aged ≥65 y, and were mainly recruited through an existing 
database of volunteers with interest in participating in studies of Wageningen 
University, the Netherlands. The exclusion criteria were as follows: [1] score of 
>16 on the Center for Epidemiologic Studies Depression Scale (CES-D )20; [2] 
score of <21 points on the Mini-Mental State Examination (MMSE)21; [3] current 
or recent (<4 weeks) use of fish oil supplements; [4] current use of antidepressant 
medication; [5] current use of medication for dementia; [6] serious liver disease; 
[7] consumption of >4 glasses of alcohol/d; [8] inability to participate as judged 
by the responsible medical doctor; [9] allergy to fish; [10] swallowing problems, 
[11] current or recent (i.e. < 2mo) participation in another clinical trial, or [12] 
intake of fish >4 times/week or >800 mg EPA+DHA/d from fish, as estimated 
from a fish consumption questionnaire. Additionally, compliance with capsule 
use during the 2-week placebo run-in period had to be ≥80% on the basis 
of self-report. The study was approved by the Medical Ethical Committee of 
Wageningen University and all subjects gave written informed consent.
Study design
An independent person randomized subjects by means of computer-generated 
random numbers in stratified permuted blocks of size 6. Stratification factors 
included age (< and ≥69 y), sex, MMSE (< and ≥28), and CES-D screening test 
score (<5 and ≥5). Individuals were randomly allocated to receive a daily dose 
of fish oil containing either a low dose of ~400 mg EPA+DHA, a high dose of 
~1,800 mg EPA+DHA, or a placebo oil (sunflower oil high in oleic acid) for 26 
weeks (Lipid Nutrition/Loders Croklaan, Wormerveer, the Netherlands). The oils 
were administered in six soft gelatin capsules daily, each containing 900 mg oil 
and 2.7 mg tocopherol as antioxidant (Banner Pharmacaps Europe BV, Tilburg, 
the Netherlands). Fish oil capsules provided a mean (± SD) daily intake of 1,093 
± 17 mg EPA and 847 ± 23 mg DHA in the high-dose group and 226 ± 3 mg 
EPA and 176 ± 4 mg DHA in the low-dose group, as estimated from 20 random 
samples taken at regular times during the study. The placebo capsules contained 
mainly oleic acid (C18:1n-9). The capsules were individually packaged in foil pill 
strips containing the daily dose of six pills per strip to facilitate compliance and 
recording of capsule use (Medipack, Gorredijk, the Netherlands). The capsules 
with fish oil or placebo oil were indistinguishable in appearance. Staff members 
and participants were blinded toward treatment allocation until completion of 
the trial and after completion of data analysis. Participants visited the research 
centre at baseline and after 13 and 26 weeks of intervention. At baseline and at 
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13 weeks, participants received a 14-week supply of capsules (one week extra 
as reserve). Compliance was judged by calculating the unused capsules in the 
returned foil strips and by reviewing a diary in which participants registered the 
number of capsules that were not consumed.
Sample size was calculated on the basis of the CES-D; a difference of three 
points was considered clinically relevant. With a mean (± SD) of 9 ± 7 for Dutch 
elderly22, a minimum sample size of 85 subjects per group would be required 
to detect a difference (power=80%, 2-sided α=0.05). Taking into account a 
dropout rate of 15%, a sample size of 100 subjects per treatment group was 
considered adequate.
Assessment of mental well-being
Trained research assistants performed mental well-being tests at baseline and 
after 13 and 26 weeks of intervention under supervision of a neuropsychologist. 
The participants were tested by the same research assistant, whenever possible, 
using a standard protocol. To assess mental well-being, four questionnaires were 
used: [1] CES-D: a 20-item scale developed to measure depressive symptoms 
experienced in the past week20. The scale generates a total score ranging from 0 
to 60; higher scores reflect more depressive symptoms. Adequate reliability and 
validity with elderly people was previously established23-25, [2] The Montgomery-
Åsberg Depression Rating Scale (MADRS): a 10-item, observer-rated scale that 
is explicitly designed to measure changes in depressive symptoms26. This scale 
generates a total score, which can range from 0 to 60; higher scores reflect more 
depressive symptoms. Adequate validity was established previously27, [3] Short 
version of Geriatric Depression Rating Scale (GDS-15): a 15-item test with yes 
and no answers designed specifically for rating depression in the elderly. The 
total score ranges from 0 to 15, and the list has been tested and used extensively 
in the older population28. This scale is easy to administer and has been well 
validated in both home and clinical settings. The GDS has been used only at 
baseline and after 26 weeks of intervention, and [4] Subscale of the Hospital 
Anxiety and Depression Scale (HADS-A): used to identify anxiety symptoms; 
possible scores range from 0 to 2129.
Additionally, in a subgroup of 104 subjects, the Dutch version of the Profile 
of Mood states short form (s-POMS)30 was administered and the CES-D was 
repeated. These additional measurements were performed at weeks 17 and 21 
of the study by telephone interview. The s-POMS is a 32-item questionnaire with 
good psychometric properties that assesses five components of mood: depression, 
fatigue, anger, tension and loss of vigor. The total scores range from 0 to 128.
Other measurements
Fasting venous blood samples were collected at baseline and after 13 and 26 
weeks of intervention. A blood sample for measurement of n-3 PUFAs was 
collected into 10-mL EDTA-containing evacuated tubes and then immediately 
placed in ice water, centrifuged at 2,000 x g at a temperature of 4°C, and 
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then stored at –80°C until analyzed. Plasma cholesteryl ester n-3 PUFAs were 
measured as described previously31. 
Information on medical history, drug use, alcohol consumption, smoking 
habits, educational level and marital status was obtained by questionnaire and 
reviewed for completeness by a research assistant. Education was categorized 
into three categories according to criteria of Statistics Netherlands (CBS). The 
level of physical activity was estimated by means of a previously described 
questionnaire based on the duration and intensity of sport, household, and 
leisure-time activities32.
A food-frequency questionnaire was administered at screening, at baseline, and 
after 13 and 26 weeks of intervention to estimate fish intake in the previous 
three mo. Research assistants, who were all trained by the same dietician, 
interviewed the subjects. After answering a single general question about their 
average frequency of fish consumption per month, participants had to indicate 
on a 60-item list which kinds of fish they had consumed and how often. These 
60 items were categorized into three groups on the basis of the amount of fat 
in the different types of fish, i.e. lean, medium-fat and fatty fish. Furthermore, 
information was obtained on how the fish was consumed: as main meal 
component during dinner, as a snack, or on toast or with a bread meal. EPA+DHA 
intake was calculated by multiplying the frequencies of portions of fish consumed 
per month from each group by an EPA+DHA conversion factor33. 
Body height was measured at baseline with a wall-mounted stadiometer to the 
nearest 0.1 cm. Body weight and waist circumference were measured at each 
center visit while the subjects were in a standing position and wearing light 
clothing and no shoes. Body weight was measured to the nearest 0.1 kg with a 
calibrated digital scale. Waist circumference was measured in duplicate to the 
nearest 0.1 cm at the midpoint between the lowest rib and the top of the iliac 
crest with a nonelastic tape.
Statistical analyses
Data analysis was performed on an intention-to-treat basis and according to 
a predefined data analysis plan using SPSS 12.0.1 (SPSS Inc, Chicago, IL). A 
2-sided P-value <0.05 was considered statistically significant.
Baseline characteristics of the treatment groups were compared by one-factor 
analysis of variance (ANOVA) or with a Kruskal-Wallis test for continuous 
variables and a chi-square for categorical variables. Because the mental well-
being outcome measures were not normally distributed, differential changes 
between the three intervention groups were tested by using a Kruskal-Wallis 
test. These analyses were performed for effect after 13 and after 26 weeks. The 
six repeated CES-D measurements performed in a subgroup were also compared 
using Kruskal-Wallis as well as the two s-POMS measurements performed in the 
same subgroup in weeks 17 and 21. Secondary analysis involved a per-protocol 
analysis and exploratory post hoc analyses in a subgroup of individuals in the 
tertile with the highest CES-D scores at baseline.
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Figure 4.1  Flow diagram of participants throughout the study. 
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CES-D, Center for Epidemiologic 
Studies Depression Scale; MMSE, Mini-Mental State Examination.
 528 invited 
377 assessed for eligibility 
351 screened 
325 run-in period 
E x c lu d e d  (n =2 6 ) 
• Planning difficulties (n =2) 
• Use of n-3 capsules (n =1) 
• Disease (n =6) 
• Disease of spouse (n =1) 
• Second thoughts (n =16) 
E x c lu d e d  (n =2 6 ) 
• MMSE score <21 (n =1) 
• CES-D score >16 (n =13) 
• Habitual EPA+DHA intake > 800 
mg/day (n =12) 
W it h d re w  (n =2 3 ) 
• Side effects capsules (n =2) 
• Difficulties with swallowing 
capsules (n =5) 
• Life threatening disease (n =1) 
• Surgery (n =2) 
• Personal problems (n =3) 
• Second thoughts (n =10) 
100 assigned  
EPA+DHA 400 mg 
96 assigned  
EPA+DHA 1,800 mg 
106 assigned placebo 
W e e k  1 3 : 
Analyzed: n =105 
Excluded: n =1  
(discontinued 
intervention) 
W e e k  2 6 : 
Analyzed: n =103 
Excluded: n =3  
(2 deceased, 1 
discontinued 
intervention) 
W e e k  1 3 : 
Analyzed: n =100 
Excluded: none 
W e e k  2 6 :  
Analyzed: n =100 
Excluded: none 
W e e k  1 3 : 
Analyzed: n =95 
Excluded: n =1 
(discontinued 
intervention)  
W e e k  2 6 : 
Analyzed: n =96 
Excluded: none 
302 randomized 
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Results
Randomization and attrition
Of 528 individuals who expressed an interest in participating, 302 subjects 
who fulfilled the inclusion criteria were randomized to receive [1] 1,800 mg/
day EPA+DHA (n=96), [2] 400 mg EPA+DHA (n=100), or [3] placebo (n=106) 
(Figure 4.1). During the study nine subjects discontinued the use of capsules: 
five because of gastrointestinal complaints, two because participation became 
too burdensome and, two because they died before the end of the intervention. 
Of those subjects lost to drop-out, seven subjects were still tested after 13 weeks 
and six subjects after 26 weeks to be able to include them in the intention-to-
treat analyses (n=300 at week 13 and n=299 at week 26).
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Table 4.1  Characteristics of 302 subjects participating in a randomized, placebo-controlled 
trial, by treatment groupa
Values are mean ± SD and/or median (Q1-Q3), depending on the distribution
a No significant difference among the three treatment groups, P<0.05 (one-way ANOVA/ Kruskal-Wallis for 
continuous variables and chi-square analysis for categorical variables)
b Mean consumption in consumers only 
c Higher scores indicate a poorer mental well-being
1,800 mg EPA+DHA
(n=96)
400 mg EPA+DHA
(n=100)
Placebo
(n=106)
Age (years) 69.9 ± 3.4 69.5 ± 3.2 70.1 ± 3.7
Sex, Male (%) 55 55 56
Married, living together (%) 80 81 77
Education Low/ Middle/ High (%) 10/ 54/ 35 11/ 49/ 40 5/ 59/ 37
BMI (kg/m2) 26.1 ± 3.0 26.2 ± 3.4 26.5 ± 3.9
Waist circumference (cm) 94.5 ± 11.4 94.2 ± 10.6 95.9 ± 12.1
Physical activity score 11.5 ± 6.4 11.1 ± 6.2 11.4 ± 6.2
Smoker/ Ex-smoker/ Never 
smoker (%)
8/64/28 8/54/38 10/56/34
Alcohol consumers (%) 80 87 88
Median alcohol consumption 
(glasses/ week)b
10 (6-14) 8 (4-14) 8 (4-14)
Fish consumption (times/ month) 7 (4-9) 5 (3-9) 6 (4-8)
EPA+DHA intake (mg/day) 306 (131-592) 278 (103-487) 316 (166-584)
Plasma EPA+DHA (mass%) 1.9 ± 0.9 1.9 ± 1.1 1.9 ± 1.1
MMSE (Mini-Mental State 
Examination)
28 (27-29) 28 (27-29) 28 (27-29)
CES-D (0-60)c 5.9 ± 5.5; 5.0 (2.0-8.8) 6.1 ± 4.9; 5.0 (2.0-8.8) 6.8 ± 5.2; 6.0 (2.0-10.0)
MADRS (0-60)c 3.9 ± 4.4; 3.0 (0.0-6.0) 3.8 ± 4.2; 3.0 (0.0-5.0) 3.8 ± 3.5; 3.0 (1.0-7.0)
GDS-15 (0-15)c 0.8 ± 1.2; 0.0 (0.0-1.0) 0.9 ± 1.1; 0.5 (0.0-1.0) 0.9 ± 1.2; 1.0 (0.0-1.0)
HADS-A (0-21)c 2.1 ± 2.3; 1.0 (0.0-3.0) 2.1 ± 2.1; 2.0 (0.0-3.0) 2.7 ± 2.7; 2.0 (1.0-4.0)
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Participants’ characteristics and compliance 
The mean age of the participants was 70 y, and 55% of the population was 
male. At baseline, treatment groups were equally distributed with regard to 
demographic, anthropometric and lifestyle factors (Table 4.1). 
Apart from the individuals who stopped treatment prematurely, the average 
adherence to treatments based on counts of returned capsules was high (96%; 
<80% for only three subjects) and did not differ between the treatment groups. 
Compliance was confirmed by a change in the proportion of EPA+DHA in plasma 
cholesteryl esters of 51% in the low-dose fish oil group (from 1.88 ± 1.12 to 2.83 
± 1.03 g/100g fatty acids), 236% in the high-dose fish oil group (from 1.90 ± 0.86 
to 6.40 ± 1.53 g/100g fatty acids) and by a small change of –2% in the placebo 
group (from 1.91 ± 1.15 to 1.87 ± 1.11 g/100g fatty acids). The supplements 
were well tolerated; main complaints concerned mild gastrointestinal discomfort. 
In the high-dose fish oil group, 14% of the subjects reported adverse events, 
including gastrointestinal problem, 13% of the subjects reported adverse events, 
including gastrointestinal problems (n=9), feeling lifeless, blurred vision, sore 
throat, and muscle pain. In the placebo group, 15% of the subjects reported 
adverse events, including gastrointestinal problems (n=12), skin irritations, 
blurred vision, transient ischemic attack, and muscle pain. At the end of the 
study, blinding of subjects toward treatment allocation (fish oil, placebo or “no 
idea”) was evaluated. The proportion of participants who thought they had 
received fish oil or placebo did not differ among the groups (P=0.15). In the 
high-dose fish oil group, 25% correctly thought that they had received fish oil 
and 54% had no idea. In the low-dose group 19% correctly thought that they 
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Table 4.2  Changes in scores on depression and anxiety questionnaires in Dutch elderly 
people after 13 and 26 weeks of supplementation, by treatment group: mean ± SDa
a No significant differences between the three treatment groups were observed, P>0.05 (Kruskal-Wallis)
b For treatment group 1; n=96 at baseline, n=95 after 13 weeks and n=96 after 26 weeks. 
c For treatment group 2; n=100 at baseline, after 13 and after 26 weeks.
d For treatment group 3; n=106 participants at baseline, n=105 13 weeks and n=103 after 26 weeks. 
e Higher scores indicate a poorer mental well-being
f The GDS-15 has only been performed at baseline and after 26 weeks of intervention
g Higher scores indicate a higher anxiety level
1,800 mg EPA+DHAb 400 mg EPA+DHAc Placebod
Depression
CES-D (0-60)e 13 weeks - baseline –0.67 ± 3.57 0.74 ± 4.08 –0.54 ± 5.07
26 weeks - baseline –0.18 ± 4.81 0.20 ± 4.28 –0.43 ± 4.68
MADRS (0-60)e 13 weeks - baseline –0.96 ± 3.52 –0.23 ± 3.65 –0.84 ± 3.50
26 weeks - baseline –1.03 ± 3.44 –0.82 ± 3.70 –0.83 ± 3.39
GDS-15 (0-15)e,f 26 weeks - baseline –0.05 ± 1.08 0.01 ± 1.12 –0.12 ± 0.96
Anxiety
HADS-A (0-21)g 13 weeks - baseline –0.16 ± 1.59 0.30 ± 1.57 –0.30 ± 1.98
26 weeks - baseline 0.10 ± 1.75 0.50 ± 2.48 –0.14 ± 1.89
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had received fish oil and 64% had no idea. In the placebo group 25% correctly 
thought that they had received placebo and 60% had no idea.
Primary and secondary outcomes 
Baseline scores on the depression questionnaires were comparable between the 
three groups. Mean CES-D scores ranged from 5.9 to 6.8, mean MADRS scores 
ranged from 3.8 to 3.9, mean GDS scores ranged from 0.8 to 1.1, and mean 
HADS-A scores ranged from 2.1 to 2.7 (Table 4.1). After 13 and 26 weeks of 
supplementation, there were no significant differential changes in the fish oil 
groups compared with the placebo group for any of the measures of mental 
well-being. Mean changes after 26 weeks were –0.2, 0.2, and –0.4 for the CES-D 
(P=0.87); –1.0, –0.8, and –0.8 for the MADRS (P=0.73); –0.1, 0.0, and –0.1 for 
the GDS (P=0.90), and 0.1, 0.5 and –0.1 for the HADS-A (P=0.26) in the high-
dose fish oil, low-dose fish oil, and placebo group, respectively (Table 4.2).
When we performed per-protocol analyses excluding the drop-outs and 
noncompliant subjects, the results were not different from those of the intention-
to-treat analyses. Exploratory analyses in a subgroup of individuals in the tertile 
with the highest CES-D scores (cut-off CES-D at baseline: ≥8) showed that mean 
changes were generally larger than changes in the total group, but changes were 
not significant between the intervention groups (Table 4.3). Mean changes after 
26 weeks were –2.3 ± 6.7, –0.1 ± 5.4, and –2.4 ± 5.7 (P=0.23) in the high-dose 
fish oil, low-dose fish oil, and placebo groups, respectively.
The course of the CES-D scores in the subgroup of 104 subjects in whom the 
CES-D was administered five times, including the telephone interviews at 
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Table 4.3  Changes in scores on depression and anxiety questionnaires in the highest 
CES-D score tertile (CES-D ≥8) at baseline after 13 and 26 weeks of supplementation, by 
treatment group: mean ± SDa
a No significant differences between the three treatment groups were observed, P>0.05 (Kruskal-Wallis)
b For treatment group 1; n=27. 
c For treatment group 2; n=33.
d For treatment group 3; n=43 after 13 weeks and n=41 after 26 weeks of intervention.
e Higher scores indicate a poorer mental well-being 
f Higher scores indicate a higher anxiety level
1,800 mg EPA+DHAb 400 mg EPA+DHAc Placebod
Depression
CES-D (0-60)e 13 weeks - baseline –2.52 ± 4.81 –0.28 ± 3.89 –1.70 ± 7.11
26 weeks - baseline –2.26 ± 6.72 –0.11 ± 5.36 –2.40 ± 5.69
MADRS (0-60)e 13 weeks - baseline –2.66 ± 4.69 –0.92 ± 4.68 –0.98 ± 4.77
26 weeks - baseline –1.99 ± 5.05 –1.91 ± 5.19 –1.88 ± 3.76
GDS-15 (0-15)e 26 weeks - baseline –0.04 ± 1.29 0.21 ± 1.67 –0.29 ± 1.17
Anxiety
HADS-A (0-21)f 13 weeks - baseline –0.44 ± 1.89 0.48 ± 1.73 –0.37 ± 2.54
26 weeks - baseline 0.44 ± 2.61 0.91 ± 3.21 –0.37 ± 2.07
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weeks 17 and 21, is shown in Figure 4.2. The course of CES-D scores was not 
significantly different between the intervention groups.
Total scores and scores for the s-POMS components depression, fatigue and 
loss of vigor at weeks 17 and 21 were not significantly different between the 
intervention groups. At week 21, scores for the mood component anger were 
significantly lower (P=0.01) in the low-dose fish oil group than in the placebo 
group (Table 4.4).
Table 4.4  POMS scores in week 17 and 21 of intervention in Dutch community dwelling 
elderly, by treatment group, values are mean ± SD
POMS 1,800 mg EPA+DHA 
(n=30)
400 mg EPA+DHA 
(n=35)
Placebo (n=39)
Total score Week 17 14.5 ± 11.2 19.6 ± 20.6 19.7 ± 14.2
Week 21 17.5 ± 16.5 15.9 ± 12.8 18.7 ± 13.3
Depression Week 17 1.7 ± 3.0 4.1 ± 6.0 2.6 ± 3.5
Week 21 2.4 ± 4.1 3.0 ± 4.0 2.3 ± 3.1
Fatigue Week 17 2.4 ± 3.4 3.0 ± 4.1 3.7 ± 3.8
Week 21 2.5 ± 3.9 2.9 ± 3.8 3.8 ± 4.3
Anger Week 17 3.4 ± 3.6 3.8 ± 6.1 3.6 ± 3.5
Week 21 4.2 ± 5.2 1.8 ± 3.1a 3.9 ± 3.8
Tension Week 17 1.5 ± 2.0 2.7 ± 4.4 3.3 ± 3.4
Week 21 2.1 ± 3.3 2.1 ± 2.9 2.9 ± 3.1
Loss of vigor Week 17 5.5 ± 3.1 6.0 ± 3.7 6.5 ± 3.4
Week 21 6.3 ± 3.8 6.1 ± 3.8 5.8 ± 3.0
Figure 4.2  Course of mean Center for Epidemiologic Studies Depression Scale (CES-D) 
scores in Dutch elderly (n=104) during the 26-weeks intervention, by treatment group. 
No significant differences between interventions were observed (P>0.05, Kruskal-Wallis 
test).
a Signifi cant diff erence between the three treatment groups was observed, P<0.05 (Kruskal-Wallis)
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Discussion
The present intervention study in older Dutch subjects showed no effect of daily 
supplementation with low or high doses of EPA+DHA on mental well-being as 
assessed by depression and anxiety questionnaires.
To the best of our knowledge, this is the first randomized, double-blind, 
placebo-controlled trial of fish oil supplementation and mental well-being in a 
nondepressed population of older adults. Compliance in our study was excellent 
and did not differ between treatment groups, which indicated that most subjects 
tolerated taking six daily capsules for 26 weeks. Drop-out rate in this study was 
3%, and seven of nine subjects who discontinued capsule use were willing to 
undergo follow-up measurements. 
We examined the effect of both a high (1,800 mg) and a low (400 mg) dose 
of EPA+DHA on mental well-being. The high “pharmacologic” dose, which 
corresponds to eating about eight portions of fish per week, was chosen to 
ensure maximum contrast between the groups to detect an effect, if present. The 
low dose corresponds to the recommended intake in the Netherlands of 450 
mg EPA+DHA/d34. Such a dose is roughly equivalent to eating two portions of 
fish per week (one of which is oily fish) and can be more easily translated into 
dietary advice. Furthermore, Kamphuis et al. found that an intake of 400 mg 
n-3 PUFAs was associated with fewer depressive symptoms in an observational 
study of 332 older Dutch men15. Yet, it is not yet clear which dose would be 
sufficiently high and most effective to influence mental well-being, especially in 
nonpatient populations. Moreover, because the causal mechanisms have not yet 
been elucidated, it is not clear whether either EPA or DHA or the combination 
of the two may influence mood.
The state of mental well-being of the subjects was assessed by a series of 
questionnaires that have been validated and used frequently in this field and in 
nondepressed community-dwelling populations25,35-38. However, because the 
questionnaires were designed to primarily assess depressive symptoms, rather 
than mental well-being, we may not have been able to demonstrate an effect 
of our intervention in this nondepressive population. 
We selected a population of individuals of ≥65 y, because depressive symptoms 
are highly prevalent in the elderly population and increase with age39. Our 
target group was a nondepressed population (CES-D score <16), because we 
aimed to investigate whether n-3 PUFA treatment could improve the state of 
mental well-being of older individuals in the general population. It was shown 
in a population-based study in the Netherlands that the distribution of CES-D 
scores in the general elderly population varied greatly, allowing room for 
improvement even among the nondepressed40. However, to be able to study 
a group of subjects more sensitive to change, it would have been sensible to 
use not only an exclusion criterion of CES-D >16, but possibly a CES-D <5 to 
exclude subjects with already optimal CES-D scores.
Our results contrast with those of another study that examined the effect of 
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n-3 PUFA supplementation in younger, healthy, nondepressed subjects, in 
which 33 subjects with a mean age of 33 y received a daily dose of 1.6 g EPA 
and 0.8 g DHA for 35 days. This intervention resulted in an increased mental 
well-being measured with a POMS questionnaire18. On the basis of the fact 
that we had a larger number of subjects in our study, who were older and were 
supplemented for a longer period, we expected an effect in our study. Power 
calculations performed by Appleton et al.17 suggest that a sample size of ≈100 
participants per group should be enough to show a clinically meaningful change 
in depressed mood, as indicated by a difference of 3-4 points on depression 
questionnaires. 
In an exploratory post hoc analysis in subjects within the tertile with the highest 
CES-D scores (CES-D: ≥8), i.e., impaired mood, we observed that scores on 
the depression questionnaires changed more during intervention, although 
not significantly so. From this finding it may be concluded that subjects with 
an impaired mental well-being may indeed benefit more from n-3 PUFA 
supplementation and emphasizes that the relatively optimal CES-D scores 
measured in our study population may be a limitation of this study. However, 
Rogers et al., who performed a trial in mildly to moderately depressed individuals 
from the general population, neither observed an effect on mood assessed with the 
HADS-A after a shorter period of supplementation with 1.5 g EPA+DHA/d19. 
Other double-blind randomized controlled trials of fish oil and depressive mood 
were mainly performed in patients with depressive disorders17. The supplemental 
doses and contents varied, ranging from 0.2 g to 9.6 g PUFAs and consisted of 
EPA alone, DHA alone, or EPA plus DHA. The overall study duration ranged 
from 28 to 180 days, and beneficial effects appeared between 2 and 8 weeks, 
which is considerably sooner than our study. 
In conclusion, in this randomized, double-blind, placebo-controlled trial, 
we observed no effect of EPA+DHA supplementation for 26 weeks on 
different measures of mental well-being in older individuals from the general 
population.
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Abstract
Objective To compare the reliability of three rating scales for assessing depressive 
symptoms in a community-based, non-clinically depressed older population.
Methods The study sample comprised of 302 independently living subjects 
aged 65 years or older. Depressive symptoms were assessed using the Center 
for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression 
Scale (GDS-15) and the Montgomery and Åsberg Depression Rating Scale 
(MADRS) at three time points: at baseline, after 13 weeks (except the GDS-15) 
and after 26 weeks. Three dimensions of reliability were compared: (i) internal 
consistency (Cronbach’s alpha), (ii) reproducibility (Spearman correlations), 
and (iii) the intra- and inter-rater reliability (Spearman correlations to compare 
the differences between correlations of subjects tested by the same vs. different 
raters at three time points).
Results Cronbach’s alpha was high for the CES-D (0.84), good for the MADRS 
(0.72) and relatively low for the GDS-15 (0.55). Reproducibility was also higher 
for the CES-D (0.71) than for the MADRS (0.61) and the GDS-15 (0.52). The 
rater had little influence on CES-D scores (intra/inter-rater ratio=0.99). The 
GDS-15 and the MADRS, however, performed better when administered by 
the same rater.
Conclusions The CES-D was the most reliable scale for measuring depressive 
symptoms in a non-clinically depressed older population.
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Introduction
Depression is a common mental disorder affecting persons of all ages and 
backgrounds. Worldwide it is one of the most important causes of disability1. 
The prevalence of clinically relevant levels of depression ranges from 10-15% 
in the general elderly population2,3. Despite the high prevalence the majority 
of depressed older patients goes undetected and does not receive treatment4. 
Comorbidity with physical illness and cognitive impairment are often mentioned 
as factors hindering detection of depressive symptoms4,5. One way to improve 
detection of depressive symptoms is by using standard depression rating scales. 
Although many such instruments are available, only rarely have their reliabilities 
been directly compared.  
In the present study we examined the reliability of three depression rating scales, 
which were used in a 6-month intervention study investigating the effect of fish 
oil on cognitive performance and mental well-being in a Dutch, non-clinically 
depressed, community-based, older population6. Three commonly used scales 
were administered to assess depressive symptoms, namely two self-report 
scales; the Center for Epidemiologic Studies Depression Scale (CES-D), the 
Geriatric Depression Rating Scale-15 (GDS-15), and one observer-rated scale; 
the Montgomery-Åsberg Depression Rating Scale (MADRS). Reliability was 
assessed by comparing their internal consistency, reproducibility, and intra- and 
inter-rater correlations.
Methods
Subjects
A total of 302 independently living subjects older than 65 years was enrolled 
in this study, of which the original aim was to investigate the effect of high and 
low doses of fish oil on depressive symptoms in a randomized controlled trial. 
Participants were recruited from an existing database of volunteers with interest 
in participating in studies of Wageningen University. Main exclusion criteria 
were: [1] score of >16 on the CES-D at time of screening7; [2] score of <21 on 
the Mini Mental State Examination (MMSE)8; [3] current use of anti-depressant 
medication; and [4] current use of medication for dementia. Subjects received 
either capsules with 400 mg EPA+DHA/day, 1,800 mg EPA+DHA/day, or 
placebo, and mental-well being was assessed at baseline and after 13 and 26 
weeks. Treatment with fish oil did not affect depressive symptoms. A detailed 
description of this study has been reported elsewhere6,9. The study was approved 
by the Medical Ethical Committee of Wageningen University and all subjects 
gave written informed consent.
Assessment of depressive symptoms
Depressive symptoms were assessed by means of three different depression 
questionnaires that were administered three times with intervals of 13 weeks 
by trained research assistants using a standard protocol. For all scales higher 
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scores indicated more depressive symptoms.
The CES-D was developed as a screening tool to measure depressive symptoms 
in the community7. This short self-report scale consists of 20 items addressing 
depressive symptoms during the past week. There are four response categories 
ranging from ‘rarely or never’ (coded as 0) to ’most or all of the time’ (coded 
as 3) with the total score ranging from 0 to 60. The CES-D is frequently used in 
elderly community-based populations10,11 and adequate reliability and validity 
were established12-14. 
The Geriatric Depression Rating Scale (GDS) was specifically designed for 
elderly15. The original version is a self-report instrument containing 30 questions, 
with a total score ranging from 0 to 30. In order to limit burden to those 
interviewed, a short version consisting of 15 items was developed by Sheikh & 
Yesavage (GDS-15)16. This scale assesses depressive symptoms during the past 
week with simple yes/no questions and the total score varies between 0 and 
15. The reliability and validity were tested as satisfactory in different elderly 
population samples17-19. The GDS-15 was only administered at baseline and 
after 26 weeks.  
The Montgomery-Åsberg Depression Rating Scale (MADRS) is an observer rated 
scale that is designed to measure changes in severity of depressive symptoms20. 
It consists of ten questions concerning the last week and has a response scale 
of 0-6 (‘no presence of symptoms’ - ’high presence of symptoms’), resulting in 
a score ranging from 0 to 60.
Statistical analyses
We excluded subjects with a CES-D score ≥16 (n=19), because these scores 
are generally interpreted as suggestive for clinically significant depression. This 
resulted in a total of 283 subjects for the present analysis. Overall scores of the 
questionnaires in our population showed a strongly skewed distribution and log-
transformations did not result in normality. Therefore, the actual scores were used 
and compared with non-parametric tests. Median scores with interquartile ranges 
(Q1-Q3) were calculated for each questionnaire on the three time points. 
For each questionnaire we examined internal consistency, reproducibility and 
intra- and inter-rater reliability. Internal consistency was measured by calculating 
Cronbach’s alpha21, which reflects the average inter-item correlation score and 
as such it will increase when the correlations between the items increase. For 
a short scale Cronbach’s alpha should be at least >0.7022. 
Reproducibility was assessed using Spearman correlation coefficients. This 
reflects the level of stability of the measure over time within the same subject10. 
We also examined reproducibility separately for the groups receiving fish oil 
treatment (high or low dose) or placebo, although no between-group differences 
were expected since treatment was ineffective. 
The influence of the raters on the scores of the depression scales (the intra- 
and inter-rater reliability) was assessed by comparing Spearman correlation 
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coefficients. The correlations of scores of subjects who were rated by the same 
rater at the three time points (baseline, 13 weeks and 26 weeks) were compared 
with the correlations of scores of subjects who were rated by different raters at 
the three time points. To exclude effects of instability of the measure over time, 
an intra/inter rater ratio of the correlations was calculated. A ratio of 1 indicates 
no influence of the rater on the test scores. Statistical analyses were performed 
using SPSS 15.0 for Windows.
Results
Subjects’ characteristics
Data from a total of 283 subjects were used in this analysis. Subjects had a 
mean age of 70 years and 57% was male. Seventy-eight percent was married 
or was living with a spouse. The median (Q1-Q3) scores of the CES-D, the 
MADRS and the GDS-15 at the three time points and the history of affective and 
psychiatric disorders are presented in Table 5.1. In the past, 3% of the subjects 
experienced a depression, 1% a psychiatric disorder, and 9% received therapy 
for psychiatric complaints. Further details on subject characteristics have been 
described elsewhere6. Spearman correlations of the CES-D, the MADRS and the 
GDS-15 between the different measurements are shown in Table 5.2.
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Table 5.1  Characteristics of 283 Dutch non-clinically depressed, community-based, older 
subjects
a Mean ± SD
b Median (Q1-Q3), higher scores indicate more depressive symptoms
Characteristics
Age (years)a 71.8 ± 3.4
Sex, Male (%) 57
Married, living together (%) 78
Education Low/ Middle/ High (%) 9/ 53/ 38
CES-D (0-60)b 5.0 (2.0-8.0)
MADRS (0-60)b 2.0 (0.0-5.0)
GDS-15 (0-15)b 0.0 (0.0-1.0)
Depression in the past (%) 3
Psychiatric disorder in the past (%) 1
Therapy psychiatric complaints in the past (%) 9
Table 5.2  Spearman correlation coefficients of the CES-D, MADRS and GDS-15 at the 
different time points
T = 0 and T= 13 wk 
(n=300)
T = 0 and T = 26 wk 
(n=299)
T = 13 wk and 26 wk 
(n=298)
CES-D 0.73 0.67 0.72
MADRS 0.62 0.59 0.61
GDS-15 – 0.52 –
98
Reliability 
The results of the three dimensions of reliability are presented in Table 5.3. 
Cronbach’s alphas were on average 0.79, 0.68 and 0.41 for the CES-D, MADRS 
and the GDS-15, respectively. The GDS-15 scored lowest, both at baseline and 
after 26 weeks. The score of the MADRS was in between for all time points. 
The average test-retest Spearman correlation coefficients for reproducibility in 
the group as a whole were 0.68, 0.56 and 0.50 for the CES-D, MADRS and the 
GDS-15, respectively. When examining only the placebo group, corresponding 
values were 0.70 and 0.57 and 0.49. In both fish oil groups combined, values 
were similar, i.e. 0.67, and 0.56 and 0.50, respectively. 
For the CES-D the intra/inter rater ratio was 0.99, indicating that the rater was 
of no influence on the performance of this questionnaire. For the GDS-15 we 
observed a high intra/inter rater ratio (1.34), i.e. having different raters resulted 
in poorer correlations. The intra/inter rater ratio for the MADRS was 1.18.
Discussion
In this study the reliability of three commonly used rating scales of depressive 
symptoms was compared in a non-clinically depressed, community-based older 
population. On all three dimensions of reliability that we examined, CES-D 
performed best, followed by MADRS and GDS-15, respectively.
We assessed the reliability of the three depression scales in a large number of 
subjects (n=283) with a relatively long duration of follow-up and measurements 
at three time points. By assessing the reliability in an older, non-clinically 
depressed population, important knowledge is gained on which scales perform 
best in early detection of depressive symptoms in this kind of population. The 
present analysis was embedded in an intervention study that focused on the 
effect of fish oil on mental health. Since no changes in depressive symptoms 
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Table 5.3  Three dimensions of reliability of the CES-D, MADRS and GDS-15 in a Dutch, 
community-based, older population
CES-D MADRS GDS-15
Cronbach’s alpha T = 0 0.74 0.64 0.40
T = 13 wk 0.82 0.72 –
T = 26 wk 0.82 0.67 0.41
Average 0.79 0.68 0.41
Spearman correlation coefficients T = 0 vs T = 13 wk 0.70 0.57 –
T = 0 vs T = 26 wk 0.64 0.54 0.50
T = 13 vs T = 26 wk 0.70 0.57 –
Average 0.68 0.56 0.50
Spearman correlation coefficients Same rater 0.66 0.59 0.55
Different rater 0.67 0.50 0.41
Intra/inter ratio 0.99 1.18 1.34
99
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were observed in any of the treatment groups6, the data of both the fish oil and 
placebo groups were suitable for examining the reliability of the three depression 
questionnaires, including the reproducibility.
Cronbach’s alpha is a commonly used measure for internal consistency and 
reliability. However, its value has recently been debated23-25. Assumptions, 
like equal item variances, are often not met and the reliability of a test may be 
underestimated in case of single test administration. We calculated Cronbach’s 
alpha at three time points, which gives a better estimate of the reliability.
The internal consistency of the CES-D in our study is adequate according to 
standard criterions (α>0.70)22 and in line with previous studies in non-patient 
older individuals (Table 5.4)10,11,26. The internal consistency of the MADRS 
(α=0.68) was acceptable, indicating that the items of the MADRS reflect 
depressive symptoms in a healthy study population reasonably well. Three other 
studies on the internal consistency of the MADRS showed inconsistent results in 
different study populations (Table 5.4)27-29. The Cronbach’s alpha of 0.41 for the 
GDS-15 in our study is low, which might be attributed to the strongly skewed 
distribution and the small variance, probably due to the yes/no answer format. 
Other studies reported better results in various study populations with a higher 
number of depressed subjects (Table 5.4)15,19,26,29,30.
The reproducibility correlation coefficients of the CES-D in the present study 
were higher than in previous studies (Table 5.4)7,10. Although Radloff used 
almost the same intervals as we did (2, 3 and 6 months), our reproducibility 
may be better because of our non-clinically depressed and probably more stable 
population. The lower reproducibility of Lewinsohn and colleagues may be 
due to the long time interval of 2.4 years, during which more actual changes 
in mood are likely to occur. The MADRS had a moderate reproducibility 
(correlation of 0.56), which probably reflects the higher sensitivity of the MADRS 
for detecting small changes of depressive symptoms, where the MADRS was 
designed for. No comparable studies investigating the reproducibility of the 
MADRS were found. The reproducibility correlation of the GDS-15 of 0.50 is 
lower than reproducibility correlations of the two other questionnaires and also 
lower compared to GDS-15 in other studies, although these data are not very 
consistent (Table 5.4)4,15,31. The reproducibility is likely to be largely influenced 
by the yes/no answer format.
The intra/inter rater reliability of the CES-D in the present study was close to one, 
so the effect of having different raters is practically of no influence. This was 
expected because it is a self-report scale, and different raters used a standardized 
protocol for administering the test. Conversely, on the GDS-15, which is also 
a self-report scale, the rater was of influence, which was an unexpected result. 
For the MADRS the intra/inter rater ratio was 1.18, which is most likely caused 
by the fact that the rater’s opinion forms part of the test score. Comparing our 
inter-rater reliability with findings in other studies is difficult, because we did 
not test the inter-rater reliability by doing a joint interview with two raters at 
the same time, but by single raters at three different time points and calculation 
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of the intra/inter rater ratio. Montgomery and Åsberg observed an inter-rater 
reliability between the 0.89 and 0.97, but their correlations were also based on 
a joint interview with two raters20.
Conclusion 
Based on our results, the CES-D appeared to be a better tool than the GDS-15 
and MADRS for measuring depressive symptoms in a non-clinically depressed, 
healthy older population.
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Abstract
Background Individuals with coronary heart disease are at increased risk of poor 
mental well-being. Dietary intake of eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), the main n-3 fatty acids from fish, may be beneficial to 
mental well-being.
Method In 644 participants, aged 60-80 years, with a history of myocardial 
infarction, the association of EPA+DHA and fish intake with mental well-being 
was examined. Habitual food intake was assessed with a 203-item food frequency 
questionnaire. Depressive symptoms were assessed with the self-report Geriatric 
Depression Scale (GDS-15) and dispositional optimism with the Revised Life 
Orientation Test (LOT-R) and a 4-item questionnaire (4Q). In Cox-regression 
models modified for cross-sectional analyses we adjusted for sex, age, energy 
intake, body mass index, family history of depression, education, marital status, 
smoking, physical activity, and intake of saturated fat, alcohol and fiber.
Results Compared with the lower tertile, subjects in the higher tertile of EPA+DHA 
intake had a lower prevalence of depressive symptoms, but this association was 
not statistically significant (prevalence ratio [PR] 0.78; 95% Confidence Interval 
[CI] = 0.50; 1.22, P-trend 0.27). The higher tertile of EPA+DHA intake was 
positively associated with dispositional optimism measured with the 4Q (PR 0.69; 
95% CI 0.46-1.03, P-trend 0.05), but not according to the LOT-R. Fish intake 
was not related to either depressive symptoms or dispositional optimism.
Conclusion Intake of EPA+DHA was positively associated with dispositional 
optimism assessed with the 4Q, but not with optimism assessed with the LOT-R 
or with depressive symptoms.
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Introduction
Poor mental well-being and coronary heart disease (CHD) often co-occur. 
Depression is a strong risk factor for the development of CHD and is associated 
with a worse prognosis of CHD1. In post-myocardial infarction (MI) patients 
the risk of depression is three times as high as compared to the general healthy 
population2. Therefore, the American Heart Association recommends to routinely 
screen for depressive disorders in coronary patients3.
A low intake of fish and marine n-3 polyunsaturated fatty acids (n-3 PUFA), 
especially of eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid 
(DHA, C22:6n-3), could increase the risk of CHD4 and may also predispose to 
depression. Because n-3 PUFAs are a major component of neural membranes and 
act as precursors of compounds involved in immune and inflammatory responses, 
it is biologically plausible that these PUFA could play a role in mood and 
behavioral disorders5. Appleton et al. reviewed the clinical and epidemiological 
evidence of n-3 PUFA and fish with depression until the beginning of 2008 and 
concluded that in both clinical as well as in observational studies depression may 
be associated with n-3 PUFA and fish intake and n-3 PUFA status, but results 
are inconclusive6. A meta-analysis of randomized controlled trials on n-3 PUFA 
supplementation and depression, which were mainly performed in depressed 
patients, pointed towards a beneficial effect, although the pooling of results was 
hampered by the heterogeneity of populations and type of interventions7. More 
recently, the results of a trial performed in 302 Dutch older subjects provided 
with 400 mg/d or 1,800 mg/d of EPA+DHA for 26 weeks have been published 
and did not show an effect on mental well-being8. Studies that focused on the 
association between n-3 PUFA and depression in coronary patients showed that 
depression was associated with lower plasma or membrane n-3 PUFA levels, 
in particular of DHA9-13.
Depression is not simply the reverse of optimism, but both affect mental well-
being and because the intake of fish or n-3 PUFA may alleviate depressive 
symptoms, it may also enhance optimism. Dispositional optimism is defined 
in terms of generalized positive expectancies for one’s future14 and has been 
associated with more healthy dietary and other lifestyle habits15,16, and also 
with less cardiovascular mortality17. In a prospective study in 773 community-
dwelling elderly men it was shown that dispositional optimism was associated 
with healthy lifestyle and dietary habits, including eating ≥400 mg EPA+DHA/
day16. Another study in 8,690 men and women aged 31 years showed that lack 
of optimism was associated with unhealthy dietary and other habits in general, 
including a low fish intake, but only in women15. 
In the present study, we examined the association of mental well-being, based on 
the lack of depressive symptoms and on the presence of dispositional optimism, 
with EPA+DHA and fish intake in an older population with a history of coronary 
heart disease.
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Subjects and methods
Subjects
We used baseline data of the Alpha Omega Trial, a randomized placebo-
controlled double-blind intervention study designed to investigate the effect 
of the n-3 PUFA alpha linolenic acid (ALA), EPA and DHA on cardiovascular 
mortality. Participants were free-living men and women aged 60-80 years with 
a documented history of myocardial infarction within the past 10 years. Main 
exclusion criteria were: [1] habitual fish intake >150 g/d; [2] habitual alcohol 
intake >6 drinks/d; [3] recent (within 2 weeks before study entry) or current use 
of fish oil or other n-3 capsules; or [4] dementia or severe cognitive impairment 
(Mini-Mental State Examination (MMSE) score <2218). The Medical Ethics 
Committee South West Holland approved the study and all participants gave 
written informed consent.
The sample examined in the present analysis comprised 791 participants who 
were enrolled in 2006, during the final part of the recruitment phase and who 
completed questionnaires on mental well-being. We excluded those with missing 
EPA+DHA intake data (n=97), and those who reported improbable energy intakes 
(n=10) (<500 or>3,500 kcal/d for women and <800 or >4,000 kcal/d for men)19. 
Furthermore, we excluded current users of anti-depressant medication (n=18) 
and subjects without complete data on all three measures of mental well-being 
(n=22). This resulted in a total of 644 subjects for the current analyses.
Assessment of mental well-being
Depressive symptoms were measured using the Geriatric Depression Screening 
Scale (GDS-15)20. The GDS-15 is a 15-item yes/no self-report questionnaire 
designed to screen for depressive symptoms during the past week in elderly 
subjects. The total score ranges from 0 to 15, with higher scores indicating more 
depressive symptoms. In elderly people a good sensitivity (0.88) and specificity 
(0.76) for depression was found for a cut-off point of ≥421. 
Dispositional optimism was assessed by using two questionnaires: the Life 
Orientation Test – Revised (LOT-R) and a 4-item questionnaire (4Q). The LOT-R 
consists of 10 coded items of which four statements are filler items not used in 
scoring22. Of the six items that are scored, three are keyed in a positive direction 
and three in a negative direction. There are five answer categories ranging from 
“strongly disagree” (coded as 0) to “strongly agree” (coded as 4). Negatively 
worded items (i.e. items 3, 7 and 9) are reversely coded before scoring. The 
total score ranges from 0 to 24 and higher scores indicate greater optimism. 
Because there is, to the best of our knowledge, no cut-off point for the LOT-R, 
we defined low dispositional optimism as the ≈20% of the subjects with the 
lowest scores yielding <12 as a cut-off.
The 4Q was previously used in the Zutphen Elderly Study and was predictive 
of both subsequent depressive symptoms23 and cardiovascular mortality17. It 
consists of the following four questions: “I still expect much from life”; “I do 
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not look forward to the years to come”; “My days seem to pass by slowly”, 
and “I am still full of plans”. The response format is a 3-point scale ranging 
from “fully in agreement” (coded as 0) to “not in agreement” (coded as 2). The 
additional answer category “do not know” is also coded as the midpoint (coded 
as 1). The two negatively worded items (i.e. items 2 and 3) are reversely coded 
before scoring, so higher scores again indicate greater optimism. A score <6, as 
previously defined in the Zutphen Elderly Study24, was used as cut-off to indicate 
low dispositional optimism.
Assessment of diet, EPA+DHA, and fish consumption
Habitual food intake during the previous month was estimated with a 203-
item food frequency questionnaire (FFQ), which was specifically developed 
for the Alpha Omega Trial. This list is based on a previously validated FFQ 
that was designed to estimate the intake of total energy, total fat, cholesterol, 
and saturated, monounsaturated, and polyunsaturated fatty acids in adults25. 
This questionnaire was updated, adapted for people aged 60-80 years, and 
extended with questions to estimate intakes of ALA, EPA, and DHA. Questions 
on frequency, amount, type, and cooking method of fish were also included. 
Trained dieticians checked the returned questionnaires and obtained 
information by phone on important unclear or missing important items. The food 
consumption data were converted into nutrient intakes by using the Netherlands 
Food Composition Table 200126.
Assessment of lifestyle and health
Trained research nurses performed baseline examinations at the hospital or at 
the subjects’ home. Body weight and height were measured and body mass 
index (BMI) was calculated as weight (in kg) divided by height squared (m2). 
Blood pressure was measured twice and the average was calculated. Blood 
samples were obtained for measurement of glucose, total cholesterol, and HDL 
cholesterol. Self-administered questionnaires were used to collect information 
on medical history, medication use, smoking habits (current/ former/never), 
educational level (low/ intermediate/high), and marital status (living together 
with wife, partner, or others/ alone). Subjects were considered physically 
active when they reported 30 minutes of moderate or heavy exercise per day 
as assessed by the physical activity scale for the elderly (PASE) questionnaire27. 
Hypercholesterolemia was defined as total serum cholesterol of ≥6.5 mmol/l 
or use of lipid-lowering medication. Hypertension was defined as systolic 
blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of 
antihypertensive medication. Diabetes was assessed by self-report or serum 
glucose ≥11.1 mmol/l, or present treatment with oral antidiabetic medication 
or insulin.
Chapter 6Association of fish fatty acids with mental well-being
112
Statistical analyses
If mental well-being measures had one missing response, the missing item was 
assigned the mean value of the other items on that particular scale for that 
participant. When >1 item on a particular questionnaire was missing, no total 
score was computed and the participant was not included in the analyses.
Baseline characteristics of the subjects were calculated for all subjects and for 
men and women separately. To examine the agreement between the LOT-R and 
the 4Q we used Spearman rank correlation and cross tabulations to examine 
whether subjects were categorized into the same tertile of dispositional optimism 
by the two questionnaires. The associations of the prevalence of depressive 
symptoms (GDS-15 ≥4) and the absence of dispositional optimism (4Q <6 
or LOT-R <12) with tertiles of EPA+DHA and fish were examined using a 
Cox-regression model with robust error variance, modified for cross-sectional 
analyses28,29. Associations are presented as prevalence ratios (PR) with 95% 
confidence intervals (95% CI) with the lower tertile of intake as reference group. 
Analyses were adjusted for sex, age, and family history of depression in the first 
model and in the second model more socio-demographic, lifestyle, and food 
intake factors were added, namely, BMI, education, marital status, smoking 
status, physical activity, energy intake, intake of saturated fat, alcohol, and fiber. 
Tests of linear trend across increasing tertiles of EPA+DHA and fish intake were 
performed by using the median values of intake for each tertile. 
A two sided P-value of <0.05 was considered statistically significant and the 
statistical analyses were performed using SAS Version 9.1 (SAS Institute Inc., 
Cary, North Carolina, USA).
Results
Population characteristics
The study population comprised 644 participants, 500 men with a mean age 
of 69 years and 144 women with a mean age of 70 years (Table 6.1). Based 
on GDS-15 scores with a cut-off point ≥4, 17% of the subjects had depressive 
symptoms and this was twice as high in women (29%) compared to men (14%). 
Based on LOT-R scores with cut-off point <12 the percentage of low dispositional 
optimism was 15% and based on 4Q scores with cut-off point <6 the percentage 
of low dispositional optimism was 22%. Women were slightly less optimistic 
than men as measured with the LOT-R (16% vs. 15%) and as well as with the 
4Q (32% vs. 19%). Median fish intake was 15 g/d and 40% of the participants 
consumed fish less than once per week, 40% consumed fish once per week and 
20% consumed fish more than once per week. The median intake of EPA+DHA 
was 130 mg/d, women consuming slightly less than men (120 vs.140 mg/d). 
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Table 6.1  Characteristics of 644 Dutch subjects aged 60-80 years with a history of myocardial 
infarctiona
a Values are mean ± SD, median (interquartile range: Q1-Q3) for skewed data, or percentages.
b GDS-15: Geriatric Depression Scale-15, higher scores indicate poorer mental well-being20.
c LOT-R: Life Orientation Test - Revised, higher scores indicate greater optimism22.
d 4Q: 4-item questionnaire on dispositional optimism, higher scores indicate greater optimism23.
e MMSE: Mini-Mental State Examination, higher scores indicate better cognitive function18.
f BMI: body mass index.
g Defined as ≥30 minutes/d of physical activity.
h Low: primary education or less; intermediate: secondary general or vocational education; high: higher 
vocational education, university.
i Defined as total serum cholesterol concentrations ≥6.5 mmol/l or use of lipid-lowering medication.
j Defined as systolic ≥140 mmHg or diastolic ≥90 mmHg or use of antihypertensive medication.
k Defined by self-report, as serum glucose ≥11.1 mmol/l or as treatment with oral antidiabetic medication or 
insulin.
l EPA: eicosapentaenoic acid.
m DHA: docosahexaenoic acid.
Total (n=644) Men (n=500) Women (n=144)
Age (y) 69 ± 6 69 ± 6 70 ± 6
Score GDS-15 (0-15)b 1 (0-3) 1 (0-3) 2 (1-4)
Score ≥4 (%) 17 14 29
Score LOT-R (0-24)c 15 (13-17) 15 (13-17) 14 (12-16)
Score ≥12 (%) 85 85 84
Score 4Q (0-8)d 7 (6-8) 7 (6-8) 6 (5-8)
Score ≥6 (%) 78 81 68
Family history depressive symptoms (%) 16 16 16
Previous treatment for depressive symptoms (%) 13 12 17
Living alone (%) 17 10 44
MMSE score (0-30)e 28.5 (27-29) 29 (27-30) 28 (27-29)
BMI (kg/m2)f 28 ± 4 28 ± 4 28 ± 5
Physical activity (%)g 66 68 60
Education (%) low/ intermediate/ highh 55/ 33/ 12 52/ 35/ 14 66/ 27/ 7
Smoking status (%) current/ former/ never 15/ 67/ 18 13/ 74/ 13 20/ 44/ 36
Hypercholesterolemia (%)i 87 86 90
Blood pressure (mmHg)
Systolic 139 ± 22 138 ± 21 140 ± 23
Diastolic 78 ± 11 79 ± 11 75 ± 12
Hypertension (%)j 93 93 90
Diabetes mellitus (%)k 20 18 27
Dietary intake
Energy intake (kJ/d) 8,002 ± 2,090 8,330 ± 2,086 6,864 ± 1,669
Saturated fat (g/d) 26 ± 10 28 ± 10 21 ± 6
EPA (mg/d)l 50 (20-80) 50 (20-80) 50 (20-90)
DHA (mg/d)m 80 (40-130) 90 (50-130) 70 (40-145)
Fiber (g/d) 22 ± 7 22 ± 7 21 ± 7
Daily alcohol intake:
0 glasses (%) 28 20 54
0.1-2.9 glasses (%) 65 70 44
≥3 glasses (%) 8 9 1
Total fish consumption (g/d) 15 (8-17) 15 (8-18) 15 (5-17)
Fish intake:
<1/ week (%) 40 40 41
1/ week (%) 40 41 36
>1/ week (%) 20 19 23
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Depressive symptoms
Compared with the lowest tertile, subjects in the highest tertile of EPA+DHA 
intake had a significantly lower prevalence of depressive symptoms (prevalence 
ratio [PR] 0.56; 95% CI = 0.36; 0.88, P-trend 0.009), which was no longer 
significant after adjustment for confounders (PR 0.78; 95% CI = 0.50; 1.22, 
P-trend 0.27) (Table 6.2). For fish intake the unadjusted PR of depressive 
symptoms for the highest tertile was 0.73 (95% CI = 0.48; 1.12, P-trend 0.14) 
and the multivariable adjusted PR was 0.94 (95% CI = 0.62; 1.42, P-trend 0.57) 
(Table 6.3). Adding the 18 users of anti-depressant medication to the depressive 
symptoms group did not change these results (data not shown).
Dispositional optimism
Of the subjects 46% was categorized in the same tertile with the LOT-R and 4Q. 
Furthermore, 47% was categorized in the adjacent tertile for the LOT-R and 4Q 
and 7% was categorized into the opposite tertile. Spearman rank correlation 
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Table 6.2  Prevalence ratiosa for the association of EPA+DHA intake with depressive 
symptomsb and dispositional optimismc in older subjects with a history of myocardial 
infarction
a Prevalence ratios (95% CI) obtained using Cox regression with robust error variance.
b Depressive symptoms are defined as a score of ≥4 on the Geriatric Depression Screening Scale (GDS-15).
c Low optimism is defined as a score <6 on the 4-item questionnaire (4Q) or a score <12 on the Life Orientation 
Test - Revised (LOT-R).
d Cut-off and median (Q1-Q3) per tertile.
e P-trend refers to a linear trend in regression coefficients across tertiles of intake using the median values of 
each tertile.
f Adjusted for sex, age, and family history of depression.
g Adjusted for BMI, education, marital status, smoking status, physical activity, energy intake, intake of 
saturated fat, alcohol, and fiber (n=636).
EPA+DHA (mg/d)d P-trende
≤90
40 (10;70) 
(n=221)
90-180 
140 (120;160)
(n=214)
≥180
360 (220;460)
(n=209)
Depressive symptoms on the GDS-15
Crude association 1 0.86 (0.59;1.25) 0.56 (0.36;0.88) 0.009
Model 1f 1 0.92 (0.64;1.34) 0.60 (0.39;0.94) 0.02
Model 2g 1 1.07 (0.74;1.56) 0.78 (0.50;1.22) 0.27
Low optimism on the 4Q
Crude association 1 0.93 (0.67;1.28) 0.52 (0.35;0.78) 0.003
Model 1f 1 0.98 (0.72;1.33) 0.57 (0.39;0.85) 0.003
Model 2g 1 1.05 (0.76;1.44) 0.69 (0.46;1.03) 0.05
Low optimism on the LOT-R
Crude association 1 0.84 (0.54;1.30) 0.86 (0.55;1.34) 0.57
Model 1f 1 0.84 (0.54;1.31) 0.88 (0.57;1.37) 0.65
Model 2g 1 0.92 (0.59;1.42) 1.13 (0.72;1.79) 0.53
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between the two questionnaires was 0.44 (P<0.0001).
For dispositional optimism measured with the 4Q the unadjusted PR for the 
highest tertile of EPA+DHA intake as compared to the reference group was 0.52 
(95% CI = 0.35; 0.78, P-trend 0.003) and the statistical significant trend remained 
after adjustment for confounders (PR 0.69; 95% CI = 0.46; 1.03, P-trend 0.05) 
(Table 6.2). However, dispositional optimism measured with the LOT-R was not 
associated with EPA+DHA intake. Fish intake was not related to dispositional 
optimism neither measured with the LOT-R nor with 4Q (Table 6.3).
Discussion
In this study in Dutch, older subjects with established coronary heart disease 
there was a significant positive association between EPA+DHA intake and 
dispositional optimism assessed with the 4Q, but not with the LOT-R. The 
inverse association of depressive symptoms with EPA+DHA intake was no longer 
statistically significant after adjusting for confounders.
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Table 6.3  Prevalence ratiosa for the association of fish intake with depressive symptomsb 
and dispositional optimismc in older subjects with a history of myocardial infarction
a Prevalence ratios (95% CI) obtained using Cox regression with robust error variance.
b Depressive symptoms are defined as a score of ≥4 on the Geriatric Depression Screening Scale (GDS-15).
c Low optimism is defined as a score <6 on the 4-item questionnaire (4Q) or a score <12 on the Life Orientation 
Test - Revised (LOT-R).
d Cut-off and median (Q1-Q3) per tertile.
e P-trend refers to a linear trend in regression coefficients across tertiles of intake using the median values of 
each tertile.
f Adjusted for sex, age, and family history of depression.
g Adjusted for BMI, education, marital status, smoking status, physical activity, energy intake, intake of 
saturated fat, alcohol, and fiber (n=636).
Fish (g/d)d
≤9.8
4.3 (0.0;7.7)
(n=214)
9.8-<16.2
15.0 (11.8;15.5)
(n=214)
≥16.2
36.8 (17.4;40.5)
(n=216)
P-trende
Depressive symptoms on the GDS-15
Crude association 1 0.91 (0.61;1.34) 0.73 (0.48;1.12) 0.14
Model 1f 1 0.94 (0.64;1.39) 0.75 (0.50;1.14) 0.13
Model 2g 1 1.19 (0.81;1.75) 0.94 (0.62;1.42) 0.57
Low optimism on the 4Q
Crude association 1 0.80 (0.57;1.13) 0.71 (0.49;1.01) 0.07
Model 1f 1 0.84 (0.60;1.16) 0.74 (0.52;1.04) 0.09
Model 2g 1 0.93 (0.66;1.30) 0.85 (0.60;1.21) 0.37
Low optimism on the LOT-R
Crude association 1 1.00 (0.65;1.55) 0.85 (0.54;1.34) 0.44
Model 1f 1 1.02 (0.66;1.57) 0.86 (0.54;1.35) 0.47
Model 2g 1 1.13 (0.73;1.76) 1.03 (0.65;1.63) 0.96
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To assess depressive symptoms we used the self-administered GDS-15 which has 
a good sensitivity (0.88) and specificity (0.76) to screen for depression in an older 
population21. To assess dispositional optimism two questionnaires were used. The 
LOT-R assesses respondents’ expectations for the future and is considered the 
standard psychological optimism test with good psychometric properties22. The 
other optimism test, the 4Q, was shown to represent a rather stable personality 
measure over time, and was predictive of subsequent depressive symptoms 
and cardiovascular mortality in the Zutphen Elderly Study17,23, but has not been 
validated against other measures of mental well-being. 
Dietary intake of the previous month was assessed by a FFQ that was based on 
a validated FFQ for estimating total energy and fatty acid intake25. A general 
disadvantage of FFQs is that they are memory based which could result in over- 
or underestimation of intake. Fish consumption may also be subject to reporting 
bias due to the known possible health benefits of fish. However, for ranking 
individuals according to their intake FFQs are suitable. Fish consumption was 
assessed including the frequency, amount, and type of fish, but our sample size 
and the range of intake were too small to separately analyze different types of 
fish in relation to mental well-being. We observed that associations between 
fish intake and mental well-being were weaker than associations between 
EPA+DHA and mental well-being, which supports the idea that EPA+DHA, as 
the major nutrient in fish, attributed mostly to the beneficial association with 
mental well-being. 
Other observational studies showed that both depression30 and lack of 
dispositional optimism are associated with unhealthy lifestyle and dietary 
habits15,16. Fish and EPA+DHA intake may be considered part of a healthy diet 
and lifestyle, which may explain why our associations between mental well-
being and EPA+DHA intake and fish were attenuated after adjusting for many 
important lifestyle and dietary variables in the multivariable adjusted models. 
Appleton et al. concluded that depression was associated with fish intake both 
directly and indirectly, as a result of the absence of fish in a diet associated with 
depressed mood and in a lifestyle associated with depressed mood30. Thus, it is 
possible that mental well-being is more influenced by a healthy dietary pattern 
and lifestyle, than exclusively by fish or EPA+DHA intake. Conversely, MI 
patients with depression were found to be less likely to adhere to dietary and 
lifestyle recommendations than MI patients without depression31. Thus, more 
optimal mental well-being might lead one to use a healthy diet. 
Our results, though not significant, pointed to the same direction as other studies 
on depression in coronary heart patients, which all showed that depression was 
associated with lower plasma or membrane levels of n-3 PUFA, in particular 
DHA9-13. However, one study also observed that the effect was no longer 
significant after adjustment for confounders, whereas only two of these studies 
adjusted for lifestyle confounders and none for other nutritional confounders. 
EPA+DHA intake is associated with blood levels of moderate strength32. The 
correlation between EPA+DHA intake and EPA+DHA concentrations in plasma 
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cholesteryl esters in our study was 0.37 (unpublished results). Our results are 
consistent with some cross-sectional studies in general populations that also 
found no association between intake and depression33-35. Yet, several other 
cross-sectional studies did observe an inverse association30,36-39. Our study 
population predominantly comprised men and some studies observed an 
association between fish and EPA+DHA intake and depressive symptoms only 
in women36,37,40. Contrarily, Astorg et al. observed stronger associations of fatty 
fish or n-3 PUFA intake with (recurrent) depressive episodes in men compared 
to women41. Sex may thus interact with the association between depression and 
EPA+DHA and fish. In a stratified analysis in male participants only (data not 
shown) we observed weaker associations between EPA+DHA and fish intake 
compared to our whole study population so a gender difference may indeed 
be an explanation for the fact that we did not observe a significant association 
in our total population. 
To the best of our knowledge, there is only one other study that found an 
association between dispositional optimism and EPA+DHA intake16. In this 
study dispositional optimism was also measured with the 4Q and higher mean 
dispositional optimism scores were only observed with EPA+DHA intakes ≥400 
mg/day compared with EPA+DHA intakes <400 mg/day. However, we did not 
observe an association of EPA+DHA intake and dispositional optimism measured 
with the LOT-R. These questionnaires may differ, because the 4Q also captures 
life engagement, vitality, motivation, and feeling a purpose in life17, rather than 
generalized positive outcome expectancies that is the focus of the LOT-R22. 
Nevertheless, 46% of the participants were classified into the same tertile with 
both the LOT-R and 4Q and Spearman rank correlation was 0.44 indicating 
reasonable agreement between the two questionnaires. 
The present study also has some limitations that need to be considered. First, we 
performed a cross-sectional analysis from which causality cannot be inferred. As 
pointed out by Kamphuis et al. reverse causality is an alternative explanation, 
because depression may induce loss of appetite, decreased food consumption, 
and weight loss39. Second, although we adjusted our analyses for the most 
important potential confounders residual confounding cannot be completely 
ruled out. Third, the differences in intakes of fish and EPA+DHA between the 
tertiles may have been too small to find an association. Fourth, we did not 
assess clinical depressive disorders through structured clinical interviews based 
on the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. 
Finally, selection bias could be an issue in our study since depressive subjects 
could be less willing to participate in a 3-year intervention study, questioning 
generalizability. 
In conclusion, in this population of Dutch older subjects with a history of 
coronary heart disease there was a significant positive association between 
EPA+DHA intake and dispositional optimism assessed with the 4Q, but not 
with the LOT-R. There was also a tendency for less depressive symptoms with 
a higher EPA+DHA or fish intake, but after adjustment for confounders these 
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Abstract
Objectives To investigate the effect of eicosapentaenoic acid (EPA) plus docosa-
hexaenoic acid (DHA) supplementation on quality of life (QOL).
Design Randomized, double-blind, placebo-controlled trial.
Setting Independently living individuals from the general older Dutch popula-
tion.
Participants Three hundred two individuals aged 65 years and older without 
depression or dementia.
Intervention 1,800 mg/d EPA+DHA (n=96), 400 mg/d EPA+DHA (n=100), or 
placebo capsules (n=106) for 26 weeks.
Measurements QOL was assessed using the short version of the World Health 
Organization QOL questionnaire (WHOQOL-BREF). The WHOQOL-BREF 
covers four domains: physical health, psychological health, social relationships 
and satisfaction with environment. The total score range is 26 to 130 with higher 
scores indicating a more favorable condition.
Results Mean age of the participants was 70, and 55% were male. Plasma 
concentrations of EPA+DHA increased 238% in the high-dose and 51% in the 
low-dose EPA+DHA group, reflecting excellent adherence. Median baseline 
total WHOQOL scores ranged from 107 to 110 in the three groups and were 
not significantly different from each other. After 26 weeks, the mean difference 
from placebo was –1.42 (95% confidence interval (CI) = –3.40; 0.57) for the 
high-dose and 0.02 (95% CI = –1.95; 1.99) for the low-dose fish oil group. 
Treatment with 1,800 mg or 400 mg EPA+DHA did not affect total QOL or any 
of the separate domains after 13 or 26 weeks of intervention.
Conclusion Supplementation with high or low doses of fish oil for 26 weeks did 
not influence the QOL of healthy older individuals.
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Introduction
The World Health Organization (WHO) has defined quality of life (QOL) as 
an individual’s perception of their position in life in the context of culture and 
value systems in which they live and in relation to their goals, expectations, 
standards and concerns1. It is a broad-ranging concept affected in a complex 
way by physical health, psychological state, level of independence, social 
relationships, and relationship to salient features of their environment2. Improving 
QOL is becoming an increasingly important outcome in elderly research, and 
for studies of health promotion, generic outcomes are even more relevant than 
disorder-specific outcomes.
Current evidence indicates that low intake and low levels of n-3 polyunsaturated 
fatty acids (PUFAs), such as eicosapentaenoic acid (EPA, C20:5n-3) and 
docosahexaenoic acid (DHA, C22:6n-3), are associated with mental health 
problems, which are among the leading causes of impaired QOL in old age3. 
Because n-3 PUFAs are a major component of neural membranes and act as 
precursors of compounds involved in immune and inflammatory responses, 
it is biologically plausible that they could play a role in mental processes and 
thus affect QOL4.
Two observational studies performed in the same population of New Zealand 
adults have assessed the association between n-3 PUFAs and QOL. The Medical 
Outcomes Short Form (36) Health Survey (SF-36) was used and indicated a 
significant positive association between fish intake and self-reported scores on 
the mental health part of the SF-36 in 4,644 subjects5 and found a significant 
positive trend across quintiles of the proportion of EPA in serum phospholipids 
for self-reported scores on the physical health part, but not for the mental health 
part of the SF-36 in 2,793 subjects6. Furthermore, several observational studies 
relating n-3 PUFAs to mood, which is a strong determinant of impaired QOL, 
provide support for an association between depressed mood and fish intake 
or between depressed mood and n-3 PUFAs concentrations in the blood7. 
Clinical trials have mainly been conducted in patients with depressive disorders 
and yielded inconsistent findings for n-3 PUFA supplementation8. Recently, a 
trial in mild to moderately depressed individuals from the general population 
showed no effect after 3 months of supplementation with 1.5 g EPA+DHA per 
day9. Only one trial has been performed in healthy subjects (n=33; mean age 
33), who experienced an improvement in mood during daily supplementation 
of 1.6 g EPA and 0.8 g DHA for 35 days10. 
Despite the availability of valid and reliable QOL instruments, they have seldom 
been applied in efficacy trials that address mental well-being11, but such data are 
sorely needed because caregivers and professionals may wish to improve the 
patients’ QOL, especially for patients with dementia or cognitive impairment, 
for which pharmacological treatment is often ineffective. A double-blind 
randomized placebo-controlled trial of the effect of fish oil supplementation 
on cognitive performance and depressive symptoms was conducted12,13. In this 
trial of 302 elderly Dutch subjects, QOL was additionally assessed using the 
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WHOQOL-BREF questionnaire. Effects of high and low doses of n-3 PUFA on 
QOL, including subdomains, are presented here.
Methods
Participants
Between November 2005 and February 2006, subjects were screened; intervention 
took place between February 2006 and November 2006. All subjects were aged 
65 and older. The main exclusion criteria were a score greater than 16 on the 
Centre for Epidemiological Studies Depression Scale (CES-D)14; a score of less 
than 21 points on the Mini-Mental State Examination (MMSE)15; current or recent 
(<4 weeks) use of fish oil supplements; intake of fish more than four times per 
week or more than 800 mg of EPA+DHA from fish per day, as estimated from a 
fish consumption questionnaire; current use of pharmacological antidepressants; 
current use of medication for dementia; and consumption of more than four 
glasses of alcohol per day. Additionally, adherence to capsule use during the 
2-week placebo run-in period had to be at least 80% on the basis of self-report. 
The Medical Ethical Committee of Wageningen University approved this study 
and all subjects gave written informed consent.
Study design
Primary outcomes of this trial were cognitive performance and depressive 
symptoms; the results, together with a detailed description of this study, have 
been reported elsewhere12,13. An independent person randomized subjects using 
computer-generated random numbers in stratified permuted blocks of size six. 
Stratification factors included age (<69 and ≥69y), sex, MMSE (<28 and ≥28), 
and CES-D screening test score (<5 and ≥5). Individuals received a daily dose 
of fish oil containing a high dose of EPA+DHA (~1,800 mg), a low dose of 
EPA+DHA (~400 mg), or a placebo oil (high oleic sunflower oil) for 26 weeks 
(Lipid Nutrition, Wormerveer, the Netherlands). The high daily dose of fish oil 
provided 1,093 ± 17 mg EPA and 847 ± 23 mg of DHA, which corresponds 
to eating approximately eight portions of fish per week. The low daily dose of 
fish oil provided 226 ± 3 mg EPA and 176 ± 4 mg of DHA, which is roughly 
equivalent to eating one to two servings of oily fish per week. The capsules with 
fish oil or placebo oil were indistinguishable in appearance. Adherence was 
judged according to counts of capsules returned and a diary in which participants 
registered the number of capsules that they did not consume.
Sample size calculation was based on the two primary outcomes of this study: 
cognitive performance (Word Learning Test: difference of four points; mean ± 
SD of 45 ± 8)16 and depressive symptoms (CES-D: difference of three points; 
mean ± SD of 9 ± 7)17; a minimum sample size of 63 and 85 subjects per group, 
respectively, was required to detect a difference (power 80%, two-sided α=0.05). 
Anticipating a possible dropout rate of 15%, 100 subjects per treatment group 
were included. With this sample size we would have been able to detect a 
difference of 2.4 points on the WHOQOL questionnaire.
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Assessment of QOL
In this study, the short version of the WHOQOL, the WHOQOL-BREF, was 
used18. The WHOQOL is a 100-item QOL instrument developed by the WHO 
to facilitate cross-cultural comparisons in QOL research19. The WHOQOL 
instruments focus on an individual’s own views of their well-being. The 
WHOQOL-BREF was developed to enable a brief but accurate assessment 
of QOL in routine clinical work, epidemiological studies, and clinical trials. 
The questionnaire comprised 26 items, including two general items and 24 
items covering four domains: physical health, psychological health, social 
relationships, and environment. The scores of the two general items range 
from 1 to 5 and the domain scores range from 7 to 35, 6 to 30, 3 to 15 and 8 
to 40, respectively. The total score range of the WHOQOL-BREF is 26 to 130 
with higher scores indicating a favorable condition. The reference period is the 
previous 2 weeks and questions are scored on a 5-point Likert scale. Studies have 
shown good content validity, discriminant validity and test-retest reliability20,21. 
The QOL questionnaire was self-administered and checked for completeness 
by a research assistant at the study center at baseline and after 13 and 26 weeks 
of intervention.
Other measurements
A fasting venous blood sample for determination of n-3 PUFAs was collected 
at baseline and after 13 and 26 weeks of intervention. N-3 PUFAs in plasma 
cholesteryl esters were determined as described previously22.
Information on medical history, drug use, alcohol consumption, smoking habits, 
educational level, marital status and physical activity level was obtained using 
a questionnaire and reviewed by a research assistant for completeness. A food-
frequency questionnaire was administered at screening, at baseline, and after 13 
and 26 weeks of intervention to estimate fish intake in the previous 3 months. 
EPA+DHA intake was calculated by multiplying the frequencies of portions of 
fish per month from each group by a conversion factor23. 
Height was measured at baseline and weight and waist circumference were 
measured at each center visit in a standing position and with participants dressed 
in light clothing and without shoes. Height was measured to the nearest 0.1 
cm using a wall-mounted stadiometer, and weight was measured to the nearest 
0.1 kg using a calibrated digital scale. Waist circumference was measured in 
duplicate to the nearest 0.1 cm at the midpoint between the lowest rib and the 
top of the iliac crest using a nonelastic tape.
Statistical analysis
Data analyses were performed on an intention-to-treat basis and according to 
a predefined data analysis plan using SPSS 12.0.1 (SPSS, Inc., Chicago, IL). A 
two-sided P-value <0.05 was considered statistically significant. Staff members 
and participants were blinded to treatment allocation until completion of the 
trial and after completion of blind data analysis.
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Baseline characteristics of treatment groups were compared by one-way 
analysis of variance (ANOVA) or Kruskal-Wallis for continuous variables and 
chi-square for categorical variables. Differential changes in QOL between the 
three intervention groups were tested using ANOVA, and the Dunnett test was 
used to compare mean changes within the treatment groups with that of the 
placebo group. These analyses were performed for effects of fish oil treatment 
after 13 and after 26 weeks. 
After performing the primary intention-to-treat analysis an additional per-protocol 
analysis, including adherent subjects only, was performed. Furthermore, some 
exploratory post hoc analyses were performed for subgroups of men and 
women separately, because based on literature, more effect could be expected 
in women24-27, and in a subgroup of individuals in the tertile with the highest 
total WHOQOL-BREF scores at baseline.
Results
Randomization and attrition
Three hundred two subjects who fulfilled the inclusion criteria were randomized 
to receive 1,800 mg per day of EPA+DHA (n=96), 400 mg per day of EPA+DHA 
(n=100), or placebo (n=106). For more details on participant flow see Figure 2.1 
and 4.1 in one of the previous publications on this trial12,13. Nine subjects did 
not complete the study: five stopped because of gastrointestinal complaints and 
two because participation became too burdensome, and two died before the end 
of the intervention. Nevertheless, seven dropouts visited the study center after 
13 weeks, and six dropouts visited the study center after 26 weeks. Therefore, 
for intention-to-treat analyses, data of 300 participants were analyzed after 13 
weeks and of 299 participants after 26 weeks of intervention. 
Participant characteristics and compliance
The mean age of the participants was 69.8 and 55% were male. Baseline 
characteristics were well balanced between the three treatment groups (Table 
7.1).
Apart from the individuals who stopped treatment prematurely, the average 
adherence to treatments based on counts of returned capsules was high (99%, 
with only 3 subjects <80%) and did not differ between the treatment groups. 
Compliance was confirmed by an increase in the proportions of EPA and DHA 
in plasma cholesteryl esters of 62% and 28% in the low-dose fish oil group (EPA 
from 1.3 ± 0.9 to 2.0 ± 0.9 and DHA from 0.6 ± 0.2 to 0.8 ± 0.2 g/100g fatty 
acids), and 305% and 94% in the high-dose fish oil group (EPA from 1.3 ± 0.7 
to 5.2 ± 1.3 and DHA from 0.6 ± 0.2 to 1.2 ± 0.2 g/100g fatty acids) and by a 
small decrease of 2% and 3% in the placebo group (EPA from 1.3 ± 1.0 to 1.2 
± 0.9 and DHA from 0.7 ± 0.2 to 0.6 ± 0.2 g/100g fatty acids). The supplements 
were well tolerated; the main complaints were mild gastrointestinal discomfort, 
and the number of complaints was not different between the three groups. At the 
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end of the study the proportion of participants who thought they had received 
fish oil or placebo did not differ among the groups (P=0.15); the recognition 
scores do not differ from chance scores.
Quality of life
Total WHOQOL-BREF scores at baseline and after 13 weeks and after 26 weeks 
of intervention were comparable between the three groups, median total scores 
at baseline were 110.0 (Q1-Q3: 101.0-116.8), 107.0 (Q1-Q3: 99.3-114.0) and 
107.0 (Q1-Q3: 100.0-113.3) in the high-dose fish oil, low-dose fish oil and 
placebo groups, respectively (Table 7.2). The scores on the four different domains 
of physical health, psychological health, social relationships and environment 
were also not significantly different from each other.
After 13 weeks and after 26 weeks of supplementation, neither of the fish oil 
groups showed better total WHOQOL-BREF scores or better on any of the four 
domains than the placebo group (Table 7.3). After 26 weeks, the mean difference 
from placebo for total WHOQOL-BREF was –1.42 (95% CI = –3.40; 0.57) in 
Table 7.1  Characteristics of 302 subjects participating in a randomized, placebo-controlled 
trial according to treatment groupa
a There were no significant differences between the three treatment groups, P<0.05 (one-way ANOVA or 
Kruskal Wallis for continuous variables and chi-square analysis for categorical variables). 
b Mean ± SD (all such values).
c Mean consumption in consumers only.
d Median (Q1-Q3) (all such values).
1,800 mg EPA+DHA
(n=96)
400 mg EPA+DHA
(n=100)
Placebo
(n=106)
Age (years) 69.9 ± 3.4b 69.5 ±  3.2 70.1 ±  3.7
Male (%) 55 55 56
Married/ living together (%) 80 81 77
Education Low/ Middle/ High (%) 10/ 54/ 35 11/ 49/ 40 5/ 59/ 37
BMI (kg/m2) 26.1 ± 3.0 26.2 ± 3.4 26.5 ± 3.9
Waist circumference (cm) 94.5 ± 11.4 94.2 ± 10.6 95.9 ± 12.1
Physical activity score 11.5 ± 6.4 11.1 ± 6.2 11.4 ± 6.2
Smoking behavior (%)
Smoker/ ex-smoker/ never smoker 8/ 64/ 28 8/ 54/ 38 10/ 56/ 34
Alcohol consumers (%) 80 87 88
Median alcohol consumption 
(glasses/week)c
10 (6-14)d 8 (4-14) 8 (4-14)
Fish consumption (times/ month) 7 (4-9) 5 (3-9) 6 (4-8)
EPA+DHA intake (mg/day) 306 (131-592) 278 (103-487) 316 (166-584)
Plasma EPA (mass%) 1.3 ± 0.7 1.3 ± 0.9 1.3 ± 1.0
Plasma DHA (mass%) 0.6 ± 0.2 0.6 ± 0.2 0.7 ± 0.2
Apolipoprotein E ε4 allele 0/ 1/ 2 (%) 68/ 29/ 3 69/ 30/ 1 71/ 26/ 2 
MMSE (Mini-Mental State Examination) 28 (27-29) 28 (27-29) 28 (27-29)
CES-D (range 0-60) 5.0 (2.0-8.8) 5.0 (2.0-8.8) 6.0 (2.0-10.0)
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the high-dose fish oil group and 0.02 (95% CI = –1.95; 1.99) in the low-dose 
fish oil group. 
Per-protocol analysis, excluding the dropouts and nonadherent subjects, did not 
change the results. Exploratory analysis in a subgroup of 98 individuals in the 
tertile with the highest total WHOQOL-BREF scores at baseline (≥113) yielded 
similar findings. Mean differences from placebo for total WHOQOL-BREF after 
26 weeks in this subgroup were –2.60 (95% CI = –5.79; 0.59) for the high-dose 
fish oil group (n=38) and –1.59 (95% CI = –4.95; 1.78) for the low-dose group 
(n=31). Exploratory analysis according to sex showed a significant change after 
26 weeks in men in the high-dose fish oil group (n=53) with a difference from 
placebo of –3.28 (95% CI = –5.85; 0.71). After 26 weeks, a significant difference 
in men in the high-dose fish oil group was also observed for the domain physical 
health (–1.00 (95% CI = –1.95; –0.05)) and for the domain environment (–1.45 
(95% CI = –2.55; –0.35)).
Table 7.2  Scores for overall quality of life (QOL) and for the four separate domains of 
QOL studied in Dutch older adults at baseline and after 13 and 26 weeks of EPA+DHA 
supplementation according to treatment group: median (Q1-Q3)a
a No significant differences between the three treatment groups were observed, P>0.05 (Kruskal-Wallis).
b Higher scores indicate better quality of life.
c n=96 at baseline, n=95 after 13 weeks, and n=96 after 26 weeks. 
d n=100 at baseline, and after 13 and 26 weeks.
e n=106 at baseline, n=104 after 13 weeks, and n=103 after 26 weeks.
Quality of life 
(minimum-maximum)b
1,800 mg EPA+DHAc 400 mg EPA+DHAd Placeboe
WHOQOL-BREF total 
(26-130)
Baseline 110.0 (101.0-116.8) 107.0 (99.3-114.0) 107.0 (100.0-113.3)
13 weeks 111.0 (101.0-117.0) 107.0 (100.0-114.0) 108.0 (100.0-115.9)
26 weeks 108.0 (100.0-118.0) 107.0 (101.3-114.0) 107.0 (100.0-115.0)
Domain I: Physical 
health (7-35)
Baseline 30.0 (27.0-33.0) 30.0 (27.0-32.0) 29.0 (26.8-31.3)
13 weeks 31.0 (27.0-33.0) 30.0 (27.0-32.0) 30.0 (27.0-32.0)
26 weeks 30.0 (27.0-33.0) 30.0 (28.0-32.0) 29.0 (27.0-31.0)
Domain II: Psycholo-
gical health (6-30)
Baseline 24.0 (22.0-26.0) 23.0 (21.0-25.0) 24.0 (21.0-25.0)
13 weeks 24.0 (21.0-26.0) 23.0 (21.0-25.0) 23.5 (21.3-26.0)
26 weeks 24.0 (21.0-26.0) 23.0 (21.3-25.0) 23.0 (22.0-26.0)
Domain III: Social 
relationships (3-15)
Baseline 12.0 (11.0-13.0) 12.0 (11.0-13.0) 12.0 (11.0-13.0)
13 weeks 12.0 (11.0-13.0) 12.0 (10.0-13.0) 12.0 (11.0-13.0)
26 weeks 12.0 (11.0-13.0) 12.0 (11.0-13.0) 12.0 (11.0-13.0)
Domain IV: 
Environment (8-40)
Baseline 35.0 (32.0-38.0) 35.0 (32.3-36.0) 34.0 (31.0-36.0)
13 weeks 35.0 (33.0-38.0) 34.0 (31.0-37.0) 34.0 (30.9-37.0)
26 weeks 35.0 (31.0-37.8) 34.0 (31.3-37.0) 34.0 (31.0-37.0)
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Discussion
To the best of the authors’ knowledge, this is the first randomized, double-blind, 
placebo-controlled trial to assess the effect of n-3 PUFAs supplementation on 
the QOL of older adults. It showed that daily supplementation with a low or 
a high dose of EPA+DHA for 26 weeks had no effect on QOL in healthy older 
subjects. Adherence was excellent and did not differ between the treatment 
groups, which indicated that most subjects tolerated taking six capsules daily 
for 26 weeks. The dropout rate was low, at 3%, and cannot therefore explain 
the findings.
QOL was assessed using the WHOQOL-BREF, a questionnaire that comprises 
physical, psychological, social, and environmental domains and studies of which 
have shown good internal consistency, excellent discriminant validity and good 
sensitivity20,21. Most of the questionnaires that assess QOL assess health-related 
QOL, whereas the WHOQOL includes a strong mental health component and 
emphasizes the perception of the individual. Because of the implications for an 
association between omega-3 PUFAs and mental well-being, the WHOQOL 
questionnaire was considered most appropriate for addressing the hypothesis.
Systematic qualitative and quantitative research in different cultures and 
populations, have generated the aspects included in the WHOQOL questionnaire 
Table 7.3  Changes in scores for overall quality of life (QOL) and for the four separate domains 
of QOL studied in Dutch older adults at baseline and after 13 and 26 weeks of EPA+DHA 
supplementation according to treatment group: mean (95% CI)
a Higher scores indicate better quality of life.
b n=96 at baseline, n=95 after 13 weeks, and n=96 after 26 weeks. 
c 2-sided P-values for the difference from placebo with the Dunnett test.
d n=100 at baseline, and after 13 and 26 weeks.
Quality of life 
(minimum-maximum)a
Change attributed 
to treatment
1,800 mg 
EPA+DHAb
Pc 400 mg 
EPA+DHAd
P
WHOQOL-BREF total 
(26-130)
After 13 weeks –0.98 (2.89; 0.94) 0.42 –1.07 (–2.97; 0.82) 0.35
After 26 weeks –1.42 (–3.40; 0.57) 0.20 0.02 (–1.95; 1.99) 1.00
Domain I: Physical 
health (7-35)
After 13 weeks –0.57 (–1.33; 0.19) 0.17 –0.57 (–1.31; 0.19) 0.17
After 26 weeks –0.39 (–1.26; 0.49) 0.51 0.25 (–0.61; 1.12) 0.75
Domain II: Psychological 
health (6-30)
After 13 weeks –0.25 (–0.85; 0.35) 0.56 –0.09 (–0.68; 0.51) 0.93
After 26 weeks –0.17 (–0.78; 0.45) 0.77 0.21 (–0.40; 0.81) 0.66
Domain III: Social 
relationships (3-15)
After 13 weeks –0.19 (–0.61; 0.23) 0.51 –0.33 (–0.74; 0.09) 0.15
After 26 weeks –0.09 (–0.51; 0.34) 0.87 –0.02 (–0.44; 0.40) 0.99
Domain IV: Environment 
(8-40)
After 13 weeks 0.17 (–0.70; 1.03) 0.88 0.08 (–0.77; 0.94) 0.97
After 26 weeks –0.67 (–1.51; 0.17) 0.14 –0.37 (–1.20; 0.46) 0.51
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and the psychometric properties have been validated in several studies20,21,28,29, 
although QOL is a subjective concept to measure because it depends on self-
report.  Mood state and an individual’s perception of QOL are strongly correlated. 
Individuals with depressive symptoms (CES-D score >16) were excluded from 
this study, reducing the chance of measuring distorted QOL scores, because 
depression leads to lower QOL scores. 
Although there is some evidence that fish oil may have a role as an adjuvant 
treatment for depression, there is little evidence to support a role in the 
prevention of depressive symptoms or promotion of mental health. To the best 
of the authors’ knowledge, this study is the first to assess whether fish oil has 
a generic effect on the QOL of older people without depression or dementia. 
These are disorders that, together with coronary heart disease, constitute the 
main causes of impaired QOL in the Netherlands30. It could be that QOL of the 
study sample was close to optimal and that further improvement could not be 
achieved with fish oil supplementation. If true, it can be concluded that low or 
high doses of fish oil are of little added value to mental health in a generally 
healthy population, although it might also be that the duration of our study was 
too short to observe changes, although no trend was observed either. 
The observation of a significant decrease of QOL measures in men in the high-
dose fish oil group is in contrast with what would be expected. Several previous 
studies observed an association between high fish intake and depression in 
women but not in men25-27, although QOL is a broader concept than depression, 
and these studies were all observational studies; sex effects have not been shown 
in trials before. Moreover, it could also be a chance finding because multiple 
comparisons were made in the current study.
The results are not consistent with two observational studies performed in a 
population of healthy New Zealand adults that showed a beneficial relationship 
between n-3 PUFAs and QOL5,6, and also with most randomized controlled 
trials that investigated the association between n-3 PUFAs and depressed mood8, 
but most of these trials were not performed in healthy subjects but in patients 
with depressive disorders with n-3 PUFA treatment on top of drug treatment. 
Of these only one examined the effect of n-3 PUFAs supplementation in 33 
healthy subjects without depression (mean age 33) who received a daily dose 
of 1.6 g of EPA and 0.8 g of DHA for 35 days10. The current study, with a larger 
number of subjects, who were older and supplemented for a longer period, did 
not confirm these findings, although in the previous study mental well-being 
was measured using a questionnaire that focuses only on mood (Profile of Mood 
States (POMS)), whereas the questionnaire used in the current study covers more 
aspects affecting QOL.
Based on this randomized double-blind placebo-controlled trial, it can be 
concluded that supplementation with high or low doses of fish oil is unlikely 
to influence the QOL of healthy older individuals. More studies investigating 
the effects of n-3 PUFAs on QOL are warranted, especially in subjects with 
impaired QOL.
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Abstract
Background Polyunsaturated fatty acids (PUFAs) can have beneficial effects on 
human immune cells, such as peripheral blood mononuclear cells (PBMCs). 
However, the mechanisms of action of PUFAs on immune cells are still largely 
unknown.
Objective The objective was to examine the effects of supplementation with the 
PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on whole-
genome PBMC gene expression profiles, in healthy Dutch elderly participating 
in a double-blind trial, by using whole-genome transcriptomics analysis.
Design The subjects were randomly allocated to one of three groups: 1) 
consumption of 1.8 g EPA+DHA/d (n=36), 2) consumption of 0.4 g EPA+DHA/d 
(n=37), or 3) consumption of 4.0 g high-oleic acid sunflower oil (HOSF)/d 
(n=38). All supplements were given in capsules. Before and after 26 weeks of 
intervention, blood samples were collected. Microarray analysis was performed 
on PBMC RNA from 23 subjects who received 1.8 g EPA+DHA/d and 25 subjects 
who received HOSF capsules. Quantitative real-time polymerase chain reaction 
was performed on all 111 subjects.
Results A high EPA+DHA intake changed the expression of 1040 genes, 
whereas HOSF intake changed the expression of only 298 genes. EPA+DHA 
intake resulted in decreased expression of genes involved in inflammatory- and 
atherogenic-related pathways, such as nuclear transcription factor κB signaling, 
eicosanoid synthesis, scavenger receptor activity, adipogenesis, and hypoxia 
signaling.
Conclusion These results are the first to show that intake of EPA+DHA for 26 
weeks can alter the gene expression profiles of PBMCs to a more antiinflammatory 
and antiatherogenic status.
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Introduction
The beneficial effects of long chain n-3 poly-unsaturated fatty acids (PUFAs), 
such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on 
inflammation1 and cardiovascular diseases2 are generally accepted. Immune 
cells, such as peripheral blood mononuclear cells (PBMCs), play a vital role in 
inflammation and the development of cardiovascular diseases. However, the 
cellular mechanisms of action of PUFAs on immune cells are not completely 
understood3. It is recognized that PUFAs can modulate cellular function through 
changes in gene expression, eg, via binding and subsequent activation of 
peroxisome proliferator-activated receptors (PPARs)4. Activation of these nuclear 
receptors is known to up- and down-regulate the expression of genes involved 
in lipid metabolism and inflammation, respectively. Moreover, PUFAs, such as 
DHA and EPA are stronger natural ligands for PPARs than are monounsaturated 
or saturated fatty acids5. We recently showed that PPARα, one of the subtypes 
of PPARs, has a functional role in human PBMCs6. 
Various long-term intervention trials have been performed to elucidate the mode 
of action of PUFAs, such as EPA and DHA, in human immune cells7; however, 
most of these trials only studied the ex vivo immunological function of these 
cells. To obtain a more comprehensive overview of the processes that are 
modulated by EPA and DHA in immune cells such a PBMCs, in vivo, a whole-
genome transcriptomic analysis would be more valuable. In a previous study 
we showed that the effects of endogenous fatty acids on human PBMCs can be 
elucidated by using a genomics approach8. However, the effects of the long-
term intake of fatty acids on PBMC gene expression profiles have not yet been 
studied. Therefore, we examined the effects of EPA+DHA supplementation for 
26 weeks on whole-genome PBMC gene expression profiles in a Dutch elderly 
population and compared the effects with those of control supplementation with 
high-oleic acid sunflower oil (HOSF).
Subjects and methods
Subjects
Three hundred fifty-one subjects ≥65 y were screened, of whom 189 were men 
and 162 were women. Three hundred two subjects (167 men and 135 women) 
were included in the study, and detailed baseline characteristics of these 
participants were described elsewhere9. From these participants, 111 subjects 
were randomly included in the present study (Figure 8.1). The participants were 
recruited according to the following exclusion criteria: current or recent (<4 
weeks) use of fish-oil supplements or intake of fish >4 times/week or >800 mg 
EPA+DHA/d from fish as estimated by using a fish-consumption questionnaire, 
serious liver disease, consumption >4 glasses of alcohol-containing beverages 
per day, unable to participate as judged by the responsible medical physician, 
allergy to fish or fish oil, swallowing problems, or participation in another clinical 
trial <2 mo before the start of the trial or at the same time. Cognitive exclusion 
criteria were also used, as described elsewhere9. Additionally, compliance with 
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capsule use during a 2-week placebo run-in period had to be ≥80% on the basis 
of self-report. All subjects gave written informed consent to participate in the 
study, and the study protocol was approved by the Medical Ethical Committee 
of Wageningen University, the Netherlands.
Study design
The subjects were randomly allocated to receive a daily dose of fish oil containing 
either a low dose of EPA+DHA (0.4 g; n=36), a high dose of EPA+DHA (1.8 
g; n=37), or HOSF (n=38) for a period of 26 weeks (Lipid Nutrition/ Loders 
Croklaan, Wormerveer, the Netherlands) (Figure 8.1). The oils were administered 
in six soft gelatin capsules daily, each of which contained 900 mg oil and 2.7 
mg tocopherol as antioxidant (Banner Pharmacaps Europe BV, Tilburg, the 
Netherlands). The fatty acid composition of the capsules was measured in 20 
capsules taken at regular times during the study.
Blood sampling and PBMC isolation
Fasting venous blood samples were collected at baseline and after 26 weeks 
of intervention. A blood sample for measurement of n-3 PUFAs was collected 
into 10-mL EDTA-Vacutainers (Becton Dickinson, Breda, the Netherlands), 
immediately placed on ice, centrifuged at 2,000 x g at a temperature of 4°C 
and then stored at –80°C until laboratory analyses. N-3 PUFAs in plasma 
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Figure 8.1  Overview of the subgroup used for the present study. EPA, eicosapentaenoic acid; 
DHA, docosahexaenoic acid; Q-PCR, quantitative real-time polymerase chain reaction.
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cholesteryl esters were measured as described previously10. Plasma free fatty 
acids and triglycerides were measured by gas–liquid chromatography and 
C-reactive protein (CRP) concentrations were determined from measurements 
of high-sensitivity CRP (hsCRP). For PBMC isolation, 4 mL blood was collected 
into Becton Dickinson Vacutainer Cell Preparation Tubes with sodium citrate. 
PBMCs were isolated immediately after blood collection according to the 
manufacturer’s instructions.
Total RNA isolation
Trained research nurses performed baseline examinations at the hospital or at 
tPBMC RNA was isolated from all PBMC samples by using a Qiagen RNeasy 
Micro kit (Qiagen, Venlo, the Netherlands). The RNA yield was quantified with 
a Nanodrop ND 1000 spectrophotometer (Nanodrop Technologies, Wilmington, 
DE, USA) and integrity was measured with an Agilent 2100 Bioanalyzer with 
RNA 6000 Nano chips (Agilent Technologies, South Queensferry, United 
Kingdom).
Microarray processing
PBMC samples from 77 subjects yielded enough RNA to perform microarray 
analysis. Deblinding showed that 25 subjects were in the high EPA+DHA 
group, 26 in the low EPA+DHA group, and 26 in the HOSF group. Microarray 
analysis was performed on baseline samples and on samples after 26 weeks of 
intervention in the high EPA+DHA group and the HOSF group. Total RNA from 
the PBMCs of these 51 subjects was labeled using a one-cycle cDNA labeling 
kit (MessageAmpTM II-Biotin Enhanced Kit; Ambion Inc, Nieuwekerk a/d IJssel, 
the Netherlands) and hybridized to human whole-genome NuGO GeneChip 
arrays encoding 17,699 genes, designed by the European Nutrigenomics 
Organisation and manufactured by Affymetrix (Affymetrix Inc, Santa Clara, CA). 
Sample labeling, hybridization to chips and image scanning were performed 
according to the manufacturer’s GeneChip Expression Analysis Technical 
Manual (Affymetrix).
Microarray analysis
Microarrays from three subjects, two from the high EPA+DHA group, and 
one from the HOSF group were excluded because they did not fulfill our 
quality-control criteria. Microarrays were analyzed by using the reorganized 
oligonucleotide probes as described by Dai et al.11. Expression values were 
calculated by using the Robust Multichip Average method. The Robust Multichip 
Average signal value estimates are based on a robust average of background-
corrected perfect match intensities, and normalization was performed using 
quantile normalization12. Only genes with normalized signals >20 on ≥10 arrays 
were defined as “expressed” and selected for further analysis. Genes were defined 
as “changed” when comparison of the normalized signal intensities showed a 
false discovery rate Q value13 <0.05 in a 2-tailed paired t test with Bayesian 
correction (Limma)14. Pathway analysis was performed by using GenMAPP 2.1 
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(www.genmapp.org), Ingenuity Pathway Analysis 5.5 (www.ingenuity.com), and 
Gene Set Enrichment Analysis 2.0.1 (www.broad.mit.edu/gsea/)15. Pathways were 
defined as significantly changed when P<0.05 (Ingenuity Pathway Analysis and 
Gene Set Enrichment Analysis) or the Z score was >1 (GenMAPP).
cDNA synthesis and real-time polymerase chain reaction
RNA from all subjects was reverse transcribed with use of a cDNA synthesis kit 
(Promega, Leiden, the Netherlands). Standard quantitative real-time polymerase 
chain reaction (Q-PCR) was performed with use of Platinum Taq DNA 
polymerase and SYBR Green on an iCycler PCR machine (Bio-Rad Laboratories 
BV, Veenendaal, the Netherlands) and duplicated at least twice. Primer 
sequences used in the PCRs were chosen based on the sequences available in 
PRIMERBANK (http://pga.mgh.harvard.edu/ primerbank/index.html). Q-PCR 
data were normalized by measuring cycle threshold ratios between candidate 
genes and a housekeeping gene, human ribosomal protein LP0.
Statistical analyses
Differences between end and baseline values of plasma metabolites and Q-PCR 
results were tested by using a paired t test. Statistical significance was accepted 
at P<0.05. Differences between groups were tested by using a 2-factor ANOVA 
with a Tukey honestly significant difference post hoc test to correct for multiple 
testing of 3 treatment groups with SPSS software (version 12.0.1; SPSS Inc, 
Chicago, IL). Statistical significance was accepted at P<0.05.
Results
Subject characteristics
Of the 302 participants enrolled in the study, blood samples were randomly 
collected from 111 healthy men and woman varying in aged 66-80 y. A subset 
of these samples was used to perform microarray hybridizations (Figure 8.1). The 
baseline characteristics of the participants are shown in Table 8.1. No significant 
differences were observed between the intervention groups, both for the whole 
group and for the subgroup in which the microarrays were performed. To confirm 
the amount of the various fatty acids the participants consumed daily, the fatty 
acid composition of the capsules was measured (Table 8.2). The high-dose 
EPA+DHA supplement provided 1,093 ± 17 mg EPA (mean ± SD) and 847 ± 
23 mg DHA daily, and the low-dose EPA+DHA supplement provided 226 ± 3 
mg EPA and 176 ± 4 mg of DHA daily. 
Plasma measurements
To check individual compliance with intake, the plasma fatty acid composition 
was determined in cholesteryl esters at baseline and after 26 weeks (Figure 8.2, 
A and B). Both EPA and DHA were significantly different (P<0.01) between the 
three intervention groups. Mean plasma EPA concentrations increased by 3.43% 
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Table 8.1  Baseline characteristics of subjects in the three groups whose peripheral blood 
mononuclear cells underwent microarray analysis or quantitative real-time polymerase 
chain reaction (Q-PCR)a
a Ranges in parentheses. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; FFA, free fatty acids; HOSF, 
high-oleic sunflower oil; hsCRP, high-sensitivity C-reactive protein. None of the baseline characteristics differed 
significantly between groups (ANOVA).
 HOSF group Low EPA+DHA 
group
High EPA+DHA group
Q-PCR Microarray Q-PCR Q-PCR Microarray
Subjects (n) 38 25 37 36 23
Sex (M/F) 25/13 15/10 20/17 21/15 15/8
Age (y) 70.9 
(66-80)
70.4 
(67-77)
70.5
(66-79)
70.3 
(67-76)
69.9 
(67-76)
Smokers (n) 3 2 4 1 0
Weight (kg) 79.1 
(59.1-108.6)
81.1 
(59.1-109.5)
75.3
 (47.6-101.8)
76.6 
(60.1-106.7)
78.1 
(60.1-106.7)
Height (m) 1.73 
(1.57-1.87)
1.72
 (1.57-1.87)
1.70
 (1.53-1.87)
1.71
 (1.58-1.86)
1.72 
(1.58-1.86)
BMI (kg/m2) 26.5 
(20.2-37.2)
27.6
 (20.2-42.3)
25.8
 (19.9-34.9)
26.2 
(21.12-33.6)
26.5
 (21.7-33.6)
Triglycerides (mmol/L) 1.18 
(0.4-2.7)
1.20
 (0.5-2.7)
1.17
 (0.2-3.8)
1.14
 (0.4-3.3)
1.02
 (0.4-2.0)
FFAs (mmol/L) 0.34 
(0.06-0.98)
0.36 
(0.06-0.98)
0.36
 (0.08-0.99)
0.38
 (0.12-0.71)
0.35
 (0.12-0.59)
EPA (% by wt) 1.30
(0.4-8.5)
1.38
 (0.4-8.5)
1.43
 (0.4-5.0)
1.26
 (0.4-4.4)
1.44 
(0.6-4.4)
DHA (% by wt) 0.64 
(0.4-1.3)
0.63
 (0.4-1.3)
0.66 
(0.2-1.6)
0.62
 (0.3-1.1)
0.65
 (0.3-1.1)
hsCRP (mg/L) 1.99 
(0.1-14.7)
2.07
 (0.1-14.7)
2.91
 (0.1-21.0)
2.86
 (0.1-10.5)
2.85
 (0.1-10.5)
Table 8.2  Fatty acid composition of the capsules for the three groupsa
a SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid; HOSF, high-oleic sunflower oil.
 High EPA+DHA Low EPA+DHA HOSF
SFAs 22.08 10.40 8.46
MUFAs 14.73 67.97 80.53
18:1n-9 (oleic acid) 4.66 64.38 79.63
PUFAs 56.05 20.23 11.02
c18:2n-6 (linoleic acid) 0.74 9.13 10.81
c20:5n-3 (EPA) 21.40 4.49 0.00
c22:6n-3 (DHA) 16.44 3.46 0.00
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by wt (95% CI: 2.93; 3.94) from a mean baseline concentration of 1.26% by wt 
in the high-dose EPA+DHA group and by 0.56% by wt (95% CI: 0.33; 0.80), 
from a baseline concentration of 1.43% by wt in the low-dose EPA+DHA group. 
The mean plasma DHA concentration increased by 0.54% by wt (95% CI: 0.47; 
0.62) and 0.13% by wt (95% CI: 0.08; 0.18) from mean baseline concentrations 
of 0.62% by wt and 0.66% by wt in the high- and low-dose EPA+DHA groups, 
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Figure 8.2  Mean (±SEM) changes from baseline in plasma lipid metabolites after 
intake of high-oleic sunflower oil (HOSF; n=38), low-dose eicosapentaenoic acid (EPA) + 
docosahexaenoic acid (DHA) (n=37), or high-dose EPA+DHA (n=36) capsules for 26 weeks in 
all 111 participants. A: Plasma cholesterylesters of EPA B: plasma cholesterylesters of DHA. 
C: plasma triglyceride concentrations D: plasma total free fatty acid (FFA) concentrations. 
Brackets indicate differences between groups as determined with a 2-factor ANOVA with 
Tukey honestly significant difference correction (*P<0.05; ** P<0.01). Differences within 
groups were determined with a paired t test (** P<0.01). Note that the y axes of the graphs 
differ.
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respectively. No significant changes were observed in the group that consumed 
the HOSF capsules: EPA decreased by 0.05% by wt (95% CI: –0.21; 0.12; 
baseline: 1.30% by wt), and DHA decreased by 0.03% by wt (95% CI: –0.07; 
0.01; baseline: 0.64% by wt). Plasma triglyceride concentrations decreased 
significantly after 26 weeks in the high-dose EPA+DHA group (–0.32 mmol/L; 
95% CI: –0.47; –0.16), but not in the low-dose EPA+DHA (–0.06 mmol/L; 95% 
CI: –0.18; 0.05) or HOSF (–0.04 mmol/L; 95% CI: –0.17; 0.09) group (Figure 
8.2C). Plasma free fatty acids (FFAs) also decreased significantly after 26 weeks 
in the high-dose EPA+DHA group (–0.07 mmol/L; 95% CI: –0.12; –0.01), but 
not in HOSF group (–0.02 mmol/L; 95% CI: –0.06; 0.02). FFAs in the low-
dose EPA+DHA group showed a tendency to decrease, although this was not 
statistically significant (P=0.06) (Figure 8.2D). Plasma CRP concentrations did not 
change significantly in any group. The mean decrease in the high-dose EPA+DHA 
group was –1.10 mg/L (95% CI: –2.68; 0.48), in the low-dose EPA+DHA group 
was –0.76 mg/L (95% CI: –1.72; 0.20), and in the HOSF group was -0.82 mg/L 
(95% CI: –4.29; 2.64).
Microarray analysis
Microarray hybridization was performed on PBMC RNA that was collected at 
baseline and after 26 weeks of supplementation from 25 subjects in the high 
EPA+DHA group and from 26 subjects from the HOSF group. Two arrays in 
the high-dose EPA+DHA group and one array in the HOSF group did not pass 
the quality-control criteria. Changes in gene expression were determined by 
comparing the microarray results of the samples after 26 weeks of intervention 
with the baseline samples, for both intervention groups. From the 17,699 genes 
present on the microarray, 12,256 genes were defined as expressed in PBMCs 
(Figure 8.3). Consumption of 1.8 g of EPA+DHA/d for 26 weeks resulted in gene 
expression changes of 1,040 genes, whereas consumption of the HOSF capsules 
resulted in expression changes of 298 genes (Figure 8.3). Of these genes, 140 
were overlapping between the groups, which resulted in 900 uniquely changed 
genes in the EPA+DHA group. Except for one gene, the direction of change of 
the overlapping genes was the same in the EPA+DHA and the HOSF groups 
(data not shown).
Pathway analysis
To determine the role of the genes that changed with EPA+DHA supplementation, 
we performed pathway analysis. GenMAPP analysis showed that supplementation 
with a high dose of EPA+DHA for 26 weeks significantly decreased the expression 
of genes involved in inflammatory pathways, such as eicosanoid synthesis, 
interleukin signaling and MAP kinase signaling (Figure 8.4). In addition, a 
decreased expression of genes involved in pathways related to atherosclerotic 
processes, such as cell adhesion, scavenger receptor activity, and adipogenesis 
was observed. Ingenuity pathway analysis and Gene Set Enrichment Analysis 
showed similar decreases in inflammatory signaling pathways, such as eicosanoid 
metabolism and interleukin-6 and MAP kinase signaling, with additional 
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signaling routes such as nuclear transcription factor κB (NF- κB ) and Toll-like 
receptor signaling. These programs also showed a decrease in oxidative stress, 
cell adhesion, PPAR signaling, LXR/RXR (liver X receptor/retinoid X receptor) 
activation, and hypoxia signaling in the cardiovascular system, which includes 
hypoxia initiation factor 1α signaling (data not shown). 
In addition to the genes present in the above-described pathways, several other 
genes involved in similar processes, but not present in the pathways, were down-
regulated (Figure 8.5). A list of inflammatory-related genes, such as NF-κB target 
genes, oncostatin M (OSM), Ig-like receptors, and interleukin receptors, that 
were down-regulated in the high-dose EPA+DHA group are shown in Figure 
8.5. Several plaque stability-related metallopeptidases, which also decreased 
with EPA+DHA supplementation, are also listed in Figure 8.5.
Interestingly, pathway analysis of genes changed in the HOSF group also 
showed down-regulation of genes involved in inflammation and cell adhesion 
(Figure 8.4). However, the expression of fewer genes was changed with HOSF 
intake; consequently, fewer genes were observed in the changed pathways. 
Chapter 8
Figure 8.3  Flow chart of gene selection and number of genes changed in the microarray 
analysis. Q, false discovery rate value. HOSF, high-oleic sunflower oil; EPA, eicosapentaenoic 
acid; DHA, docosahexaenoic acid.
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Figure 8.4  Ranking of differentially expressed pathways in peripheral blood mononuclear 
cells (PBMCs) after 26 weeks of supplementation with high-dose eicosapentaenoic acid 
(EPA) + docosahexaenoic acid (DHA) or high-oleic sunflower oil (HOSF) capsules in elderly 
individuals. Pathway analysis was performed with the program GenMAPP (www.genmapp.
org). The pathways included had a Z score of ≥1 and had ≥2 genes changed.
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Additionally, we studied the expression changes of previously described PPARα 
target genes in PBMCs6 and observed that 14 of these 106 PPAR response 
element-containing PPARα target genes were down-regulated, and two were 
up-regulated (Table 8.3). 
To determine whether a low dose of 0.4 g EPA+DHA/d can induce gene 
expression changes similar to those seen with a high dose of 1.8 g EPA+DHA/d, 
6 genes selected from several changed pathways were analyzed with Q-PCR 
in the whole study population of 111 individuals (Figure 8.6). Q-PCR of CD36, 
PDK4, LTA4H, ADFP, CD14 and HIF1α showed that consumption of 0.4 g 
EPA+DHA/d for 26 weeks also resulted in a down-regulation of the expression 
of these genes and that the effects were intermediate between the effect of the 
high-dose EPA+DHA group and the HOSF group. These data also confirm 
the microarray results, as reflected by the same direction of gene expression 
changes.
Discussion
In this study we assessed changes in PBMC gene expression profiles after fish-
oil or control-oil supplementation in a 26-week double-blind and randomized 
intervention trial in an elderly population. Supplementation of 1.8 g EPA+DHA/d, 
the equivalent of the consumption of 10 portions of fish weekly, resulted in 
antiinflammatory- and antiatherogenic-like changes in PBMC gene expression 
profiles. In addition, supplementation with 0.4 g EPA+DHA/d, the equivalent of 
the consumption of two portions of fish weekly, which approaches the average 
intake of EPA+DHA in various countries around the world16, resulted in similar 
(but lower) gene expression changes.
The effects of fish oil on health have been extensively studied17-19. However, the 
effect of fish-oil supplementation on whole-genome gene expression profiles in 
human PBMCs has not been examined before. The antiinflammatory-like gene 
expression profile observed in the present study is mainly characterized by a 
decreased expression of inflammatory genes, including several NF-κB target 
genes, proinflammatory cytokines, and genes involved in eicosanoid synthesis. 
Several other intervention studies in healthy subjects with varying doses of n-3 
fatty acids showed a reduction in cytokine formation after ex vivo stimulation of 
mononuclear cells20,21. The decrease in eicosanoid formation we observed was 
characterized by a down-regulation in the gene expression of enzymes involved 
in eicosanoid synthesis, such as LTA4H and ALOX-5. It is known that n-3 PUFA 
supplementation can result in a decrease in proinflammatory arachidonic acid-
derived eicosanoids1. For example, various ex vivo stimulation studies with 
inflammatory cells in healthy volunteers showed that supplementation with fish 
oil or DHA for 4 to 17 weeks resulted in a decreased production of eicosanoids1. 
In addition, intake of n-3 fatty acids for 6 weeks reduced the urinary excretion of 
leukotriene E422. Hence, our observations on PBMC gene expression are in line 
with previously observed n-3 PUFA-induced effects after ex vivo stimulation. 
The subjects who consumed the HOSF capsules showed a similar, albeit less 
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pronounced, effect on some of the inflammatory pathways changed by EPA+DHA 
supplementation. The overlapping genes were almost all changed in the same 
direction, which suggested that some of the effects on inflammation, although 
clearly less apparent, were comparable with the EPA+DHA intervention. 
Beneficial effects of MUFAs on inflammation have been reported, but only 
limited data are available23. The antiatherogenic gene expression profile that 
we observed in this study after EPA+DHA intake is characterized by a reduced 
expression of genes that play a role in several processes known to be involved 
in atherosclerotic plaque formation. PBMC subpopulations are involved in 
these processes, which include adhesion, infiltration and subsequent foam cell 
formation24. We found an EPA+DHA-induced decrease in the expression of 
genes involved in integrin-mediated cell adhesion and foam cell formation. An 
n-3 PUFA-induced decrease in the expression of monocyte and macrophage 
adhesion molecules was previously reported, but only in animal and in vitro 
studies25,26. A reduction in foam cell formation is characterized by a lower 
gene expression of the scavenger receptors CD36 and the LDL receptors and 
a decrease in the expression of genes involved in lipid accumulation, such 
as adipose differentiation-related protein. It has been shown that incubation 
of monocytes with n-3 PUFA in vitro can reduce CD36 mRNA and protein 
expression27. Incubation of macrophages with PUFA-enriched chylomicron 
remnant-like particles in vitro resulted in reduced lipid accumulation in these 
cells28. The reduced gene expression of scavenger receptors and of adipose 
differentiation-related protein that we observed in our in vivo study are in line 
Gene description Gene name Entrez ID Mean FC FDR Q
Heparin-binding EGF-like growth factor HBEGF 1839 –1.40 0.021
Pyruvate dehydrogenase kinase isozyme 4 PDK4 5166 –1.25 0.027
Zinc finger E-box-binding homeobox 2 ZEB2 9839 –1.21 0.004
Vascular endothelial growth factor A VEGFA 7422 –1.19 0.024
Small inducible cytokine B16 precursor CXCL16 58191 –1.17 0.010
Transcription regulator protein BACH1 BACH1 571 –1.15 0.003
Microphthalmia-associated transcr. factor MITF 4286 –1.15 0.021
Myeloid-assoc. differentiation marker MYADM 91663 –1.14 0.003
Platelet glycoprotein 4 CD36 948 –1.13 0.049
MARVEL domain containing 1 MARVELD 83742 –1.12 0.027
TNF receptor superfamily member 8 TNFRSF8 943 –1.11 0.045
Dihydropyrimidinase-related protein 2 DPYSL2 1808 –1.10 0.026
Adipose differentiation-related protein ADFP 123 –1.10 0.031
Suppressor of tumorigenicity protein 14 ST14 6768 –1.09 0.037
Uncharacterized protein C15orf17 C15orf17 57184 1.11 0.043
Protein Chibby CBY1 25776 1.11 0.036
Table 8.3  Previously described PPARα target genes in PBMCs6 found to be changed upon 
high EPA+DHA supplementation. FC, fold change; FDR Q, false discovery rate Q valuea
a SFC, fold change; FDR Q, false discovery rate Q value; EGF, endothelial growth factor; TNF, tumor necrosis 
factor.
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Figure 8.5  Genes changed after eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 
supplementation in various functional groups that were overrepresented by the pathway 
analyses software programs GenMAPP (www.genmapp.org), Ingenuity Pathway Analysis 
(www.ingenuity.com), and Gene Set Enrichment Analysis (www.broad.mit.edu.gsea/), 
supplemented with changed genes also related to these processes. Asterisks indicate that 
the genes appear in multiple functional groups. FC, fold change; NF-κB, nuclear transcription 
factor κB; ROS, reactive oxygen species; PPAR, peroxisome proliferator-activated receptors; 
HIF, hypoxia-induced factor.
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with these in vitro data and might imply that the monocytes present within the 
PBMCs are less prone to differentiate into foam cells after 26 weeks of EPA+DHA 
supplementation. Besides the abovementioned changes in foam cell formation, 
we also observed decreases in genes such as matrix metalloproteinases and 
disintegrin metalloproteinases, which are related to plaque stability, a process 
that normally occurs after infiltration and foam cell formation. These genes 
are known to destabilize atherosclerotic plaques, which can result in plaque 
rupture29. Also, the hypoxia inducible factor 1α gene (HIF1α) and its main target 
gene, the vascular endothelial growth factor gene (VEGF), were down-regulated30. 
Both genes are known to regulate atherosclerotic plaque angiogenesis, which 
destabilizes and progresses the lesion. Plaque stability has been found to increase 
after n-3 PUFA supplementation31.
The high-dose EPA+DHA intake in our study also increased the expression of 
nitric oxide synthase 3, which plays a role in the protection of the vessel wall 
from atherosclerosis32. Increased expression of nitric oxide synthase 3 in murine 
macrophages and in vitro in human vascular wall cells after supplementation or 
incubation with EPA+DHA has been shown before33-35. Importantly, all studies 
described above illustrate short term in vitro experiments or animal studies, 
whereas we observed our effects in healthy humans after 26 weeks of n-3 PUFA 
intake. Because we observed changes in PBMC gene expression profiles with 
EPA+DHA supplementation that indicate antiinflammatory and antiatherogenic-
like modifications, we speculate that EPA+DHA supplementation might improve 
the preatherosclerotic condition in elderly people. 
An interesting point to discuss is whether the changes in gene transcription 
profiles were due to a direct effect of EPA+DHA on mononuclear cells or 
whether the changes reflected the response of PBMCs to EPA+DHA-induced 
systemic adaptations in the body. A nice illustration in this respect is the 
unexpected finding of down-regulation of PPARα target genes after EPA+DHA 
supplementation. On the basis of mice and in vitro studies, in which a more 
pronounced expression of PPAR target genes was observed on EPA and DHA 
intakes than on monounsaturated fatty acid intake5, we expected an increase 
in PPARα target genes on EPA+DHA supplementation instead of the observed 
decreases. A possible explanation for these unexpected findings may lie in 
systemic long-term adaptations via effects of EPA+DHA on gut or liver, resulting 
in reduced plasma FFA and triglyceride (TG) concentrations. The observed 
down-regulation of PPAR target genes might have been caused by these reduced 
plasma FFA and TG concentrations. Hence, PBMC gene expression profiles 
could also be viewed as a reflection of the physiologic state of subjects, as we 
showed previously8. 
Microarrays were performed only in the subjects who consumed the high dose 
of EPA+DHA only, reflecting a relatively high consumption of 10 portions of 
fish weekly. However, Q-PCR results showed that a lower dose, representing 
the intake of two portions of fish weekly, resulted in lower, but similar, gene 
expression changes. This finding suggests that lower amounts of fish intake may 
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Driven by accumulating evidence of potential benefits of fish fatty acids on 
mental health in old age, we investigated the role of EPA+DHA and fish in 
relation to cognitive performance and mental well-being of older people. We 
examined this by means of a randomized, double-blind intervention study 
(RCT), a cross-sectional study and a prospective study in populations with no 
clinical diagnosis of dementia or depression. We also examined changes in gene 
expression profiles after supplementation with EPA+DHA, as an early marker 
of metabolic changes. In this final chapter the main findings of our studies are 
summarized and discussed in a broader context. Also, directions for future 
research and implications for public health are given.
Main findings
The main findings described in this thesis are presented in Table 9.1. The RCT 
performed in a population of 302 healthy older individuals showed no effect of 
6 months supplementation with 400 mg or 1,800 mg EPA+DHA compared with 
placebo on cognitive performance (chapter 2), neither on depressive symptoms 
(chapter 4) nor on quality of life (chapter 7). We compared the reliability of 
the questionnaires used to measure depressive symptoms in the RCT, and the 
CES-D performed best in this population, followed by MADRS and GDS-15 
(chapter 5). EPA+DHA supplementation for 6 months caused changes in gene 
expression profiles in peripheral blood mononuclear cells (PBMCs), indicating a 
less inflammatory and less atherogenic status (chapter 8). No association between 
fatty fish or n-3 PUFA intake and cognitive decline was found after a follow-up 
period of 6 years in a population of older US men (chapter 3). In a population 
of Dutch subjects with a history of coronary heart disease, intake of EPA+DHA 
was positively associated with dispositional optimism assessed with one of the 
two questionnaires used, but not with depressive symptoms (chapter 6). 
The main conclusion of this thesis is that, based on the studies that we performed, 
low doses or high doses of EPA+DHA are unlikely to improve cognitive 
performance or mental well-being of older people without clinical diagnosis 
of dementia or depression on the short-term. Furthermore, our data did not 
confirm the hypothesis that intake of fish in the low range commonly consumed 
in Western populations is related to cognitive performance or mental well-being 
in populations of older people without clinical dementia or depression.
Intervention study: methodological considerations
A major part of this thesis is based on a 26-week RCT, which showed that 
low doses as well as high doses of supplemental EPA+DHA did not improve 
cognitive performance (chapter 2), depressive symptoms (chapter 4) or quality 
of life (chapter 7) of older people. The RCT was mainly designed based on 
available knowledge emerging from cross-sectional and prospective studies, and 
a limited number of trials with the same outcome measures. There are several 
considerations related to the methodology of the RCT and to the advanced 
scientific progress in the field that are relevant to discuss here.
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Table 9.1  Main findings of the studies described in this thesis
Abbreviations: RCT: Randomized controlled trial; CES-D: Center for Epidemiologic Studies Depression Scale; 
MADRS: Montgomery-Åsberg Depression Rating Scale; GDS: Geriatric Depression Scale; PCR: polymerase chain 
reaction; PBMCs: peripheral blood mononuclear cells
Chapter Study Population Exposure Results
Cognitive performance
2 RCT 302 Dutch elderly 
aged >65 years
400 mg EPA+DHA; 
1,800 mg EPA+DHA 
or placebo for 26 
weeks
No effect of EPA+DHA 
supplementation 
on cognitive 
performance
3 Prospective study 
with 6y follow-up
1,025 older men living 
in the Boston area, 
United States
Intake of EPA+DHA 
and (fatty) fish
Neither intake of 
EPA+DHA nor of fatty 
fish was associated 
with cognitive 
performance or with 
cognitive decline over 
6 years of follow-up. 
Mental well-being
4 RCT 302 Dutch elderly 
aged >65 years
400 mg EPA+DHA; 
1,800 mg EPA+DHA 
or placebo for 26 
weeks
No effect of EPA+DHA 
supplementation on 
mental well-being
5 Study of reliability 
of depression 
scales
302 Dutch elderly 
aged >65 years
Not applicable CES-D performed 
best to measure 
depression in this 
population, followed 
by MADRS and GDS-
15
6 Cross-sectional 
study
644 Dutch elderly 
aged 60-80 years with 
a history of myocardial 
infarction
Intake of EPA+DHA 
and fish
No association 
between EPA+DHA 
or fish intake and 
depression, possible 
association between 
EPA+DHA, but not fish 
and optimism
Quality of life
7 RCT 302 Dutch elderly 
aged >65 years
400 mg EPA+DHA; 
1,800 mg EPA+DHA 
or placebo for 26 
weeks
Quality of life was 
not influenced 
by EPA+DHA 
supplementation.
Gene expression
8 RCT 111 Dutch elderly 
aged >65 years
400 mg EPA+DHA; 
1,800 mg EPA+DHA 
or placebo for 26 
weeks
Intake of EPA+DHA 
altered gene 
expression profiles of 
PBMCs to a more anti-
inflammatory status
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Study population
The RCT on EPA+DHA supplementation was set up to study cognitive 
performance and mental well-being in a general Dutch population of men and 
women aged 65 years and older, who had no clinical diagnosis of dementia or 
depression. Therefore, individuals with cognitive impairment (MMSE <21 points) 
and depression (CES-D >16) were excluded. In a population-based study in the 
Netherlands it has been shown that the CES-D scores in the elderly show large 
variation, allowing room for improvement also among the non-depressed1. 
Studying an apparently healthy population with a good mental health status 
may have the disadvantage that additional beneficial effects of EPA+DHA 
supplementation cannot be observed. On the other hand, there is the advantage 
of less interference with e.g. (co)morbidity or drug treatment. Moreover, it reduces 
the likelihood of intervening too late, when symptoms of cognitive impairment 
are no longer reversible.
We chose a study population with a suboptimal EPA+DHA status that is more 
likely to benefit from supplementation. EPA+DHA status was assessed during the 
screening phase by means of a FFQ that was specifically designed to measure fish 
intake. Subjects with an intake of more than 800 mg of EPA+DHA from fish per 
day were excluded from our study. Furthermore, we determined EPA+DHA in 
plasma cholesteryl esters, which reflect EPA+DHA intake over the past weeks2. 
These measurements confirmed the suboptimal EPA+DHA status of our subjects, 
as expected in Dutch older people because of their low habitual fish intake3. The 
plasma EPA+DHA levels in our subjects corresponded to those of other older 
populations in Western countries where fish intake is low4-6.
Study duration
When we designed our 26-week RCT, two other trials of EPA+DHA 
supplementation and cognitive performance had been performed that reported 
beneficial effects after respectively 4 weeks7 and 6 months8. A more recent 
trial showed no effect after 6 months of supplementation9. RCTs of cognitive 
performance and other nutrients such as B-vitamins, acetyl-L-carnitine or foods 
or drinks fortified with multiple micronutrients, showed effects after 4 weeks to 
3 years10-13. In these studies measured effects were not clearly linked to study 
duration. In RCTs of EPA+DHA supplementation and depression, effects (if 
any) became already visible within 2-8 weeks. With a study duration of 26 
weeks we were only able to examine relatively short-term changes in cognitive 
performance or mental well-being. Therefore, we cannot exclude a possible 
beneficial effect of long-term intake of EPA+DHA on cognitive performance or 
depressive symptoms.
Dose and type of intervention
We used a low (400 mg) as well as a high (1,800 mg) daily dose of EPA+DHA. 
The low dose corresponds to the recommended intake by the Netherlands 
Health Council of at least 450 mg EPA+DHA from fish per day, which is roughly 
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equivalent to eating two portions of fish per week, one of which is oily fish14. The 
high dose corresponds to eating about ten portions of fish per week, which is 
hardly achievable via dietary intake. With this high dose we aimed at maximum 
contrast between the groups to detect an effect, if present. In the few RCTs on 
cognitive performance daily doses ranged from 0.7 g DHA8 to 1.7 g DHA + 0.6 g 
EPA9. Effective doses in RCTs on depression ranged from 1.0 g to 9.6 g EPA+DHA 
per day. It is not yet clear whether beneficial effects of fish or fish oil are due to 
EPA, DHA or a combination of both. Effects of the type of n-3 PUFA may also 
be different per outcome measure, favoring a more beneficial effect of DHA for 
cognitive performance, while for depression generally a more favorable effect 
of EPA has been shown15. Since we included cognitive performance as well as 
depression as primary outcome measures in our RCT, we chose the combination 
of EPA and DHA in the same form and ratio (3:2) as it appears in fish.
Placebo group
Randomization and inclusion of a control group is of utmost importance for 
the internal validity of a RCT to ensure that observed effects, if any, are fully 
attributable to the treatment and not to other factors. We used high oleic sunflower 
oil (HOSF) as the placebo, which is high in monounsaturated n-9 fatty acids of 
which regular consumption in the diet is ≈30 g/d. Therefore, the additional ≈2 
g provided with our placebo added relatively little to this amount. Moreover, 
human body fat stores contain approximately 50% oleic acid16, which is about 
7 kg in an average 70 kg human and compared to this amount our daily dose 
would equal less than 0.03% of the total oleic acid stores in the body. Also, HOSF 
is considered a relatively neutral oil that has not been associated with mental 
health, contrary to for example olive oil which contains, next to oleic acid, also 
antioxidants and phenolics which have anti-inflammatory actions17,18. In our RCT 
all treatment groups showed improvements in test scores, which emphasizes 
the necessity of a placebo group for comparative purposes. Improvements may 
be due to learning effects, though we used parallel versions of cognitive tests 
to minimize these effects. Improvements may also be attributed to the subjects’ 
belief in a beneficial effect of fish oil (“expectation bias”).
Blinding
RCTs should preferably be double-blind, i.e. subjects and research staff must be 
unaware about the type of treatment until data-analysis is completed. In previous 
RCTs of fish oil the maintenance of blinding was shown to be difficult, because 
of adverse effects related to high doses of fish oil, mainly gastrointestinal, and 
because of a “fishy” aftertaste19,20. An evaluation after our RCT indicated that 
adverse effects were not different between the intervention and placebo groups 
and also that the proportion of participants who thought they had received 
fish oil or placebo did not differ among the groups. This could be due to the 
high quality of the fish oil that we used (Marinol) or to the fact that the dose 
we provided was lower than doses of EPA+DHA that were provided in several 
other studies19,21-23.
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Randomization
To prevent selection bias in a RCT, subjects should be randomly divided over 
the intervention and placebo groups. To ensure an equal balance of baseline 
values that may be of influence on the response of mental health to EPA+DHA 
supplementation, we stratified subjects by age, gender, MMSE score and CES-D 
score prior to randomization. Randomization in our study was successful, 
because demographic, anthropometric and lifestyle characteristics of the subjects 
were well balanced over the three intervention groups. Randomization was 
maintained throughout the study period since there was no selective drop-out 
related to the interventions.
Compliance
Subjects in our RCT consumed six large capsules per day (i.e. 900 mg), and 
because of this amount they were advised to consume the capsules three times 
a day during a meal. Compliance was checked by means of diaries in which 
subjects recorded capsule use, by counting remaining capsules that were returned 
by the subjects, and by n-3 PUFA assessment in plasma cholesteryl esters. All 
measures reflected high compliance; apart from the subjects who stopped 
prematurely, only three subjects consumed less than 80% of the capsules. We 
performed our primary analysis of the results according to the intention-to-treat 
(ITT) principle. In ITT analysis data of all randomized subjects are analyzed 
regardless of whether subjects followed the protocol or not. ITT has become the 
preferred way of analyzing RCTs, although there is also controversy on this issue. 
The main objection is that ITT analysis does not answer the essential question 
of RCTs, i.e. whether the treatments differ in efficacy24. This is especially the 
case if many subjects are non-compliant. In our RCT the dropout rate was only 
3% and we did obtained follow-up measurements of seven of the nine subjects 
who dropped-out. Only three subjects had used <80% of the capsules. Thus, 
the majority of the subjects included in our ITT analysis still complied with our 
study protocol and therefore we believe that ITT analysis in our RCT provided 
us with a proper answer to the question whether EPA+DHA treatment had an 
effect on mental health. Furthermore, per-protocol analysis, that included only 
compliant subjects yielded similar results. 
Assessment of cognitive performance
We examined cognitive performance by means of tests that had no ‘ceiling 
effects’ are were considered sufficiently sensitive to detect age-related cognitive 
decline (chapter 2)25. Standard protocols were used by research staff to reduce 
variation in assessment due to external factors and parallel versions of tests 
were used to minimize learning effects. We applied five different cognitive tests: 
the Word Learning Test, Wechsler’s Digit Span test, the Trail Making Test, the 
Stroop Color Word test, and the Verbal Fluency test. These tests covered four 
neuropsychological domains, namely sensorimotor speed, memory, executive 
function, and attention. For each domain we calculated a compound cognitive 
score by means of Z scores. All cognitive domains, except attention, were 
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assessed by at least three tests that measured different aspects and degrees of 
complexities, which has been proposed as the preferred method of cognitive 
testing26. By using compound scores, the number of cognitive test outcomes 
and, consequently, the risk of chance findings is reduced. Focusing on separate 
cognitive domains is important, because different mechanisms could affect 
decline of specific cognitive domains and could therefore be influenced by 
different treatments and within a different time-span.
Assessment of mental well-being
Among the numerous tests that are available to assess depression, we selected 
the Center for Epidemiologic Studies Depression Scale (CES-D)27, Geriatric 
Depression Scale (GDS-15)28, and Montgomery-Åsberg Rating Scale (MADRS)29 
(chapter 4). Additionally, we administered the Hospital Anxiety and Depression 
Scale (HADS-A) to assess anxiety30. All tests were administered by trained 
research assistants in a standardized way, which was especially important for 
the MADRS, because this is an observer rated scale. The CES-D is a commonly 
used screening tool in elderly populations. The GDS-15 is designed to detect 
depression in the elderly and it has been shown to detect changes in depressive 
symptoms31. The MADRS is considered more sensitive to measure treatment 
effects29. We have assessed the reliability of the three depression rating scales, 
CES-D, GDS-15 and MADRS, by comparing the internal consistency (Cronbach’s 
alpha), test-retest reliability, and the intra- and inter-rater reliability (chapter 
5). On all three items the CES-D was the most reliable scale for measuring 
depressive symptoms in our older population without clinical depression. 
There are several other depression scales that are commonly used, but that we 
did not select for different reasons. The Zung Self-Rating Depression Scale32 
and the Beck Depression Inventory (BDI)33 are intended for measuring the 
severity of depression in psychiatric patients and they have been shown to be 
less sensitive to changes following treatment34. For the Zung scale this could 
be due to the fact that symptoms over an undefined time frame are assessed. 
The Hamilton Depression Scale (HDS, HAMD or HDRS)35 has been considered 
the gold standard, but disadvantages are that the HDS contains many somatic 
items and has been shown to have a low internal consistency36. Moreover, it is 
an observer-rated scale intended to be used in a clinical setting by health care 
professionals to assess the severity of depressive symptoms.
In a later phase we administered the short form of the Profile of Mood States 
(s-POMS)37 in a subgroup of 104 subjects after 17 and 21 weeks of intervention, 
by means of telephone interviews. The s-POMS is an instrument for monitoring 
changes in mood, which can easily be applied in different settings38. Because 
baseline data were lacking, we could not assess intra-individual changes after 
26 weeks. However, scores on the POMS after 17 and 21 weeks were similar 
in all three groups, indicating no effect of EPA+DHA on mood, which was in 
line with the results of the other mental well-being questionnaires. 
Also, as a secondary outcome, we assessed quality of life (QOL) (chapter 7) 
using the short version of the World Health Organization QOL questionnaire 
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(WHOQOL-BREF)39. Most questionnaires that assess QOL focus on health-related 
QOL, whereas the WHOQOL includes a strong mental health component and 
emphasizes the perception of the individual. Because our aim was to examine the 
association between EPA+DHA and mental health, the WHOQOL questionnaire 
was considered the most appropriate scale. EPA+DHA supplementation during 
26 weeks had no effect on QOL, which was also in line with the other mental 
well-being questionnaires.
Comparison with other studies
We investigated the effects of EPA+DHA supplementation on mental health in 
a non-demented and non-depressed population. To the best of our knowledge, 
no other RCTs of EPA+DHA and cognitive performance have been performed 
in a non-demented population. Two RCTs in demented subjects showed a 
beneficial effect of EPA+DHA supplementation on cognitive performance, but 
they add little weight to the evidence because one was small in sample size 
(n=20)8 and the other one was of short duration (4 weeks)7. Another RCT in 174 
subjects with mild to moderate AD did not show an effect after 6 months of 
supplementation, except in a subgroup of 32 subjects with very mild cognitive 
dysfunction (MMSE >27 points)9. Data from other RCTs are awaited, including 
an ongoing 2-year RCT in the UK in 868 non-demented older people who are 
supplemented with EPA and DHA40. 
With regard to mental well-being in non-clinical populations, data are available 
from two RCTs41,42. The first study was conducted in a young non-depressed 
population (mean age 33 years) and found a beneficial effect after 35 days of 
supplementation with 2.8 g/d total n-3 PUFA. The second study in subjects 
with mild to moderate depression failed to show an effect after 84 days of 
daily supplementation with 1.5 g EPA+DHA. More RCTs have been performed 
in clinically depressed populations, where EPA and/or DHA were provided 
as an adjunctive to usual medical treatment. These RCTs were combined in 
a meta-analysis and here some evidence for a beneficial effect of EPA+DHA 
was found43. It has been speculated that n-3 PUFA status may be important in 
clinical or severe levels of depression, but not at less severe levels44. This is 
supported by a cross-sectional study where the inverse association of plasma 
EPA concentrations with depressive symptoms was stronger in subjects treated 
with antidepressant drugs45.
Novel findings on gene expression profiles
We examined the effect of EPA+DHA supplementation on gene expression in 
a random subgroup of 111 subjects who participated in our RCT (chapter 8). 
EPA+DHA supplementation for 26 weeks altered gene expression profiles in 
peripheral blood mononuclear cells (PBMCs) to a more anti-inflammatory and 
anti-atherogenic status in a dose-dependent way. PBMCs could be a model for 
gene expression elsewhere in the body and the impact of fish oil supplementation 
on whole genome gene expression profiles in human PBMCs has not been 
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examined before. Our findings of the effect of EPA+DHA supplementation 
on gene expression related to inflammation and atherogenesis may provide 
preliminary clues to EPA+DHA activated mechanisms that could be involved 
in mental health. These findings merit further investigation.
Observational studies: methodological considerations
Observational epidemiological studies could provide relevant information for the 
design of RCTs and are also useful for getting insight into long-term effects. Part of 
this thesis is based on observational studies, which may have weaknesses related 
to the study design that could affect the validity of the findings. The strengths 
and limitations of the prospective study (chapter 3) and a cross-sectional study 
(chapter 6) that we have performed are discussed below.
Study design
A major limitation of observational studies as compared with RCTs is that no 
definite conclusions can be drawn about the causality of the relation. We 
examined the association of EPA+DHA and fish intake with depression and 
dispositional optimism in a population of older subjects with a history of 
myocardial infarction, using cross-sectional baseline data of a large intervention 
study (Alpha Omega Trial) (chapter 6). A main limitation of this design is that 
exposure and outcome are assessed at the same moment in time which makes 
it difficult to assess the temporality of the association. It is possible that low fish 
consumption is a predisposing factor for depression, but it could also be that the 
presence of depressive symptoms decreases dietary intake of fish fatty acids due 
to loss of appetite or other reasons (reverse causation). Therefore, we excluded 
subjects using anti-depressant medication from the analysis. 
We examined the association between EPA+DHA and fish intake and cognitive 
performance and cognitive change in older men of the Normative Aging (NAS) 
study, using a prospective design (chapter 3). We examined fish intake at baseline 
and cognitive performance during 6 years of follow-up. Reverse causation is not 
an issue here, because intake was assessed prior to the assessment of cognitive 
performance. Furthermore, the advantage of a longitudinal design is that changes 
over time can be assessed and for changes in cognitive performance 6 years of 
follow-up is a reliable period.
Internal validity
Subjects in our cross-sectional study on depression and dispositional optimism 
(chapter 6) had a history of myocardial infarction within the past 10 years 
and are of older age (mean age 69 years), which may cause survival bias. Our 
prospective study on cognitive change (chapter 3) was performed in older US 
men who participated in the Normative Aging Study (NAS). A total of 2,280 
men had been enrolled in 1970. Cognitive testing started in 1993, after nearly 
25 years of follow-up, and at that time 1,216 men were still in the study. 
Missing data during these years were mostly due to mortality (42%), follow-up 
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measurements of mailed questionnaires only (38%), or loss to follow-up and 
drop-out (20%). During the 6-years of follow-up for our prospective analysis 
the number of subjects participating in the consecutive cognitive test series 
decreased substantially (from 1,025 to 671 after 3 years to 313 after 6 years of 
follow-up). Therefore, bias due to incomplete follow-up may have influenced our 
results. However, we compared completers with non-completers for differences 
in age, education, fish intake, and cognitive scores and except for the fact that 
subjects with complete follow-up were on average 2 years younger; they were 
not different from the subjects with incomplete follow-up. To prevent bias due 
to selective drop-out, we analyzed the data with a repeated mixed coefficients 
model (SAS PROC MIXED procedure) for our analyses, that took account of 
subjects with incomplete follow-up data. 
A second potential source of bias in an observational study may occur from 
misclassification of the exposure. Our cross-sectional study on depressive 
symptoms and dispositional optimism (chapter 6), and the prospective study of 
US men (chapter 3) did not include cognitively impaired subjects. We assume 
that these subjects were able to adequately recall their dietary pattern, including 
fish consumption. In both observational studies fish intake was assessed by a 
FFQ. The FFQ in the Normative Aging Study (NAS) (chapter 3) focused on 
consumption of foods over the past year and has been validated in several 
studies46-48. The four questions on seafood intake were sufficient to characterize 
habitual intake of seafood and correlations between two measurements 1 year 
apart ranged from 0.48 (fish) to 0.67 (shellfish)48. The correlation of fish intake 
estimated with the FFQ validated against two 1-week dietary records was 0.6147. 
The FFQ in the Alpha Omega trial (chapter 6) focused on the past month and 
was based on a validated FFQ for estimating the intake of total energy and fatty 
acids49. This FFQ was modified for estimating intake of ALA, EPA and DHA of the 
older population in the Alpha Omega Trial. The correlation between EPA+DHA 
intake and plasma EPA+DHA was 0.37. Although a FFQ cannot accurately assess 
absolute dietary intakes, it is a suitable tool to rank individuals. 
Our observational findings can be confounded by factors that are both related 
to fish intake and mental health. When examining cognitive decline (chapter 3) 
and mental well-being (chapter 6), we adjusted for established confounders like 
age, gender, educational level, BMI, smoking, alcohol consumption, physical 
activity, and total energy. Additionally, we added indicators for the type of 
dietary pattern, such as saturated fat, vitamin C, vitamin E, and fiber. As in all 
observational studies there may still be residual confounding due to unknown 
confounders or imprecise measurement of confounders. Improving the accuracy 
of measurement of confounders would be preferable, but this is often not feasible 
in large epidemiological studies.
Assessment of cognitive performance
In many observational studies cognitive functioning is assessed using the Mini-
Mental State Examination (MMSE)50 or other tests of global cognitive function. 
Originally, the MMSE was designed as a screening tool to assess the global 
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cognitive state of subjects by the clinician, but now it is also frequently used 
as a measure of cognitive performance or cognitive change in epidemiological 
studies51. However, it has been shown that it is not a sensitive tool for the 
assessment of short-term cognitive impairment52. Also, the MMSE as well as 
other global measures of cognitive function cannot detect changes in different 
cognitive domains. We used an extensive battery of nine cognitive tests and 
their subtests, which were appropriate for an aging population, and focused on 
specific cognitive domains. We calculated a compound cognitive score for each 
domain by means of factor analysis (chapter 3). This resulted in three factors: a 
memory/language factor; a visuospatial/attention facto, and a speed factor. This 
made the cognitive construct more robust and reduced the number of outcome 
variables, which reduced chance findings.
Assessment of mental well-being
We used the GDS-15 to measure depression, as an indicator of mental well-
being28. The GDS-15 is easy to administer and designed for use in an older 
population. We assessed dispositional optimism by means of the Revised 
Lifestyle Orientation Test (LOT-R)53 and a 4-item questionnaire (4Q) that was 
previously used in the Zutphen elderly study54. The LOT-R is a commonly used 
psychological optimism test with good psychometric properties53. Scores on the 
4Q have been shown to be relatively stable over time55, but have not yet been 
validated against other measures of mental well-being. Including measures of 
dispositional optimism is new in the field of fish fatty acids research and though 
depression is not simply the reverse of optimism, optimism has been shown to 
protect against the development of depressive symptoms54. Furthermore, it has 
also been associated with healthy lifestyle and dietary habits56. 
Comparison with other studies
The association between EPA+DHA and fish and cognitive performance in 
older adults has been examined in several epidemiological studies of which 
an overview is given in chapter 1 (Table 1.1). All together, the results of cross-
sectional studies observed either an inverse association or no association, 
whereas longitudinal studies mostly showed an inverse association. Most 
studies have only used a global measure of cognitive performance, which we 
consider a limitation because cognitive function in older adults could decline 
differentially in specific cognitive domains25. Also, if n-3 PUFA are associated 
with cognitive functioning, they may affect specific cognitive domains differently, 
as different mechanisms could underlie specific domains. It is, however, unclear 
yet which mechanisms may principally underlie this association in general and 
which mechanisms may underlie changes in specific cognitive domains. To the 
best of our knowledge, three studies addressed the association between n-3 
PUFA and cognitive performance in specific cognitive domains. Two showed 
a reduced risk of impaired cognitive performance on speed related tests with 
higher intake of fatty fish or n-3 PUFA57, or with higher plasma n-3 PUFA levels 
over 3 years58 and one showed that higher proportions of plasma n-3 PUFA 
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reduced the risk of decline in verbal fluency over 6 years of follow-up4. These 
studies were all conducted in healthy, middle-aged populations with a mean 
age between 56 and 60 years. The NAS population was about 10 years older 
with a mean age of 68 years. Two of these studies4,58 assessed n-3 PUFA status 
by plasma cholesterylesters or plasma phospholipids. Studies using biomarkers 
often observe stronger associations, because biomarkers are less prone to 
misclassification than dietary intake data. The other study, conducted by Kalmijn 
et al., assessed intake of fatty fish and marine n-3 PUFA with a FFQ, like we did, 
and they observed an inverse association with cognitive performance57. Mean 
intake values in their population were 11 g of total fish, 3 g of fatty fish, and 165 
mg of EPA+DHA per day. Intake in the Normative Aging Study population was 
considerably higher with an average intake of 43 g of total fish, 23 g of fatty fish 
and 280 mg of EPA+DHA per day. The range of intake was larger and included 
also non-fish eaters. However, we have to note that comparing actual intakes 
based on FFQs, and in this case two different FFQs, should be done cautiously. 
Another limitation for a good comparison between these studies is that different 
cognitive tests were used to measure the same cognitive domains. Thus, the 
studies investigating effects from n-3 PUFA in older people on separate cognitive 
domains are too scarce and heterogeneous to draw definite conclusions.
With regard to depression, observational studies are summarized in Table 1.3 in 
chapter 1. All studies, except one, were cross-sectional and most studies (n=17) 
showed an inverse association of EPA+DHA or fish intake with depression, 
whereas four studies did not. Ten studies focused on intake of fish and/or n-3 
PUFA like we did and all, except two, showed an inverse association. In nine 
studies n-3 PUFA were measured in blood and all, except one, were performed 
in populations with (major) depression. These studies consistently showed an 
inverse association. In the other two studies in healthy adults, n-3 PUFA was 
measured in adipose tissue, which was also inversely related to depression. Fish 
and EPA+DHA intake in our study was lower compared to most other cross-
sectional studies on EPA+DHA or fish intake and mental well-being where mean 
intakes ranged from 1 to ≥2 portions of fish per week59-64. However, Colangelo 
et al. and Kamphuis et al. observed an inverse association in populations who 
consumed less EPA+DHA (mean intake of 143 and 101 mg/d, respectively) 
than our study population65,66. Studies of fish fatty acids were all performed 
in the general population, while our cross-sectional study was performed in a 
population of subjects with a history of coronary heart disease who had a higher 
prevalence of depression, i.e. 17% compared with 1 to 15% in the general 
population67,68. There are five other cross-sectional studies on n-3 PUFA and 
depression in patients with acute coronary syndromes, i.e. myocardial infarction 
or unstable angina69-73. In these studies serum n-3 PUFA concentrations were 
examined and all studies showed significantly lower concentrations in depressed 
individuals.
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Reflection and future directions
Our RCT did not show an effect of EPA+DHA supplementation on cognitive 
performance or mental well-being. This result was confirmed by the observational 
studies we conducted. Nevertheless, we cannot deny the total body of evidence 
indicating a beneficial effect, although overall results lack consistency. More 
research is therefore needed, and several aspects that could be relevant for future 
studies are discussed below.
What kind of studies? For cognitive performance, especially RCTs are lacking, 
but some are ongoing and results are awaited for. For depression more RCTs, 
particularly in non-depressed populations, are needed. Moreover, prospective 
studies will be of added value to study associations over several years, a time 
period needed to capture long-term effects that cannot be covered by RCTs. 
Furthermore, results from these observational studies could yield relevant 
information on EPA+DHA dose and type of study population for future RCTs. As 
long as no effective treatments are available, epidemiological research should 
be continued to identify modifiable risk factors. 
Which populations? We assessed the association between fish fatty acids 
and mental health in populations with no clinical diagnosis of dementia or 
depression. We aimed to examine effects in the preclinical phase to obtain 
insight in possibilities for prevention. However, it may be that in individuals 
who are still too healthy no changes can be detected within a time-span of 26 
weeks. Conversely, in already cognitively impaired or demented subjects it may 
be too late for dietary supplementation to counteract the process of cognitive 
decline. Future RCTs in non-clinical populations may focus on more sensitive 
groups, such as subjects with amnestic Mild Cognitive Impairment (MCI) or 
subjective memory complaints, subjects with a suboptimal n-3 PUFA status or 
carriers of the APOE-ε4 allele. Amnestic MCI patients or subjects with subjective 
memory complaints show deterioration in specific cognitive functions and this 
pathological process could possibly be influenced by EPA+DHA treatment. In 
depleted subjects there is more room for improvement of n-3 PUFA status. In 
our RCT we observed an effect of EPA+DHA supplementation specifically on the 
cognitive domain of ‘attention’ in a subgroup of carriers of the APOE-ε4 allele. 
Conversely, Huang et al. found in an epidemiological study, that consumption 
of fish was associated with a reduced risk of AD only in subjects without the 
APOE-ε4 allele74. A differential effect of n-3 PUFA for APOE genotypes warrants 
further investigation.
How long? The European task force under the auspices of the European 
Alzheimer Disease Consortium, agreed that the study duration of RCTs focusing 
on cognitive decline should be at least 18 months75. Such period is considered 
to be sufficient to detect changes, if any, for slowly developing disorders like 
cognitive decline and AD. For studying genetic determinants cross-sectional 
studies are suitable since ‘reverse causation’ cannot occur. To capture long-term 
effects of EPA+DHA or fish intake on slowly developing processes like age-related 
cognitive decline, however, prospective studies of sufficiently long duration 
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are needed76. Currently, it is not clear which short-term (weeks or months) or 
long-term mechanisms (years) could underlie an effect of EPA+DHA on mental 
health, if any. When designing future studies, one should carefully think about 
the appropriate time window to capture the effect of EPA+DHA, depending on 
whether short-term or long-term mechanisms are involved. These considerations 
also influence the choice of specific dimensions of brain function that are to 
be studied. With regard to short-term mechanisms, gene expression studies, as 
described in chapter 8 are a promising field, because these may elucidate early 
changes that could lead to changes in mental health.
Which exposure? Daily doses of EPA+DHA supplementation ranged from 0.7 
to 2.3 g in RCTs focusing on cognitive performance and from 1.0 to 9.6 g in 
RCTs focusing on depression. It is not clear which dose is most effective and 
this could also depend on the habitual fish intake of the target group. Future 
dose-finding trials will be helpful in establishing optimum doses for use in RCTs. 
One should also take into account that high doses of fish oil could have more 
adverse effects and are more prone to a fishy aftertaste, which could cause 
deblinding of treatment. However, these effects could be reduced when high 
quality, refined fish oils with a high concentration of EPA+DHA are used, also 
to reduce the amount of capsules to be ingested each day20. EPA and DHA can 
be used as separate or combined treatments. It has been speculated that DHA 
mainly exerts an effect on cognitive performance, whereas EPA seems to be 
more effective in mood disorders15, but more comparisons of EPA and DHA 
are needed to clarify the combined and separate effects on different outcome 
measures. With regard to observational studies, the range of fish intake should 
be sufficiently large, and non-fish eaters should be included to be able to detect 
associations for small amounts of EPA+DHA intake.
Which endpoints? We assessed cognitive performance, depression, and QOL 
as measures of mental health. There is no gold standard for the validation of 
cognitive tests and mental well-being questionnaires. For depression often a 
diagnostic judgment by a clinician using the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV)77 is used, but this is usually not feasible in large 
studies. The wide variety of tests that are used hinders the comparisons between 
studies and meta-analyses in this field. We propose to use a standard battery 
of cognitive tests  that include domain-specific outcome measures. These tests 
should preferably be applied in combination with imaging techniques, such as 
MRI, Trans Cranial Doppler ultrasound (TCD), or biological markers such as tau 
isoforms and amyloid β, to get more insight in underlying mechanisms of action. 
However, suitable biomarkers in the field of nutritional research and mental 
health still need to be established and validated. If this can be achieved, a whole 
array of opportunities will become available to obtain insight in processes in 
specific brain areas that can be modified by nutrient intake. Although imaging 
techniques are relatively expensive, they have the additional advantage that study 
sample size or duration of follow-up can be reduced. Several previous studies 
suggested that multiple factors might be involved in the occurrence of AD at late 
ages. Because of the probable multi-factorial nature of AD, it seems logical to 
General discussionChapter 9
171
initiate multi-domain interventions, including for instance nutritional, physical, 
and cognitive training to examine their potential synergistic effects78.
Public health implications
The prevalence of depression and dementia is high and due to the aging of the 
population, these numbers will likely increase in the coming years. For dementia 
there is a lack of effective treatment. For depression current treatment is often 
not satisfactory, despite the fact that more than 40 antidepressants are available 
on the market. The recurrence rate in people with a history of depression 
is high80, and less than 50% of patients achieve full remission79. Moreover, 
pharmacological treatment often has unpleasant side effects81. Depression in 
older people can remain undetected and only part of the elderly in need receives 
treatment82. This calls for effective preventive measures. The importance of a 
healthy lifestyle is advocated for the maintenance of a good mental and physical 
health. The Netherlands Health Council recommends in the 2006 Dietary 
Guidelines an intake of at least 450 mg EPA+DHA from fish per day, which 
is roughly equivalent to eating two portions of fish per week, one of which is 
oily fish14. This advice is mainly based on the beneficial effects of EPA+DHA 
on cardiovascular health. Based on the results of this thesis and other scientific 
evidence, there is no reason to change the current recommendation to improve 
mental health of the general population.
The focus of research so far has mainly been on health effects of n-3 PUFA from 
fish, but fish is also a good source of proteins, vitamin D and selenium, which 
could also be beneficial to health83. Moreover, fish is a good alternative protein 
source for meat that is a major source of saturated fat. Therefore, we would 
recommend a food-based approach for increasing the intake of EPA+DHA, 
except for individuals who do not eat fish, for whom foods fortified with n-3 
PUFA or fish oil capsules may be good alternatives. Incorporating fish in a dietary 
pattern may have additional advantages due to interactions with micro- and 
macronutrients from other foods, which also need to be considered in future 
studies. Three studies have examined cognitive impairment in relation to the 
Mediterranean diet, that includes fish. Adherence to this diet reduced the risk of 
developing Mild Cognitive Impairment (MCI) and AD, mortality from AD, and 
reduced conversion of MCI to AD84-86. However, in etiologic research where one 
aims at elucidating the causal relationships with individual foods or nutrients, 
a “reductionist approach” is required. Both complementary approaches are 
needed to come to effective public health measures.  
Fish may have several health benefits, but there is also concern about 
contaminants, such as methyl mercury, dioxins, and polychlorinated biphenyls. 
These substances are mainly found in fish species that are high in the food chain, 
such as swordfish, shark, tuna and king mackerel87. Mozaffarian et al. reviewed 
the risks and benefits of fish consumption in relation to cardiovascular disease 
and neurodevelopment and neurologic function. They concluded that the 
benefits of modest fish consumption (1-2 servings/week) outweigh the risks and, 
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Concluding remarks
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mental health. Examination of gene expression profiles in white blood cells 
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needs to be established.
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The growing aging population will lead to an increase in age-related diseases, 
including dementia and depression. Both diseases have a serious impact on 
mental health and quality of life. Evidence is accumulating that mental health 
is favorably affected by intake of very-long-chain n-3 polyunsaturated fatty 
acids from fish, i.e. eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA). Epidemiological and experimental studies suggest that EPA+DHA may 
slow down cognitive decline, delay the onset of dementia and improve mental 
well-being. In this thesis we further investigated the potential benefits of fish 
and EPA+DHA on mental health of older people without clinical dementia or 
depression.
In chapter 2 of this thesis, we examined the effect of EPA+DHA supplementation 
on cognitive performance in a double-blind, placebo-controlled trial (RCT). A 
total of 302 individuals aged 65 years or older without cognitive impairment were 
randomly allocated to capsules with a low dose of EPA+DHA (400 mg per day) or 
a high dose of EPA+DHA (1,800 mg per day), or placebo for 26 weeks. Cognitive 
performance was assessed by means of an extensive neuropsychological test 
battery that included the cognitive domains of attention, sensorimotor speed, 
memory and executive function. Overall, there was no significant effect on any of 
these cognitive domains for either low-dose or high-dose fish oil supplementation 
compared to placebo.
Evidence from cross-sectional and prospective studies suggests that an increased 
intake of fish and EPA+DHA could protect against age-related cognitive 
decline and dementia. However, the results are inconsistent and studies that 
address changes in specific cognitive domains are limited. We investigated the 
association of fish and EPA+DHA intake with cognitive performance and 6-year 
cognitive decline in specific domains of cognitive functioning in 1,025 older 
US men (chapter 3). The fatty fish consumption ranged from 0.2 to 4.2 servings 
per week. The intake of fatty fish or EPA+DHA was not related to cognitive 
performance or change in cognitive function during 6 years of follow-up. 
Trials of EPA+DHA supplementation and depression have mainly been 
performed in depressed patients, with conflicting results. In non-clinically 
depressed populations trials are scarce. In the previously mentioned RCT we 
additionally investigated the effect of EPA+DHA supplementation on mental 
well-being (chapter 4). Changes in different aspects of mental well-being 
(depressive symptoms, anxiety, and mood) were assessed by means of the Center 
for Epidemiologic Studies Depression Scale (CES-D), Montgomery-Åsberg Rating 
Scale (MADRS), Geriatric Depression Scale (GDS-15), Hospital Anxiety and 
Depression Scale (HADS-A), and the short form of the Profile of Mood States 
(s-POMS). CES-D scores were around 6-7 and did not differ significantly between 
the low dose EPA+DHA, high dose EPA+DHA and placebo group at the start 
of the study. Mean changes in CES-D scores after 26 weeks were –0.2, 0.2 and 
–0.4 (P=0.87), respectively. Treatment with 400 or 1,800 mg/d of EPA+DHA 
had no effect on any of the measures of mental well-being after 13 or 26 weeks 
of intervention.
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In chapter 5 we evaluated the reliability of three depression rating scales (CES-D, 
MADRS, and GDS-15) in the general older population of our RCT. Three 
dimensions of reliability were compared: 1) internal consistency by means of 
Cronbach’s alpha, 2) reproducibility by means of Spearman correlations (rs), and 
3) the intra- and inter-rater reliability. The internal consistency was high for the 
CES-D (Cronbach’s alpha of 0.84), good for the MADRS (0.72) and relatively low 
for the GDS-15 (0.55). Reproducibility was also higher for the CES-D (rs=0.71) 
than for the MADRS (0.61) and the GDS-15 (0.52). The rater had little influence 
on CES-D scores (intra-/inter-rater ratio=0.99). The GDS-15 and the MADRS, 
however, performed better when administered by the same rater. We conclude 
that CES-D is the preferred scale for measuring depressive symptoms in a non-
clinically depressed older population.
Epidemiological studies generally point toward a beneficial effect of fish and 
EPA+DHA intake against depression. Most observational studies have been 
performed in populations with a low prevalence of mental disturbances. We 
examined the association of EPA+DHA and fish intake with mental well-being 
in 644 free-living subjects aged 60-80 years, who had a history of myocardial 
infarction (chapter 6) and a higher prevalence of depressive symptoms (17%) 
compared with the general population (3 to 12%). Depressive symptoms 
were assessed with the self-report Geriatric Screening Scale (GDS-15) and 
dispositional optimism with the Revised Life Orientation Test (LOT-R), and a 
4-item questionnaire (4Q). Compared with the lower tertile, subjects in the higher 
tertile of EPA+DHA intake had a lower prevalence of depressive symptoms, but 
this was not statistically significant (prevalence ratio [PR] 0.78; 95% Confidence 
Interval [CI]: 0.50; 1.22, P-trend 0.27). Findings on dispositional optimism were 
only statistically significant when assessed with the 4Q (PR 1.09; 95% CI: 1.01; 
1.23, P-trend 0.05). For fish intake, similar though weaker associations were 
found. 
Cognitive impairment and depression both affect quality of life. We assessed 
quality of life (QOL) in the RCT by using the short version of the World Health 
Organization QOL questionnaire (WHOQOL-BREF) (chapter 7). After 26 weeks, 
the mean difference in score compared with placebo was 0.02 (–1.95; 1.99) 
for the low-dose and an improvement of –1.42 (95% CI: –3.40; 0.57) for the 
high-dose fish oil group. Treatment with 400 mg or 1,800 mg EPA+DHA did 
not affect total QOL after 13 or 26 weeks of intervention.
Furthermore, we investigated early effects of EPA+DHA on processes that could 
be related to mental health by examining the effect of low- and high-dose 
supplementation with EPA+DHA on gene expression profiles in human white 
blood cells (chapter 8). We found that subjects who had been supplemented 
with EPA+DHA during 6 months had a less inflammatory and less atherogenic 
status.
The main findings, methodological considerations and interpretation of the 
findings of the studies described in this thesis are discussed in chapter 9. Also, 
directions for future research and implications for public health are considered. 
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The main conclusion of this thesis is that in the short-term, low or high doses 
of supplemental EPA+DHA are unlikely to improve cognitive performance or 
mental well-being of older people without a clinical diagnosis of dementia or 
depression. Our observational studies in populations with a low fish intake did 
not provide evidence for an important role of EPA+DHA in cognitive performance 
or mental well-being. Based on this thesis and the total evidence in the field, we 
conclude that the beneficial effect of EPA+DHA on mental health in the general 
population still needs to be established.
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Door de groeiende populatie ouderen zal ook het aantal leeftijdsgerelateerde 
ziektes stijgen, waaronder dementie en depressie. Beide hebben een grote invloed 
op de mentale gezondheid en de kwaliteit van leven. De laatste jaren staan de 
langketenige meervoudig onverzadigde omega-3 vetzuren, in het bijzonder de 
visvetzuren eicosapentaeenzuur (EPA, C20:5n-3) en docosahexaeenzuur (DHA, 
C22:6n-3), in de belangstelling vanwege hun mogelijk gunstige invloed op de 
mentale gezondheid. Epidemiologisch en experimenteel onderzoek suggereert 
dat EPA+DHA de cognitieve achteruitgang en het ontwikkelen van dementie 
vertragen en het mentaal welbevinden kunnen verbeteren. In dit proefschrift 
hebben we de invloed van vis en EPA+DHA op de mentale gezondheid van 
ouderen zonder klinische dementie of depressie verder onderzocht.
In hoofdstuk 2 is het effect van dagelijkse suppletie met een lage en een hoge 
dosis EPA+DHA op cognitief functioneren bij ouderen onderzocht in een 
dubbelblind, gerandomiseerd, placebo-gecontroleerd interventieonderzoek. Op 
basis van loting zijn 302 deelnemers ingedeeld in drie groepen die gedurende 
26 weken capsules kregen met daarin een lage dosis EPA+DHA (400 mg/dag), 
een hoge dosis EPA+DHA (1800 mg/dag) of zonnebloemolie (placebo). Cognitief 
functioneren is gemeten door middel van een uitgebreide set cognitieve testen die 
waren gericht op de cognitieve domeinen “aandacht”, “snelheid”, “geheugen” 
en “executief functioneren”. De lage en hoge dosis EPA+DHA hadden geen 
effect op deze cognitieve domeinen.
Resultaten uit epidemiologisch onderzoek doen vermoeden dat een verhoogde 
consumptie van EPA+DHA en vis mogelijk beschermt tegen leeftijdsgerelateerde 
cognitieve achteruitgang en dementie. De bevindingen zijn echter niet consistent 
en met name onderzoeken naar veranderingen in specifieke cognitieve domeinen 
ontbreken. We hebben in 1025 oudere Amerikaanse mannen onderzocht of 
de inname van EPA+DHA en vis samenhangt met cognitief functioneren en 
cognitieve achteruitgang in specifieke cognitieve domeinen over een periode 
van 6 jaar (hoofdstuk 3).  De consumptie van vette vis varieerde van 0,2 tot 4,2 
porties per week. Het eten van vette vis of EPA+DHA bleek niet gerelateerd aan 
cognitief functioneren of cognitieve achteruitgang. 
Experimenteel onderzoek naar het effect van EPA+DHA suppletie op depressie 
is voornamelijk gedaan in depressieve patiënten en de resultaten ervan zijn 
niet eenduidig. In personen zonder klinische depressie is nog nauwelijks 
interventieonderzoek gedaan. Wij hebben het effect van een lage en hoge dosis 
EPA+DHA op mentaal welbevinden onderzocht in een 6 maanden durend 
interventieonderzoek (hoofdstuk 4). Veranderingen in verschillende aspecten 
van mentaal welbevinden (depressieve symptomen, angst en stemming) zijn 
onderzocht met behulp van de “Center for Epidemiologic Studies Depression 
Scale” (CES-D), “Montgomery-Åsberg Rating Scale” (MADRS), “Geriatric 
Depression Scale” (GDS-15), “Hospital Anxiety and Depression Scale” (HADS-A) 
en de verkorte versie van de “Profile of Mood States” (s-POMS). De deelnemers 
hadden een CES-D score van 6-7 bij aanvang van het onderzoek. De gemiddelde 
veranderingen in CES-D scores na 26 weken waren –0,2 in de groep met de 
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lage dosis EPA+DHA, +0,2 in de groep met de hoge dosis EPA+DHA en –0,4 
in de placebogroep, hetgeen niet significant verschilde (P=0,87). Behandeling 
met 400 of 1800 mg EPA+DHA per dag had na 13 en 26 weken geen effect op 
het mentaal welbevinden gemeten met bovenstaande vragenlijsten.
In hoofdstuk 5 hebben we de betrouwbaarheid van drie depressievragenlijsten 
(CES-D, MADRS, and GDS-15) onderzocht in de niet-klinische populatie van 
ons interventieonderzoek. Drie aspecten van betrouwbaarheid zijn vergeleken, 
namelijk 1) interne consistentie met Cronbach’s alpha, 2) reproduceerbaarheid 
met Spearman correlaties (rs) en 3) de betrouwbaarheid binnen en tussen de 
testafnemers. De interne consistentie was hoog voor de CES-D (Cronbach’s alpha 
van 0,84), goed voor de MADRS (0,72) en relatief laag voor de GDS-15 (0,55). 
De reproduceerbaarheid was hoger voor de CES-D (rs=0,71) dan voor de MADRS 
(0,61) en de GDS-15 (0,52). De testafnemer had weinig invloed op de CES-D 
scores. De scores op de GDS-15 en de MADRS waren echter betrouwbaarder 
wanneer de vragenlijsten door dezelfde persoon werden afgenomen. We 
concluderen dat de CES-D de voorkeur verdient boven de andere genoemde 
vragenlijsten als het gaat om het meten van depressieve symptomen in een 
algemene oudere populatie.
Epidemiologisch onderzoek laat over het algemeen een gunstig effect zien van 
EPA+DHA- en visinname op depressie. Veel van dit onderzoek is uitgevoerd 
in populaties waarin depressie weinig voorkomt. Wij hebben de inname van 
EPA+DHA en vis in relatie tot depressie onderzocht in 644 zelfstandig wonende 
ouderen (60-80 jaar) die in de voorafgaande 10 jaar een hartinfarct hadden 
doorgemaakt (hoofdstuk 6). Deze populatie heeft een hogere prevalentie van 
depressie symptomen (17%) vergeleken met de algemene populatie (3 tot 
12%). Naast depressieve symptomen, gemeten met de “Geriatric Screening 
Scale” (GDS-15), is de aanwezigheid van dispositioneel optimisme vastgesteld 
met de “Revised Life Orientation Test” (LOT-R) en een 4-item vragenlijst (4Q). 
Personen met de laagste inname van EPA+DHA (eerste tertiel) hadden minder 
depressieve symptomen dan personen met de hoogste inname van EPA+DHA, 
maar dit was niet statistisch significant (prevalentieratio [PR]: 0,78; 95% 
betrouwbaarheidsinterval [CI]: 0,50; 1,22, P-trend 0,27). Voor dispositioneel 
optimisme gemeten met de 4Q werd een gunstig verband met EPA+DHA 
gevonden (PR 1,09; 95% CI 1,01; 1,23, P-trend 0,05), maar dit werd niet 
bevestigd door de LOT-R. De associaties voor visconsumptie waren zwakker 
maar wezen in dezelfde richting.
Cognitieve achteruitgang en depressie hebben beide een grote invloed 
op de kwaliteit van leven. Bij de deelnemers aan het bovengenoemde 
interventieonderzoek hebben we de kwaliteit van leven gemeten met behulp 
van de verkorte versie van de “World Health Organization Quality of Life 
questionnaire” (WHOQOL-BREF) (hoofdstuk 7). Na 26 weken zagen we een 
verandering van 0,02 (95% CI: –1,95; 1,99) in de groep met de lage dosis en 
–1,42 (–3,40; 0,57) in de groep met de hoge dosis EPA+DHA. Suppletie met 
400 mg of 1800 mg EPA+DHA had dus geen meetbaar effect op de kwaliteit 
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van leven na 13 of 26 weken interventie.
Verder hebben we onderzocht of EPA+DHA van invloed kunnen zijn op 
mogelijke mechanismen die gerelateerd zijn aan de mentale gezondheid, door 
het bestuderen van de genexpressie in witte bloedcellen na suppletie met een 
lage of hoge dosis EPA+DHA (hoofdstuk 8). We vonden dat EPA+DHA suppletie 
gedurende zes maanden resulteerde in een genexpressieprofiel dat minder 
inflammatoir en minder atherogeen was. 
De belangrijkste resultaten en methodologische aspecten van de onderzoeken in 
dit proefschrift worden besproken in hoofdstuk 9. Verder worden hier suggesties 
gedaan voor toekomstig onderzoek en wordt de betekenis van de bevindingen 
voor de volksgezondheid bediscussieerd. De belangrijkste conclusie van dit 
proefschrift is dat het verhogen van de inname van EPA+DHA op relatief korte 
termijn weinig invloed heeft op het cognitief functioneren en mentaal welbevinden 
van ouderen zonder klinische dementie of depressie. Onze epidemiologische 
bevindingen bevestigen daarnaast de hypothese dat visconsumptie van belang 
is voor de mentale gezondheid van ouderen in Westerse landen niet. Gebaseerd 
op dit proefschrift en het totaal aan wetenschappelijk bewijs op dit gebied, 
concluderen we dat het tot op heden niet duidelijk is of EPA+DHA een gunstig 
effect op de mentale gezondheid van de algemene populatie hebben. 
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